Research activity information

• Apr. 2025 日本内科学会, 優秀指導教官賞


• Apr. 2024 日本内科学会, 優秀指導教官賞


• Oct. 2021 Japan Endocrine Pathology Society, Kameya Award


• Mar. 2020 Kobe University Hospital, Best Teacher Award


• Apr. 2018 日本内科学会, 日本内科学会ことはじめ2018京都 優秀指導教官賞

  Fukuoka Hidenori

  Japan society


• Apr. 2011 日本内分泌学会, 日本内分泌学会若手奨励賞, 若手奨励賞応募者

  Fukuoka Hidenori


• Jun. 2010 Endocrine Society, 91th annual meeting of the Endocrine Society Trainee Day Award, 推薦者

  Fukuoka Hidenori


• Jun. 2010 Endocrine Society, 91th annual meeting of the Endocrine Society Presidential Poster Competition Award, 優秀演題発表者

  Fukuoka Hidenori


• Jun. 2009 Pituitary Society, 11th International Pituitary Congress Travel Grant Award, 優秀演題発表者

  Fukuoka Hidenori


• Aug. 2007 日本神経内分泌学会, 日本神経内分泌学会若手研究奨励賞, 若手優秀演題発表者

  Fukuoka Hidenori


• Jun. 2007 Endocrine Society, 88th annual meeting of the Endocrine Society Travel Grant Award, 優秀演題発表者

  Fukuoka Hidenori


• Mar. 2007 日本内分泌学会, 内分泌臨床UpDate 優秀演題賞, 優秀演題発表者

  Fukuoka Hidenori


• Oct. 2006 ノバルティス, 第2回アクロメガリーフォーラム奨励賞, 優秀演題

  Fukuoka Hidenori


• Oct. 2005 ノバルティスファーマー, アクロメガリー奨励賞, 優秀演題発表者

  Fukuoka Hidenori

• Management of Cushing's disease in the initial phase~From detection to surgery~.

  Hidenori Fukuoka

  Cushing's disease is a rare endocrine disorder that presents many systemic complications, and its initial phase management can be difficult in atypical and severe cases or at institutes with limited experience. It is a disease in which several complications may have already progressed at the time of diagnosis, and complications may become more severe during the initial management phase, potentially becoming life-threatening. In addition, many patients are young, and depending on this phase management, their quality of life will significantly decline later on. Therefore, this review summarizes the evidence accumulated to date and outlines strategies for disease management, focusing on the initial stages from detection, diagnosis, and referral of patients to surgery.

  May 2025, Endocrine journal, 72(5) (5), 463 - 473, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Intracystic catecholamine variations in cystic pheochromocytoma.

  Tomoko Fujii, Hironori Bando, Masaaki Yamamoto, Maki Kanzawa, Keitaro Kanie, Shin Urai, Yasutaka Tsujimoto, Fumikazu Sawabe, Keiko Fukazawa, Asa Hanayama, Tomoko Yamada, Kei Yoshino, Hidenori Fukuoka, Wataru Ogawa

  PURPOSE: Approximately 20% of pheochromocytomas are cystic in nature. However, research on the correlation between catecholamine and metanephrine fractions in cystic fluid and peripheral blood is limited. This study investigated the relationship between catecholamine fractions and their metabolites in peripheral blood and cystic fluid. METHODS: Five patients with pathologically diagnosed cystic pheochromocytomas were included in the analysis. Catecholamine fractions and their metabolites in the cystic fluid were measured. The relationship between phenylethanolamine N-methyltransferase (PNMT) expression in tumor tissues and catecholamine fractions of cystic fluid was also assessed. RESULTS: The elevated patterns of catecholamine and metanephrine fractions in the cystic fluid were consistent with those observed in the peripheral blood of two patients. However, in two other patients. discordance was observed, with normetanephrine predominance in the peripheral blood despite adrenaline/metanephrine and noradrenaline/normetanephrine elevations in the cystic fluid. Immunohistochemical analysis revealed that PNMT expression in tumor tissues and the elevated pattern of catecholamine fractions in the peripheral blood were consistent in all patients, except for one patient with non-elevated peripheral blood catecholamines. However, in cystic fluid, the predominantly catecholamine fraction did not consistently align with PNMT expression. CONCLUSION: In cystic pheochromocytoma, the elevation patterns of catecholamine fractions in cysts may not align with those in the peripheral blood and may differ relative to PNMT expression in tumor tissues.

  Apr. 2025, Journal of endocrinological investigation, English, International magazine

  Scientific journal


• Prevalence and risk of complications in untreated patients with adult growth hormone deficiency.

  Hidenori Fukuoka, Takaaki Endo, Satoshi Tsuboi, Shingo Fujio

  PURPOSE: Adult growth hormone deficiency (AGHD) increases the prevalence of complications, including metabolic disorder, leading to increased cardiovascular mortality from cardiovascular diseases. However, no large database studies have evaluated AGHD patients without GH replacement therapy (GHRT). We investigated the prevalence of AGHD-related complications in patients without GHRT. METHODS: Patients with AGHD and associated complications were identified from the Medical Data Vision claims database using Japanese local disease codes mapped to ICD-10 codes. The prevalence of AGHD-related complications in 2020 was estimated to compare with the prevalence in the Japanese general population in the latest available year 2020. Risk factors for complications were evaluated by Kaplan-Meier curves and a Cox proportional hazard model. RESULTS: We identified 8,809 untreated patients with AGHD from April 2008 to September 2022, including 3,430 in 2020. In 2020, the prevalence of complications was higher in the AGHD population adjusted for sex and age than in the Japanese general population, e.g., diabetes mellitus, 9.3% vs. 3.6%; osteoporosis, 4.8% vs. 1.3%; and dyslipidemia, 22.0% vs. 3.9%. Age was a significant risk factor for most complications, and female sex for osteoporosis. Diabetes mellitus was a significant risk factor for dyslipidemia, ischemic heart disease, cerebrovascular disease, and all-cause death. CONCLUSION: Untreated patients with AGHD have a higher prevalence of metabolic complications than the general population despite no difference in their related risk factors. Given the low use of GHRT in this study, comprehensive treatment approaches that include GHRT need to be considered to alleviate the risk of complications.

  Feb. 2025, Pituitary, 28(2) (2), 32 - 32, English, International magazine

  Scientific journal


• Efficacy of asfotase alfa in a patient with adult-onset hypophosphatasia without obvious bone lesions: a case report with review of literature.

  Seiji Nishikage, Masaaki Yamamoto, Takahiro Niikura, Yuiko Inaba, Tomoyuki Akiyama, Risa Harada, Yoshitada Sakai, Kenji Sugawara, Kanako Tachikawa, Toshimi Michigami, Wataru Ogawa, Hidenori Fukuoka

  The use of asfotase alfa, a bone-targeted recombinant alkaline phosphatase (ALP) enzyme, for the treatment of adult-onset hypophosphatasia (HPP) remains controversial, particularly in patients without evident bone abnormalities. We report the case of a 41-year-old woman with a history of Graves' disease, who presented with progressive joint pain and severe fatigue. Despite the absence of bone lesions, the patient was diagnosed with HPP based on persistently low alkaline phosphatase levels, family history, and a novel heterozygous ALPL variant (p.Ala205Thr). Functional analysis revealed a dominant-negative effect for this variant. Her symptoms significantly interfered with her daily activities owing to uncontrolled pain and loss of motor function and were so exacerbated that high doses of acetaminophen and NSAIDs were ineffective. Treatment with asfotase alfa was initiated based on multidisciplinary team consensus. Within 3 months of treatment initiation, her pain improved significantly, as indicated by reduced scores on the visual analog scale from 6.6 to 0.9, and elimination of the need for analgesics. Additionally, her grip strength increased, and her urinary phosphoethanolamine levels and serum pyridoxal 5'-phosphate/pyridoxal ratio decreased from 90.4 to 57.8 μmol/g·creatinine and from 4.6 to 0.4, respectively. These improvements have been maintained for more than 2 years. This case highlights the potential of asfotase alfa in effectively alleviating symptoms in patients with adult-onset HPP without bone lesions, emphasizing the importance of patient selection and outcome monitoring. We also discuss the key considerations for future treatment, supported by a literature review of asfotase alfa in adult patients with HPP.

  Jan. 2025, Endocrine journal, 72(4) (4), 437 - 445, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• When to decide on testosterone replacement despite dopamine agonist therapy in male prolactinomas?

  Hidenori Fukuoka

  Oct. 2024, Pituitary, 27(5) (5), 449 - 450, English, International magazine


• 急激な症状の顕在化と共に下垂体卒中を来したCushing病の一例

  高橋 直人, 樋口 雄一, 辻本 泰貴, 浦井 伸, 坂東 弘教, 山田 倫子, 山本 雅昭, 神澤 真紀, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2024, 日本内分泌学会雑誌, 100(2) (2), 590 - 590, Japanese


• 腫瘍別にMIBG集積性が異なった両側褐色細胞腫の1例

  乾 妃那, 坂東 弘教, 山本 雅昭, 神澤 真紀, 本村 悠馬, 福岡 秀規, 齋藤 剛, 小川 渉

  (一社)日本内分泌学会, Oct. 2024, 日本内分泌学会雑誌, 100(2) (2), 623 - 623, Japanese


• 腫瘍別にMIBG集積性が異なった両側褐色細胞腫の1例

  乾 妃那, 坂東 弘教, 山本 雅昭, 神澤 真紀, 本村 悠馬, 福岡 秀規, 齋藤 剛, 小川 渉

  (一社)日本内分泌学会, Oct. 2024, 日本内分泌学会雑誌, 100(2) (2), 623 - 623, Japanese


• 急激な症状の顕在化と共に下垂体卒中を来したCushing病の一例

  高橋 直人, 樋口 雄一, 辻本 泰貴, 浦井 伸, 坂東 弘教, 山田 倫子, 山本 雅昭, 神澤 真紀, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2024, 日本内分泌学会雑誌, 100(2) (2), 590 - 590, Japanese


• Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan.

  Yuka Oi-Yo, Masaaki Yamamoto, Shin Urai, Hironori Bando, Yuka Ohmachi, Yuma Motomura, Masaki Kobatake, Yasutaka Tsujimoto, Yuriko Sasaki, Masaki Suzuki, Naoki Yamamoto, Michiko Takahashi, Genzo Iguchi, Wataru Ogawa, Yutaka Takahashi, Hidenori Fukuoka

  PURPOSE: To elucidate the long-term efficacy and safety of growth hormone replacement therapy (GHRT) in Japanese patients with adult growth hormone deficiency (AGHD). METHODS: We conducted a retrospective study. A total of 110 patients with AGHD receiving GHRT were enrolled. Clinical and laboratory data were collected annually from the beginning of the study. Statistical analysis was performed using a linear mixed-effects model. RESULTS: Of all patients, 46.4% were males, 70.9% had adult-onset GHD, and follow-up was up to 196 months, with a median of 68 months. The insulin-like growth factor-1 standard deviation score increased after the start of GHRT and remained constant for more than 11 years. Seventeen patients were followed up for more than 11 years. The body mass index increased. Waist circumference decreased in the short term but increased in the long term. The diastolic blood pressure decreased 1-5 years after the start of GHRT, and the systolic blood pressure increased 11 years after GHRT. Moreover, a long-term decrease in low-density lipoprotein cholesterol, an increase in high-density lipoprotein cholesterol, and a decrease in aspartate aminotransferase and alanine aminotransferase levels were observed. The glycosylated hemoglobin level increased after 3 years. The bone mineral density in the lumbar spine and total hip increased significantly 3 years after the start of GHRT. Finally, the number of adverse events was eight. CONCLUSION: We demonstrated the metabolic effectiveness and safety of GHRT in Japanese patients with AGHD over a long follow-up period of 16 years.

  Sep. 2024, Pituitary, 27(5) (5), 605 - 613, English, International magazine

  Scientific journal


• Understanding negative feedback: Changes in high-molecular-weight adrenocorticotropic hormone in adrenocorticotropic hormone-independent Cushing's syndrome.

  Yuto Ichinose, Mei Nakatsuji, Hironori Bando, Masaaki Yamamoto, Maki Kanzawa, Kei Yoshino, Hidenori Fukuoka, Wataru Ogawa

  Cushing's syndrome is characterized by chronic glucocorticoid oversecretion and diverse clinical manifestations. Distinguishing between adrenocorticotropic hormone (ACTH)-independent and ACTH-dependent forms is crucial for determining treatment options. Plasma ACTH levels aid in the differential diagnosis, with undetectable or low levels suggesting ACTH-independent hypercortisolemia. ACTH is derived from pro-opiomelanocortin, and its processing involves prohormone convertase 1/3. High-molecular-weight ACTH is generally found in ACTH-producing pituitary tumors and ectopic ACTH syndrome. The mechanism of negative feedback and the process of high-molecular-weight ACTH alternation during ACTH-independent Cushing's syndrome remain unclear. A 40-year-old woman with hypertension and multiple fractures developed symptoms suggestive of Cushing's syndrome. Computed tomography revealed a left adrenocortical tumor along with atrophy of the right adrenal gland. ACTH levels were undetectable at the previous clinic, indicating ACTH-independent Cushing's syndrome. However, subsequent measurements at our hospital revealed non-suppressed ACTH (18.1 pg/mL), prompting further investigation. Gel exclusion chromatography confirmed the presence of high-molecular-weight ACTH. Metyrapone treatment decreased the cortisol levels. In this situation, in which ACTH levels should be elevated, a decrease in high-molecular-weight ACTH levels was observed. Histological findings revealed cortisol-producing adenoma without ACTH expression. This case highlights the importance of assay differences in evaluating ACTH concentrations and introduces a novel finding of circulating high-molecular-weight ACTH. The observed decline in high-molecular-weight ACTH levels suggests a potential time lag in the negative feedback within the hypothalamic-pituitary-adrenal axis exhibited by glucocorticoids. This temporal aspect of the regulation of ACTH-related molecules warrants further exploration to enhance our understanding of the hypothalamic-pituitary-adrenal axis feedback mechanism.

  Aug. 2024, Journal of neuroendocrinology, 36(11) (11), e13438, English, International magazine

  Scientific journal


• Acquired isolated ACTH deficiency co-occurrence with breast cancer irrespective of paraneoplastic syndrome: coincidence or inevitability.

  Shin Urai, Hironori Bando, Mei Nakatsuji, Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa

  SUMMARY: A 52-year-old female patient with breast cancer presented with a history of fatigue and malaise 1 year prior. She was diagnosed with isolated adrenocorticotropic hormone (ACTH) deficiency (IAD) on endocrinological examination. Her pituitary gland showed normal morphology. Paraneoplastic IAD associated with breast cancer was suspected; however, immunofluorescence staining revealed no ectopic ACTH or proopiomelanocortin expression in the tumor tissue. Subsequently, the patient was diagnosed with idiopathic acquired IAD concurrent with breast cancer, ruling out paraneoplastic syndrome. Although malignancy should be considered a potential cause of IAD, not all patients with concurrent IAD and malignancy necessarily develop paraneoplastic syndrome. LEARNING POINTS: Several adrenal insufficiency symptoms are similar to the nonspecific symptoms associated with malignancies, and therefore, the diagnosis of IAD remains challenging, especially in patients with cancer. When we encounter a case of IAD accompanied by a malignant tumor, it is important to suspect that paraneoplastic IAD, a novel clinical condition as secondary hypophysitis, may be the etiologic agent. Although malignant tumours should be considered a potential cause of IAD, not all patients with concurrent IAD and malignancy necessarily develop paraneoplastic autoimmune hypophysitis.

  Jul. 2024, Endocrinology, diabetes & metabolism case reports, 2024(3) (3), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Diagnostic dilemma in Cushing's syndrome: discrepancy between patient-reported and physician-assessed manifestations.

  Yuma Motomura, Shin Urai, Hironori Bando, Masaaki Yamamoto, Masaki Suzuki, Naoki Yamamoto, Genzo Iguchi, Wataru Ogawa, Hidenori Fukuoka

  PURPOSE: Early diagnosis and immediate treatment of Cushing's syndrome (CS) are critical for a better prognosis but remain a challenge. However, few comprehensive reports have focused on this issue or investigated whether patient-reported manifestations are consistent with physician-assessed symptoms of CS. This study aimed to clarify the differences in patient-reported and physician-assessed manifestations of signs and symptoms of CS that prevent early diagnosis. METHODS: This single-center retrospective study included 52 patients with CS (16 with Cushing's disease and 36 with adrenal CS). Upon clinical diagnosis, medical records were used to independently review the patient-reported and physician-assessed manifestations of typical (such as purple striae and proximal myopathy) and nonspecific features (such as hirsutism and hypertension). The correlations and differences between the patient-reported and physician-assessed manifestations were then analyzed. RESULTS: We observed a positive correlation between the total number of manifestations of nonspecific features reported by patients and those assessed by physicians, but not for typical features. Moreover, manifestations reported by the patients were less frequent than those assessed by physicians for typical features, leading to discrepancies between the two groups. In contrast, there were no differences in most nonspecific features between the patient-reported and physician-assessed manifestations. Notably, the concordance between patient-reported and physician-assessed manifestations of typical features was not associated with urinary free cortisol levels. CONCLUSION: Regardless of disease severity, patients often do not complain of the typical features of CS that are crucial for formulating a diagnosis.

  Jun. 2024, Endocrine, 86(1) (1), 417 - 427, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Dailyからweekly GH製剤への切り替え後よりインスリン量の週内調節が必要となった1型糖尿病合併汎下垂体機能低下症の1例

  樋口 雄一, 福岡 秀規, 芳野 啓, 坂東 弘教, 山本 雅昭, 廣田 勇士, 小川 渉

  (一社)日本内分泌学会, May 2024, 日本内分泌学会雑誌, 100(1) (1), 332 - 332, Japanese


• メチラポン,カベルゴリン併用からオシロドロスタットへの切り替えを行った94歳Cushing病の一例

  津本 一秀, 山本 雅昭, 坂東 弘教, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, May 2024, 日本内分泌学会雑誌, 100(1) (1), 370 - 370, Japanese


• The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature.

  Shin Urai, Seiji Tomofuji, Hironori Bando, Maki Kanzawa, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Genzo Iguchi, Wataru Ogawa

  Anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis, a paraneoplastic syndrome resulting from an autoimmune response against PIT-1, typically manifests with undetectable levels of growth hormone (GH) and prolactin (PRL), and significantly low levels of serum thyroid-stimulating hormone (TSH) at diagnosis. These hormonal levels are highly specific to this disease and serve as key diagnostic indicators. Herein, we present a detailed clinical course of a 69-year-old male with a history of gastric cancer and lymph node metastases who developed anti-PIT-1 hypophysitis after the initiation of immune checkpoint inhibitor (ICI) therapy, specifically nivolumab, oxaliplatin, and capecitabine. The patient was referred to our department owing to decreased TSH, free triiodothyronine (T3), and free thyroxine (T4) levels after two doses of nivolumab. Initially suspected as central hypothyroidism due to ICI-related hypophysitis, further assessment confirmed the diagnosis of anti-PIT-1 hypophysitis. Notably, GH, PRL, and TSH levels markedly declined, leading to complete deficiencies 2 months after the first nivolumab dose-a pattern consistent with that of previous cases of anti-PIT-1 hypophysitis. Therefore, this report not only presents an atypical subset of ICI-related hypophysitis but also delineates the process of hormone impairment leading to complete deficiencies in anti-PIT-1 hypophysitis. This case highlights the importance of vigilant monitoring for endocrine issues in patients undergoing ICI therapy, given the escalating incidence of immune-related adverse events associated with the extensive use of ICI therapy for various cancers.

  Apr. 2024, Journal of neuroendocrinology, 36(6) (6), e13395, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Thyroid dysfunction due to trace element deficiency-not only selenium but also zinc.

  Kohei Nagano, Yuma Motomura, Hironori Bando, Masaaki Yamamoto, Keitaro Kanie, Kei Yoshino, Yushi Hirota, Tomoko Yamada, Michiko Takahashi, Hidenori Fukuoka, Wataru Ogawa

  INTRODUCTION: Levels of serum selenium (Se) and zinc (Zn) decrease when total parental nutrition (TPN) is administered without trace element supplementation for just a few weeks. These trace elements are involved in thyroid hormone metabolism and their deficiencies cause thyroid dysfunction. However, there have been few reports on the details of its clinical course. CASE PRESENTATION: A 50-year-old man presented with thyroid dysfunction due to Se and Zn deficiency. He had an approximately 70-cm residual small intestine after undergoing intestinal resection and he received TPN without trace element supplementation for one and a half months. Blood tests revealed high levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) and low levels of free triiodothyronine (FT3). An abnormal pattern of thyroid function led to suspicion of Se deficiency. Se supplementation raised FT3 levels and lowered FT4 levels to within their respective reference ranges; however, subclinical hypothyroidism persisted with transient TSH elevation. We suspected that Zn deficiency also contributed to the hypothyroidism and, therefore, initiated Zn supplementation, which resulted in normalization of thyroid function. DISCUSSION: Although thyroid dysfunction has been reported in many studies conducted on Se and Zn deficiencies, hormonal patterns vary between reports. Further accumulation of cases, including detailed data on nutritional status, would be of benefit to elucidate the clinical reality. CONCLUSION: It is important to consider Se and Zn deficiencies when TSH and FT4 levels are elevated. It should also be noted that transient TSH elevation may be observed with Se supplementation.

  Apr. 2024, Hormones (Athens, Greece), 23(4) (4), 675 - 681, English, International magazine

  Scientific journal


• ACTH産生下垂体腫瘍におけるグルココルチコイドによるPOMC関連遺伝子の発現変化

  臼谷 真理, 高安 忍, 山田 正三, 福岡 秀規, 蔭山 和則

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1427 - 1427, Japanese


• 抗PD-1抗体阻害薬投与後に発症した膵臓MRI所見と血清CPRの経時的な変化を発症早期より確認し得た劇症1型様の糖尿病の一例

  友藤 清爾, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2024, 糖尿病, 67(Suppl.1) (Suppl.1), S - 176, Japanese


• 他科入院中患者に対する糖尿病内科医の併診業務の診療実態とその経時的推移

  芳野 啓, 西影 星二, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2024, 糖尿病, 67(Suppl.1) (Suppl.1), S - 190, Japanese


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1430 - 1430, Japanese


• BMHAにおけるアルドステロン自律性分泌とその病理学的検討

  合田 菜穂, 神澤 真紀, 辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 臼井 健, 高橋 裕, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1681 - 1681, Japanese


• 甲状腺濾胞上皮に裏装された副腎嚢胞の2例

  神澤 真紀, 今川 奈央子, 塚本 龍子, 神田 知紀, 福岡 秀規, 重村 克巳, 中村 保宏, 伊藤 智雄

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1676 - 1676, Japanese


• COVID-19関連の神経内分泌病態 COVID-19ワクチン接種後に著明な低Na血症と意識障害を呈した一例

  友藤 清爾, 坂東 弘教, 山本 雅昭, 芳野 啓, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1393 - 1393, Japanese


• BMHAにおけるアルドステロン自律性分泌とその病理学的検討

  合田 菜穂, 神澤 真紀, 辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 臼井 健, 高橋 裕, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1681 - 1681, Japanese


• 偽性Cushing症候群を契機に同定に至ったNR3C1新規変異の一例

  山本 直希, 木戸 希, 坂東 弘教, 山本 雅昭, 浦井 伸, 辻本 泰貴, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1423 - 1423, Japanese


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2024, 日本内分泌学会雑誌, 99(5) (5), 1430 - 1430, Japanese


• Two Cases of Adrenal Cysts Lined by Thyroid Follicular Epithelium: Addressing Cellular Origin and Malignancy Concerns.

  Maki Kanzawa, Tomonori Kanda, Hidenori Fukuoka, Katsumi Shigemura, Yasuhiro Nakamura, Tomoo Itoh

  Adrenal cysts lined by thyroid follicular epithelium are rare, with only 14 reported cases of "ectopic thyroid tissue" to date. While the primary consideration for differential diagnosis is thyroid carcinoma metastasis, exclusion of metastases is determined based on the absence of a primary thyroid lesion, serological euthyroidism, lack of thyroglobulin elevation, and absence of epithelial atypia. Herein, we report 2 cases of adrenal cysts lined by thyroid follicular epithelium. Case 1 was a 60-year-old woman with a right adrenal cyst. Case 2 was a 51-year-old man with a left adrenal cyst. Over time, both cysts became larger, necessitating an adrenalectomy. Cystic epithelia were lined with thyroid follicular epithelium, exhibiting moderate atypia. Human bone marrow endothelial cell marker-1 and galectin-3 were focally positive; CK19 was positive in Case 1, and all 3 markers were positive in Case 2, previously reported as an immunophenotype of thyroid carcinoma. CD56 expression was positive in both cases. Targeted next-generation sequencing revealed several low-frequency mutations; however, no major driver alterations for thyroid cancer were detected. Adrenal cysts can be lined by thyroid follicular epithelium. Challenges arise in determining the malignant or benign nature of adrenal cysts.

  Apr. 2024, JCEM case reports, 2(4) (4), luae058, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Fluctuations in serum adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.

  Hironori Bando, Masaaki Yamamoto, Shin Urai, Yuma Motomura, Yuriko Sasaki, Yuka Ohmachi, Masaki Kobatake, Yasutaka Tsujimoto, Yuka Oi-Yo, Masaki Suzuki, Naoki Yamamoto, Michiko Takahashi, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa

  Immune checkpoint inhibitor (ICI)-related hypophysitis (RH) is a common immune-related adverse event. The early detection of ICI-RH prevents life-threatening adrenal insufficiency. However, good predictors of secondary adrenal insufficiency in ICI-RH have not yet been reported. We hypothesized that fluctuations in serum adrenocorticotropic hormone (ACTH) and cortisol levels occur similarly to those in thyroid-stimulating hormone and thyroid hormone (thyroxine and triiodothyronine) levels in ICI-related thyroiditis. Here, we sought to test this hypothesis. Patients who used ICI and had a history of measurement of serum ACTH and cortisol concentrations were retrieved from electronic medical records, and those with a history of glucocorticoid use were excluded from the analysis. We evaluated fluctuations in serum ACTH and cortisol concentrations and the development of ICI-RH. For patients with ICI-RH, data at three points (before ICI administration (pre), maximum ACTH concentration (peak), and onset of ICI-RH) were analyzed to evaluate hormone fluctuations. A total of 202 patients were retrieved from the medical record. Forty-three patients were diagnosed with ICI-RH. Twenty-six out of 43 patients had sufficient data to evaluate fluctuations in serum ACTH and cortisol concentrations and no history of glucocorticoid use. ACTH concentrations changed from 37.4 (29.9-48.3) (pre) to 64.4 (46.5-106.2) (peak) pg/mL (1.72-fold increase, p=0.0026) in the patients with ICI-RH before the onset. There were no differences in cortisol concentrations between the pre and peak values in patients with ICI-RH. We also evaluated the fluctuations in serum ACTH and cortisol levels in patients who did not receive ICI-RH (62 cases). However, elevation of serum ACTH levels was not observed in patients without ICI-RH, suggesting that transient elevation of serum ACTH levels is a unique phenomenon in patients with ICI-RH. In conclusion, serum ACTH levels were transiently elevated in some patients with ICI-RH before the onset of secondary adrenal insufficiency. Monitoring the ACTH levels and their fluctuations may help predict the onset of ICI-RH.

  Feb. 2024, Journal for immunotherapy of cancer, 12(2) (2), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Effects of the cortisol milieu on tumor-infiltrating immune cells (TIICs) in corticotroph tumors.

  Maki Kanzawa, Hiroki Shichi, Keitaro Kanie, Masaaki Yamamoto, Naoki Yamamoto, Yasutaka Tsujimoto, Hironori Bando, Genzo Iguchi, Shigehisa Kitano, Naoko Inoshita, Shozo Yamada, Wataru Ogawa, Tomoo Itoh, Hidenori Fukuoka

  BACKGROUND: Corticotrophs are susceptible to lymphocyte cytotoxicity, as seen in hypophysitis, suggesting that an immunological approach may be a potential strategy for corticotroph-derived tumors. OBJECTIVES: We aimed clarify whether corticotroph tumors that induce hypercortisolemia (ACTHomas) could be targets for immunotherapy. METHODS: Tumor-infiltrating immune cells were immunohistochemically analyzed. ACTHomas (Naïve: ACTHomas without preoperative treatment) were compared with other pituitary tumors, and further divided into three different cortisol-exposed milieus: Naïve, Met (ACTHomas with preoperative metyrapone), and SCA (silent corticotroph adenomas). A three-dimensional cell culture of resected tumors was used to analyze the effects of immune checkpoint inhibitors. RESULTS: The number of tumor-infiltrating lymphocytes (TILs) was low in ACTHomas. Among these, the number of CD8+ cells was lower in ACTHomas than in both somatotroph) and gonadotroph tumors (P < 0.01 and P < 0.01, respectively). Then we compared the differences in TILs among Naïve, Met, and SCA. The number of CD4+ cells, but not CD8+ cells, was higher in both Met and SCA than in Naïve. Next, we investigated tumor-associated macrophages, which could negatively affect T cell infiltration. The numbers of CD163+ and CD204+ cells were positively associated with cortisol levels. Moreover, tumor size was positively correlated with the number of CD204+ cells. CONCLUSIONS: We found the possibility that ACTHomas were immunologically cold in a cortisol-independent manner. In contrast, the tumor infiltration of CD4+ cells and M2-macrophages were associated with the cortisol milieu. Future studies are needed to validate these results and develop effective immunotherapy while considering the cortisol milieu.

  Feb. 2024, Endocrinology, 165(4) (4), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Prolonged Hypokalemia Following Metyrapone Treatment for Primary Bilateral Macronodular Adrenal Cortical Disease.

  Yonekazu Kidawara, Miki Kakutani-Hatayama, Hidenori Fukuoka, Hidenori Koyama

  Surgical treatment is generally the standard therapeutic regimen used for primary bilateral macronodular adrenal cortical disease (PBMACD). However, in cases for which surgery is difficult or in which there is mild cortisol hypersecretion, metyrapone treatment can be selected. Although hypokalemia has been occasionally noted following metyrapone administration for Cushing syndrome associated with an adrenal adenoma, all such cases have been reported to be transient. Hypokalemia induced by metyrapone treatment is thought to occur due to excessive suppression of cortisol secretion, resulting in overproduction of adrenocorticotropic hormone from the pituitary gland, ultimately leading to excessive production of 11-deoxycorticosterone (DOC) in the adrenal cortex. A 52-year-old man diagnosed with PBMACD and started on metyrapone treatment subsequently presented with persistent hypokalemia. Interestingly, following initiation of metyrapone, blood test findings indicated marginal changes in serum cortisol, adrenocorticotropic hormone, and dehydroepiandrosterone sulfate levels, even when DOC levels were already markedly elevated. In addition to the effects of metyrapone, the present findings suggest a unique DOC synthesis regulatory mechanism involved in the pathogenesis of PBMACD.

  Feb. 2024, JCEM case reports, 2(2) (2), luae015, English, International magazine

  Scientific journal


• ハイブリッドクローズドループ(HCL)療法下でフルマラソンを完走した1型糖尿病の2例

  乾 妃那, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 84 - 84, Japanese


• 多職種連携のもとで実施した減量・代謝改善手術4例の経験

  芳野 啓, 廣田 勇士, 裏川 直樹, 山木 愛久, 西影 星二, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 85 - 85, Japanese


• 緩徐な経過を辿った免疫関連副作用(irAE)による1型様の糖尿病の1例

  齋藤 修一郎, 芳野 啓, 小畠 正樹, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 89 - 89, Japanese


• 複数の膵島関連自己抗体が陽性だがprobable判定であった緩徐進行1型糖尿病の1例

  湯川 恒弘, 深澤 圭似子, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 102 - 102, Japanese


• ハイブリッドクローズドループ(HCL)療法下でフルマラソンを完走した1型糖尿病の2例

  乾 妃那, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 84 - 84, Japanese


• 多職種連携のもとで実施した減量・代謝改善手術4例の経験

  芳野 啓, 廣田 勇士, 裏川 直樹, 山木 愛久, 西影 星二, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 85 - 85, Japanese


• 緩徐な経過を辿った免疫関連副作用(irAE)による1型様の糖尿病の1例

  齋藤 修一郎, 芳野 啓, 小畠 正樹, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 89 - 89, Japanese


• 複数の膵島関連自己抗体が陽性だがprobable判定であった緩徐進行1型糖尿病の1例

  湯川 恒弘, 深澤 圭似子, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Feb. 2024, 糖尿病, 67(2) (2), 102 - 102, Japanese


• The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.

  Yuka Ohmachi, Masaaki Yamamoto, Yuiko Inaba, Shohei Makino, Shin Urai, Risa Matsumoto, Hironori Bando, Keitaro Kanie, Yasutaka Tsujimoto, Yuma Motomura, Yuriko Sasaki, Yuka Oi-Yo, Naoki Yamamoto, Masaki Suzuki, Michiko Takahashi, Genzo Iguchi, Maki Kanzawa, Junya Furukawa, Katsumi Shigemura, Satoshi Mizobuchi, Wataru Ogawa, Hidenori Fukuoka

  PURPOSE: Preoperative medical management is critical to prevent intraoperative cardiovascular complications in patients with pheochromocytomas and paragangliomas (PPGLs). Initial treatment involves α-adrenergic receptor blockers. However, while the routine use of metyrosine alongside these blockers is not strongly recommended due to a lack of evidence supporting its efficacy and associated safety concerns, there are previous studies on combination therapy with phenoxybenzamine and metyrosine. There are few reports on combination therapy with the selective α1-adrenergic receptor blocker doxazosin. Therefore, we investigated this combination treatment, which theoretically can affect perioperative outcomes in patients with PPGLs. To our knowledge, this is the first such study. METHODS: This retrospective single-center observational study involved 51 patients who underwent surgical resection of PPGLs at Kobe University Hospital between 2014 and 2022. All patients received doxazosin at maximum doses. Fourteen patients received concomitant metyrosine, while 37 received doxazosin alone. Their perioperative outcomes were compared. RESULTS: No severe event, such as acute coronary syndrome, was observed in either group. Intraoperatively, the doxazosin + metyrosine group exhibited a lower median minimum systolic blood pressure (56 [54-60] vs. 68 [59-74] mmHg, P = 0.03) and required lower median remifentanil (P = 0.04) and diltiazem (P = 0.02) doses than the doxazosin-alone group. CONCLUSION: The combination of metyrosine and doxazosin as a preoperative treatment for PPGLs affects intraoperative circulatory hemodynamics, such as a reduced occurrence of blood pressure elevation during surgery. Further research is necessary to identify patients who will benefit most from this combination treatment.

  Jan. 2024, Endocrine, 84(2) (2), 694 - 703, English, International magazine

  Scientific journal


• Metyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing's syndrome.

  Yasutaka Tsujimoto, Naoki Yamamoto, Hironori Bando, Masaaki Yamamoto, Yuka Ohmachi, Yuma Motomura, Yuka Oi-Yo, Yuriko Sasaki, Masaki Suzuki, Shin Urai, Michiko Takahashi, Genzo Iguchi, Wataru Ogawa, Hidenori Fukuoka

  Metyrapone is commonly used in the initial management of Cushing's syndrome to reduce hypercortisolemia, but its optimal dosage and timing can vary significantly between patients. Currently, there are limited guidelines on adjustment methods for its administration to individual needs. This study aimed to evaluate responsiveness of each patient to metyrapone and identify the patient characteristics associated with the indices of cortisol responsiveness following a low-dose metyrapone. This single-center retrospective observational study included 15 treatment-naïve patients, 7 of whom had Cushing's disease and 8 had adrenal Cushing's syndrome. Serum cortisol levels were measured hourly from the time of administration of 250 mg of metyrapone up to four hours afterward. Parameters analyzed included the nadir of serum cortisol levels (Fnadir), the difference between basal and nadir serum cortisol levels (ΔF), the time to nadir, and the characteristics of the patients. As a result, cortisol suppression curves showed significant variability among patients, particularly in the time to nadir. While the median time to nadir was 2 hours, 20% of patients required 4 hours or more, and these responses were not associated with patient characteristics. Fnadir was positively correlated with early-morning serum cortisol levels, serum cortisol levels after low-dose dexamethasone suppression test (LDDST), and urinary free cortisol (UFC) levels, whereas ΔF was positively correlated with late-night serum cortisol levels, serum cortisol levels after LDDST, and UFC levels. In conclusion, the duration of response to metyrapone appeared unpredictable in patients with Cushing's syndrome and did not correlate with patient characteristics at baseline. Tracking the effect of metyrapone following a single low-dose administration may explain this variability and provide insights for optimizing individual dosing regimens. Further studies are required to validate these findings and guide more personalized treatment adjustments.

  2024, Frontiers in endocrinology, 15, 1511155 - 1511155, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.

  Yuma Motomura, Shin Urai, Yushi Hirota, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Wataru Ogawa

  We present a case of type 1 diabetes mellitus (T1DM) that developed in a 53-year-old man after long-term treatment with nivolumab. The patient underwent total gastrectomy for gastric cancer at 40 years of age, and he was started on nivolumab at age 48 years for treatment of a recurrent lesion that proved resistant to standard chemotherapy. Nivolumab treatment resulted in complete response, but, after the 136th infusion of the drug at age 53 years, the patient was hospitalized for sudden onset of diabetic ketoacidosis. He was diagnosed with immune checkpoint inhibitor-induced T1DM (ICI-DM), which developed 1988 days (284 weeks) after initiation of nivolumab. HLA typing revealed disease susceptibility alleles for both fulminant T1DM and ICI-DM. With the increased survival after the ICI treatment, delayed-onset irAEs after long-term use of ICI have been reported; however, delayed-onset ICI-DM remains to be elucidated. This case provides important insight into ICI-DM that develops after prolonged ICI administration, and it suggests that patients should be monitored for ICI-DM regardless of the duration of ICI therapy.

  Jan. 2024, Diabetology international, 15(1) (1), 130 - 134, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Clinical features of anti-PIT-1 hypophysitis: A new aspect of paraneoplastic autoimmune condition.

  Shin Urai, Genzo Iguchi, Keitaro Kanie, Hironori Bando, Masaaki Yamamoto, Yuka Oi, Yuya Kashitani, Keiji Iida, Maki Kanzawa, Hidenori Fukuoka, Michiko Takahashi, Yasushi Shintani, Wataru Ogawa, Yutaka Takahashi

  The pathogenesis of anti-pituitary-specific transcription factor 1 (PIT-1) hypophysitis was gradually revealed as cases emerged. Our comprehensive analysis, including all reported cases, identified a new instance of anti-PIT-1 hypophysitis post-immune checkpoint inhibitor therapy. All nine patients exhibited extremely low GH, PRL, and TSH levels; two had a slightly atrophic pituitary gland; four had thymoma, and five had malignant neoplasms of diffuse large B-cell lymphoma (DLBCL) and other origins. Patients with thymoma showed multiple autoimmune diseases. HLA-A*24:02 and/or A*02:06 were present in six and DR53 in five cases analyzed. High anti-PIT-1 antibody titers and ectopic PIT-1 expression in the cytosol and nucleus of the tumor tissues were observed in patients with thymoma or DLBCL, whereas it was exclusively observed in the nuclei of a bladder cancer patient. These findings provide new insights into the pathophysiology of paraneoplastic autoimmune hypophysitis.

  Dec. 2023, European journal of endocrinology, 190(1) (1), K1-K7, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Newer parameters of the octreotide test in patients with acromegaly.

  Shin Urai, Masaaki Yamamoto, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Keitaro Kanie, Yasunori Fujita, Hironori Bando, Hidenori Fukuoka, Michiko Takahashi, Genzo Iguchi, Yutaka Takahashi, Wataru Ogawa

  PURPOSE: Predicting the therapeutic effects of first-generation somatostatin receptor ligands (fg-SRLs) is important when assessing or planning effective treatment strategies in patients with acromegaly. The oft-used maximum growth hormone (GH) suppression rate parameter of the octreotide test has a suboptimal predictive value. Therefore, this study explored newer parameters of the octreotide test for predicting the therapeutic effect of long-acting fg-SRLs. METHODS: In this single-center retrospective study, the octreotide test parameters and the therapeutic effects of fg-SRL at 3 months were investigated in 45 consecutive treatment-naïve patients with acromegaly between April 2008 and March 2023. Additionally, the relationship between the octreotide test parameters and the therapeutic effects of fg-SRLs was investigated. Tumor shrinkage was evaluated based on changes in the longitudinal diameter of the macroadenomas. The area GH suppression rate-time under the curve (AUC) and the time to nadir GH level were calculated and compared with the maximum GH suppression rate. RESULTS: The AUC estimated reductions in serum insulin-like growth factor I, and tumor shrinkage. The time to nadir GH level predicted tumor shrinkage more robustly than the maximum GH suppression rate in patients with macroadenoma. CONCLUSION: The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.

  Nov. 2023, Pituitary, English, International magazine

  Scientific journal


• Composite paraganglioma-ganglioneuroma with atypical catecholamine profile and phenylethanolamine N-methyltransferase expression: a case report and literature review.

  Yuriko Sasaki, Maki Kanzawa, Masaaki Yamamoto, Keitaro Kanie, Hironori Bando, Kei Yoshino, Yushi Hirota, Katsumi Shigemura, Masato Fujisawa, Wataru Ogawa, Hidenori Fukuoka

  Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that secrete catecholamines and arise from the adrenal medulla or extra-adrenal sympathetic ganglia. These tumors secrete adrenaline and noradrenaline, but paragangliomas usually produce only noradrenaline because of the lack of phenylethanolamine N-methyltransferase (PNMT) expression. Composite paragangliomas, which are complex tumors consisting of multiple types of neuroblastic cells, are extremely rare. We present the case of a 46-year-old woman with an atypical catecholamine profile who was preoperatively diagnosed with pheochromocytoma. However, postoperative pathology revealed that the patient had an extra-adrenal paraganglioma accompanied by a ganglioneuroma, which led to the diagnosis of a composite tumor. Interestingly, PNMT is expressed in both paragangliomas and ganglioneuromas. In addition, we reviewed reported composite paragangliomas and compared their clinical features with those of composite pheochromocytomas. We also discuss various aspects of the etiology of composite paragangliomas and the mechanism by which PNMT is expressed in tumors.

  Nov. 2023, Endocrine journal, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• SAP療法における基礎インスリン設定量とHLC導入後の基礎インスリン注入量の比較検討

  西垣 智子, 山本 あかね, 芳野 啓, 上田 真莉子, 松岡 敦子, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  日本先進糖尿病治療研究会, Nov. 2023, 日本先進糖尿病治療研究会雑誌, 17(2) (2), 92 - 92, Japanese


• 74歳で診断に至ったSCS合併Sheehan症候群の一例

  草壁 明日香, 坂東 弘教, 山本 雅昭, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 587 - 587, Japanese


• 染色体、薬剤、環境の複合的な寄与が考えられた骨粗鬆症の一例

  友藤 清爾, 坂東 弘教, 山本 雅昭, 芳野 啓, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 608 - 608, Japanese


• ラトケ嚢胞における染色マーカーの有用性と臨床像の関連

  佐々木 百合子, 坂東 弘教, 神澤 真紀, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 井口 元三, 山本 雅昭, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, Japanese


• 偽性Cushing症候群から発見に至ったNR3C1新規変異の一例

  山本 直希, 木戸 希, 坂東 弘教, 山本 雅昭, 浦井 伸, 辻本 泰貴, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, Japanese


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 590 - 590, Japanese


• クッシング症候群におけるメチラポン単回投与への反応性の検討

  辻本 泰貴, 山本 雅昭, 坂東 弘教, 山本 直希, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 浦井 伸, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 622 - 622, Japanese


• Bilateral Suppressionを呈したアルドステロン産生腺腫の一例

  西垣 智子, 山本 雅昭, 樋口 雄一, 芳野 啓, 坂東 弘教, 松代 啓吾, 元津 倫幸, 祖父江 慶太郎, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 561 - 561, Japanese


• 家族性PBMAHを呈したARMC5_p.R173*ヘテロ接合型の1例

  樋口 雄一, 坂東 弘教, 芳野 啓, 山本 雅昭, 高橋 路子, 臼井 健, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 561 - 561, Japanese


• ラトケ嚢胞における染色マーカーの有用性と臨床像の関連

  佐々木 百合子, 坂東 弘教, 神澤 真紀, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 井口 元三, 山本 雅昭, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, Japanese


• 偽性Cushing症候群から発見に至ったNR3C1新規変異の一例

  山本 直希, 木戸 希, 坂東 弘教, 山本 雅昭, 浦井 伸, 辻本 泰貴, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, Japanese


• メチラポン漸増時にPCP増悪を認めたクッシング病疑いの一例

  木戸 希, 山本 雅昭, 坂東 弘教, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 581 - 581, Japanese


• 74歳で診断に至ったSCS合併Sheehan症候群の一例

  草壁 明日香, 坂東 弘教, 山本 雅昭, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 587 - 587, Japanese


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 590 - 590, Japanese


• 染色体、薬剤、環境の複合的な寄与が考えられた骨粗鬆症の一例

  友藤 清爾, 坂東 弘教, 山本 雅昭, 芳野 啓, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 608 - 608, Japanese


• クッシング症候群におけるメチラポン単回投与への反応性の検討

  辻本 泰貴, 山本 雅昭, 坂東 弘教, 山本 直希, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 浦井 伸, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2023, 日本内分泌学会雑誌, 99(2) (2), 622 - 622, Japanese


• Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement

  Stephan Petersenn, Maria Fleseriu, Felipe F. Casanueva, Andrea Giustina, Nienke Biermasz, Beverly M. K. Biller, Marcello Bronstein, Philippe Chanson, Hidenori Fukuoka, Monica Gadelha, Yona Greenman, Mark Gurnell, Ken K. Y. Ho, Jürgen Honegger, Adriana G. Ioachimescu, Ursula B. Kaiser, Niki Karavitaki, Laurence Katznelson, Maya Lodish, Dominique Maiter, Hani J. Marcus, Ann McCormack, Mark Molitch, Christopher A. Muir, Sebastian Neggers, Alberto M. Pereira, Rosario Pivonello, Kalmon Post, Gerald Raverot, Roberto Salvatori, Susan L. Samson, Ilan Shimon, Joanna Spencer-Segal, Greisa Vila, John Wass, Shlomo Melmed

  Springer Science and Business Media LLC, Sep. 2023, Nature Reviews Endocrinology, 19(12) (12), 722 - 740

  Scientific journal


• Instability of harmonized thyroid-stimulating hormone immunoassays in clinical practice.

  Kenichi Uto, Hironori Bando, Hidenori Fukuoka, Masaaki Yamamoto, Ayako Ogasahara, Shoko Ono, Chinami Oyabu, Itsuko Sato, Takamitsu Imanishi, Jun Saegusa, Wataru Ogawa, Yoshihiko Yano

  OBJECTIVE: Thyroid-stimulating hormone (TSH) harmonization is effective in minimizing differences between the results of immunoassays in healthy subjects. However, the effectiveness of TSH harmonization in clinical practice has not been investigated. The aim of this study was to evaluate the instability of TSH harmonization in clinical practice. METHODS: We compared the reactivities of four harmonized TSH immunoassays using combined difference plots of 431 patients. We selected patients with statistically significant deviations in TSH levels and analyzed their thyroid hormone levels and clinical characteristics. RESULTS: The combined difference plots showed that one harmonized TSH immunoassay exhibited markedly different reactivity even after TSH harmonization compared with the other three immunoassays. Among 109 patients with mild-to-moderate elevation of TSH levels, we selected 15 patients with statistically significant deviations in TSH levels according to the difference plots of three harmonized TSH immunoassays, excluding one immunoassay that showed different reactivity. The thyroid hormone levels of three patients were misclassified as hypothyroidism or normal due to deviating TSH levels. In terms of clinical characteristics, these patients were in poor nutritional status and general condition, possibly due to their severe illness (e.g., advanced metastatic cancer). CONCLUSION: We have confirmed that TSH harmonization in clinical practice is relatively stable. However, some patients showed deviating TSH levels in the harmonized TSH immunoassays, indicating the need for caution, particularly in poorly nourished patients. This finding suggests the presence of factors that contribute to the instability of TSH harmonization in such cases. Further investigation is warranted to validate these results.

  Jun. 2023, Clinical endocrinology, English, International magazine

  Scientific journal


• BMAHにおけるアルドステロン自律性分泌の検討

  合田 菜穂, 福岡 秀規, 神澤 真紀, 辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 臼井 健, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 395 - 395, Japanese


• 免疫チェックポイント阻害薬が惹起した腫瘍随伴性ACTH単独欠損症

  渡邊 美季, 浦井 伸, 坂東 弘教, 本村 悠馬, 神澤 真紀, 立原 素子, 山本 雅昭, 福岡 秀規, 井口 元三, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 295 - 295, Japanese


• 抗PIT-1下垂体炎新規2例を加えた9症例の臨床的特徴

  浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 大井 佑夏, 樫谷 悠也, 飯田 啓二, 神澤 真紀, 福岡 秀規, 井口 元三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 311 - 311, Japanese


• ラトケ嚢胞の病理学的診断におけるKRT8の有用性

  佐々木 百合子, 坂東 弘教, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 大町 侑香, 辻本 泰貴, 大井 佑夏, 鈴木 正暉, 山本 直希, 井口 元三, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 332 - 332, Japanese


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(Suppl.Update) (Suppl.Update), 51 - 54, Japanese


• 免疫チェックポイント阻害薬が惹起した腫瘍随伴性ACTH単独欠損症

  渡邊 美季, 浦井 伸, 坂東 弘教, 本村 悠馬, 神澤 真紀, 立原 素子, 山本 雅昭, 福岡 秀規, 井口 元三, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 295 - 295, Japanese


• ゲル濾過分析でACTHの性状を確認し得た異所性ACTH産生腫瘍の一例

  中辻 萌, 坂東 弘教, 山本 雅昭, 芳野 啓, 松田 琢磨, 辻本 泰貴, 本村 悠馬, 土井 健史, 田中 雄悟, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 296 - 296, Japanese


• 血中に大分子ACTH分泌を認めたコルチゾール産生副腎腺腫の一例

  一ノ瀬 祐人, 中辻 萌, 坂東 弘教, 山本 雅昭, 芳野 啓, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 301 - 301, Japanese


• 抗PIT-1下垂体炎新規2例を加えた9症例の臨床的特徴

  浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 大井 佑夏, 樫谷 悠也, 飯田 啓二, 神澤 真紀, 福岡 秀規, 井口 元三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 311 - 311, Japanese


• ラトケ嚢胞の病理学的診断におけるKRT8の有用性

  佐々木 百合子, 坂東 弘教, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 大町 侑香, 辻本 泰貴, 大井 佑夏, 鈴木 正暉, 山本 直希, 井口 元三, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 332 - 332, Japanese


• PPGLの周術期におけるメチロシン併用に関する検討

  大町 侑香, 山本 雅昭, 坂東 弘教, 巻野 将平, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 336 - 336, Japanese


• BMAHにおけるアルドステロン自律性分泌の検討

  合田 菜穂, 福岡 秀規, 神澤 真紀, 辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 臼井 健, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(1) (1), 395 - 395, Japanese


• 骨粗鬆症を契機に診断に至ったLoeys-Dietz症候群の一例

  辻本 泰貴, 山本 直希, 福満 隼人, 坂東 弘教, 山本 雅昭, 廣田 勇士, 田中 敬子, 森貞 直哉, 長坂 美和子, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(Suppl.Update) (Suppl.Update), 29 - 31, Japanese


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, May 2023, 日本内分泌学会雑誌, 99(Suppl.Update) (Suppl.Update), 51 - 54, Japanese


• GAD抗体,IA-2抗体重複陽性であった緩徐進行1型糖尿病の1例

  永野 浩平, 本村 悠馬, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2023, 糖尿病, 66(4) (4), 292 - 292, Japanese


• 複数の被疑薬が考えられたインスリン自己免疫症候群の1例

  桂 由佳梨, 芳野 啓, 浦井 伸, 内山 奏, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2023, 糖尿病, 66(4) (4), 302 - 302, Japanese


• 残存インスリン時間の調整が低血糖減少に有効であったHCL加療中1型糖尿病の1例

  黒川 晟, 芳野 啓, 大町 侑香, 上田 真莉子, 山本 あかね, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2023, 糖尿病, 66(4) (4), 307 - 307, Japanese


• Gonadotroph tumorとsomatotroph tumorのcollisionと考えられた一例

  神澤 真紀, 辻本 泰貴, 山本 雅昭, 蟹江 慶太郎, 坂東 弘教, 中井 友昭, 篠山 隆司, 井下 尚子, 福岡 秀規, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, Mar. 2023, 日本内分泌学会雑誌, 98(5) (5), 1636 - 1636, Japanese


• ACTH産生下垂体腺腫初代培養におけるグルココルチコイドによるPOMC関連遺伝子発現変化の解析

  臼谷 真理, 高安 忍, 山田 正三, 福岡 秀規, 志智 大城, 蔭山 和則, 大門 眞

  (一社)日本内分泌学会, Mar. 2023, 日本内分泌学会雑誌, 98(5) (5), 1395 - 1395, Japanese


• The Impact of Multicultural Interfacility Video Case Conference: A Novel Education Model After the COVID Pandemic.

  Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka

  CONTEXT: The COVID-19 pandemic challenged undertaking gradual educational activities for residency and fellowship trainees. However, recent technological advances have enabled broadening active learning opportunities through international online conferences. OBJECTIVE: The format of our international online endocrine case conference, launched during the pandemic, is introduced. The objective impact of this program on trainees is described. METHODS: Four academic facilities developed a semiannual international collaborative endocrinology case conference. Experts were invited as commentators to facilitate in-depth discussion. Six conferences were held between 2020 and 2022. After the fourth and sixth conferences, anonymous multiple-choice online surveys were administered to all attendees. RESULTS: Participants included trainees and faculty. At each conference, 3 to 5 cases of rare endocrine diseases from up to 4 institutions were presented, mainly by trainees. Sixty-two percent of attendees reported 4 facilities as the appropriate size for the collaboration to maintain active learning in case conferences. Eighty-two percent of attendees preferred a semiannual conference. The survey also revealed the positive impact on trainees' learning regarding diversity of medical practice, academic career development, and confidence in honing of presentation skills. CONCLUSION: We present an example of our successful virtual global case conference to enhance learning about rare endocrine cases. For the success of the collaborative case conference, we suggest smaller cross-country institutional collaborations. Preferably, they would be international, semiannually based, and with recognized experts as commentators. Since our conference has engendered multiple positive effects on trainees and faculty, continuation of virtual education should be considered even after the pandemic era.

  Feb. 2023, Journal of the Endocrine Society, 7(4) (4), bvad023, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 妊娠中に成長ホルモン補充療法の再開を要したPIT-1異常症の1例

  辻本 泰貴, 坂東 弘教, 山本 雅昭, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 山本 直希, 鈴木 正暉, 浦井 伸, 井口 元三, 高橋 路子, 栖田 園子, 尾崎 可奈, 出口 雅士, 洪 聖暖, 坊 亮輔, 粟野 宏之, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Feb. 2023, 日本内分泌学会雑誌, 98(4) (4), 1035 - 1035, Japanese


• 妊娠中に成長ホルモン補充療法の再開を要したPIT-1異常症の1例

  辻本 泰貴, 坂東 弘教, 山本 雅昭, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 山本 直希, 鈴木 正暉, 浦井 伸, 井口 元三, 高橋 路子, 栖田 園子, 尾崎 可奈, 出口 雅士, 洪 聖暖, 坊 亮輔, 粟野 宏之, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Feb. 2023, 日本内分泌学会雑誌, 98(4) (4), 1035 - 1035, Japanese


• Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors.

  Yasunori Fujita, Fumika Kamitani, Masaaki Yamamoto, Hidenori Fukuoka, Yushi Hirota, Nobuharu Nishiyama, Naho Goda, Yuko Okada, Yuiko Inaba, Hiroki Nakajima, Yukako Kurematsu, Keitaro Kanie, Hiroki Shichi, Shin Urai, Masaki Suzuki, Naoki Yamamoto, Hironori Bando, Genzo Iguchi, Hirotaka Suto, Yohei Funakoshi, Naomi Kiyota, Yutaka Takahashi, Wataru Ogawa

  CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.

  Jan. 2023, Journal of the Endocrine Society, 7(3) (3), bvad002, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody.

  Shin Urai, Miki Watanabe, Hironori Bando, Yuma Motomura, Masaaki Yamamoto, Motoko Tachihara, Maki Kanzawa, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa

  INTRODUCTION: A recently discovered facet of paraneoplastic adrenocorticotropic hormone (ACTH) deficiency exists in two forms: a paraneoplastic spontaneous isolated ACTH deficiency (IAD) and an immune checkpoint inhibitor (ICI)-related hypophysitis. Autoantibodies against corticotrophs, such as circulating anti-proopiomelanocortin (POMC) antibodies are considered disease markers. However, the number of identified cases was limited, implying that the characteristics of these autoantibodies are not fully understood. METHODS: We investigate circulating autoimmune autoantibodies in detail through a novel case of IAD that developed as a paraneoplastic autoimmune ACTH deficiency. RESULTS: The patient developed IAD after 25 weeks of ICI therapy for metastasis of large-cell neuroendocrine carcinoma at 69 years of age. Ectopic ACTH expression and infiltration of CD3+, CD4+, CD8+, and CD20+ lymphocytes were observed in the tumor tissues and circulating anti-POMC antibodies were detected specifically in the patient's serum. Moreover, detailed analyses of immunofluorescence staining using patient serum revealed that the recognition site of the autoantibody was ACTH25-39, which had not been identified in previous cases of paraneoplastic autoimmune ACTH deficiency. CONCLUSION: This case involved a combination of paraneoplastic spontaneously acquired IAD and ICI-related hypophysitis occupying the middle ground. Moreover, our study reveals new aspects of anti-POMC antibodies in patients with paraneoplastic ACTH deficiency. This report expands our understanding of the immunological landscape and provides new insights for the identification of antibodies associated with paraneoplastic autoimmune ACTH deficiency.

  2023, Frontiers in immunology, 14, 1284301 - 1284301, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Adrenocortical adenoma arising from adreno-hepatic fusion: A pitfall for an overdiagnosis.

  Eiki Inoue, Rena Uno, Maki Kanzawa, Yasuyoshi Okamura, Keisuke Okada, Tomonori Kanda, Hidenori Fukuoka, Katsumi Shigemura, Yasuhiro Nakamura, Masato Fujisawa, Wataru Ogawa, Tomoo Itoh

  Dec. 2022, Pathology international, 73(1) (1), 61 - 63, English, International magazine


• 1型糖尿病患者における心エコー図を用いた左室拡張機能の検討

  横井 愛紗, 浦井 伸, 山本 雅昭, 福岡 秀規, 岡田 裕子, 田中 秀和, 廣田 勇士, 小川 渉

  日本先進糖尿病治療研究会, Dec. 2022, 日本先進糖尿病治療研究会雑誌, 16(2) (2), 63 - 63, Japanese


• Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency

  Yutaka Takahashi, Beverly M. K. Biller, Hidenori Fukuoka, Ken K. Y. Ho, Michael Højby Rasmussen, Navid Nedjatian, Claus Sværke, Kevin C. J. Yuen, Gudmundur Johannsson

  Abstract Purpose The long-term effects of long-acting growth hormone (LAGH) analogues on glucose metabolism in adult growth hormone deficiency (AGHD) are not known. We investigated the impact of LAGH somapacitan, administered once-weekly, on glucose metabolism in patients with AGHD. Methods In post hoc-defined analyses, we compared the effects of somapacitan with daily growth hormone (GH) and placebo on fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) in patients with AGHD across a unique data set from three phase 3 randomized controlled trials (REAL 1, REAL 2 and REAL Japan). Results No new cases of diabetes mellitus were reported with somapacitan. Among GH-naïve patients (n = 120 somapacitan, n = 119 daily GH), higher changes from baseline in FPG, HOMA-IR and fasting insulin levels were observed with daily GH versus somapacitan at 34 weeks, but not at 86 weeks. HbA1c and HOMA-β did not differ between groups at either timepoint. Among treatment-naïve patients, sex, age, fasting insulin, glucose tolerance status and body mass index did not influence changes in glucose metabolism. In previously treated patients (REAL 1 extension: n = 51 somapacitan, n = 52 daily GH; REAL 2: n = 61 and n = 31, respectively; REAL Japan: n = 46 and n = 16, respectively), the difference in changes from baseline were not statistically significant between somapacitan and daily GH for any glucose metabolism parameters. Conclusions Somapacitan, compared with daily GH, did not adversely affect glucose metabolism up to 86 weeks in a large cohort of treatment-naïve or previously treated patients with AGHD. Trial registrations (date of registration): NCT02229851 (2 September 2014), NCT02382939 (3 March 2015), NCT03075644 (7 March 2017).

  Springer Science and Business Media LLC, Nov. 2022, Pituitary, 26(1) (1), 57 - 72

  Scientific journal


• Successful diagnosis and treatment of pheochromocytoma during severe coronavirus disease 2019 (COVID-19): a case report.

  Yasutaka Tsujimoto, Masaaki Yamamoto, Seiji Nishikage, Keitaro Kanie, Maki Kanzawa, Hironori Bando, Kei Yoshino, Yushi Hirota, Hidenori Fukuoka, Wataru Ogawa

  Pheochromocytoma is a rare but life-threatening condition due to catecholamine release induced by drug treatments such as β-blockers or glucocorticoids. We present a case of hypertensive crisis due to pheochromocytoma, induced after the initiation of dexamethasone and landiolol during intensive care for severe coronavirus disease 2019 (COVID-19). Based on a detailed medical history review, the patient was previously diagnosed with primary aldosteronism by confirmatory tests, moreover, an abdominal computed tomography scan identified an adrenal tumor 2 years before current admission. We tentatively diagnosed the patient with pheochromocytoma and initiated α-blockers without conducting a catecholamine report, leading to stable hemodynamics. We present a successfully managed case of pheochromocytoma concomitant with COVID-19, which has become a global crisis.

  Nov. 2022, Endocrine journal, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• High Cortisol Concentration Without Cushingoid Appearance.

  Hironori Bando, Keitaro Kanie, Masaaki Yamamoto, Hidenori Fukuoka

  Nov. 2022, The American journal of medicine, English, International magazine


• セレン欠乏症により,肝障害と甲状腺機能異常を来した一例

  永野 浩平, 本村 悠馬, 蟹江 慶太郎, 坂東 弘教, 山田 倫子, 高橋 路子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2022, 日本内分泌学会雑誌, 98(2) (2), 575 - 575, Japanese


• 嚢胞形成を伴う褐色細胞腫4例の嚢胞内カテコラミン分画の検討

  影山 智子, 坂東 弘教, 山本 雅昭, 蟹江 慶太郎, 神澤 真紀, 辻本 泰貴, 花山 亜沙, 芳野 啓, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2022, 日本内分泌学会雑誌, 98(2) (2), 598 - 598, Japanese


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2022, 日本内分泌学会雑誌, 98(2) (2), 605 - 605, Japanese


• セレン欠乏症により,肝障害と甲状腺機能異常を来した一例

  永野 浩平, 本村 悠馬, 蟹江 慶太郎, 坂東 弘教, 山田 倫子, 高橋 路子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2022, 日本内分泌学会雑誌, 98(2) (2), 575 - 575, Japanese


• 嚢胞形成を伴う褐色細胞腫4例の嚢胞内カテコラミン分画の検討

  影山 智子, 坂東 弘教, 山本 雅昭, 蟹江 慶太郎, 神澤 真紀, 辻本 泰貴, 花山 亜沙, 芳野 啓, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2022, 日本内分泌学会雑誌, 98(2) (2), 598 - 598, Japanese


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2022, 日本内分泌学会雑誌, 98(2) (2), 605 - 605, Japanese


• Survey of glucocorticoid dose escalation in patients with adrenal insufficiency during the peri-COVID-19 vaccination period.

  Hironori Bando, Masaaki Yamamoto, Michiko Takahashi, Keitaro Kanie, Yuriko Sasaki, Yuka Oi, Seiji Tomofuji, Kaori Hozumi, Seiji Nishikage, Shin Urai, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Genzo Iguchi, Hidenori Fukuoka, Wataru Ogawa

  There is uncertainty regarding the need for COVID-19 peri-vaccination glucocorticoid coverage in patients with adrenal insufficiency. In this survey conducted in a single tertiary medical institution, 167 consecutive outpatients taking physiological glucocorticoids because of adrenal insufficiency were included. The patients declared if they developed an adrenal crisis after vaccination, and the amount and duration of an increase in their glucocorticoid dosage, if any. None of the patients without preventive glucocorticoid increase suffered an adrenal crisis after COVID-19 vaccination. Only 8.3% (14 cases) and 27.5% (46 cases) of the patients needed to escalate the dose of glucocorticoids when systemic symptoms appeared after the first and second injections, respectively. Glucocorticoids were increased in patients <60 years of age more than in patients ≥60 years of age at the time of both the first (p = 0.026) and second injections (p = 0.005). Sex and the causes of adrenal insufficiency were not associated with the frequency of the patients who needed glucocorticoid dose escalation. In the cases with increased glucocorticoids, the median dosage for escalation was 10 mg (hydrocortisone equivalent). In conclusion, even without prophylactic glucocorticoid administration, adrenal crisis did not occur during the peri-COVID-19 vaccination period. The dose escalation of steroid was more frequent in younger patients following the second vaccination. Careful monitoring of adverse effects and the appropriate management of glucocorticoids when necessary are essential following COVID-19 vaccinations.

  Sep. 2022, Endocrine journal, 70(1) (1), 89 - 95, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The impact of hormonal dynamics and serum sodium fluctuations on symptomatic vasospasm after subarachnoid hemorrhage.

  Tomoaki Harada, Yoichi Uozumi, Hidenori Fukuoka, Shigeru Miyake, Daisuke Yamamoto, Yusuke Okamura, Taiji Ishii, Shotaro Tatsumi, Takashi Mizobe, Hideo Aihara, Kazuhiro Tanaka, Eiji Kohmura, Takashi Sasayama

  BACKGROUND: Symptomatic vasospasm (SVS) is a major cause of morbidity and mortality in aneurysmal subarachnoid hemorrhage (SAH), and serum sodium frequently decreases before SVS. Serum sodium changes might be regulated by sodium metabolism-related hormones. This multi-institutional prospective cohort study therefore investigated the measurement of sodium metabolism-related hormones to elucidate the pathophysiology of serum sodium changes in SAH. METHODS: SAH patients were treated with clipping or coiling from September 2017 to August 2020 at five hospitals. The laboratory data of 133 SAH patients were collected over 14 days and correlations between changes in serum sodium, sodium metabolism-related hormones (plasma adrenocorticotropic hormone (ACTH), serum cortisol, plasma arginine vasopressin (AVP)), and SVS were determined. Serum sodium concentrations were measured every day and serum sodium levels >135 mEq/L were maintained until day 14. RESULTS: Of the 133 patients, 18 developed SVS within 14 days of subarachnoid hemorrhage onset (SVS group) and 115 did not suffer from SVS (non-SVS group). Circulating AVP, ACTH, and cortisol concentrations were significantly higher on day 1 in the SVS group compared with the non-SVS group. Fluctuations in serum sodium in the SVS group were significantly higher than those in the non-SVS group. There were antiparallel fluctuations in serum sodium and potassium from days 2 to 14. CONCLUSIONS: Elevated levels of ACTH/cortisol and AVP on day 1 may be predictive markers for the occurrence of SVS. Multiple logistic regression analysis showed that serum sodium fluctuations were associated with SVS occurrence. Serum sodium fluctuations were associated with stress-related hormonal dynamics. (249 words).

  Elsevier BV, Sep. 2022, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 103, 131 - 140, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Author Correction: Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics.

  Yuiko Inaba, Masaaki Yamamoto, Shin Urai, Masaki Suzuki, Seiji Nishikage, Maki Kanzawa, Yayoi Aoyama, Tomonori Kanda, Katsumi Shigemura, Hironori Bando, Genzo Iguchi, Yasuhiro Nakamura, Masato Fujisawa, Akihisa Imagawa, Hidenori Fukuoka, Wataru Ogawa

  Aug. 2022, Scientific reports, 12(1) (1), 13238 - 13238, English, International magazine


• 輸血によりゴナドトロピン単独欠損症を呈した再生不良性貧血の一例

  山本 直希, 浦井 伸, 山本 雅昭, 坂東 弘教, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Aug. 2022, 日本内分泌学会雑誌, 98(Suppl.HPT) (Suppl.HPT), 81 - 83, Japanese


• Corticotroph adenomaにおける腫瘍浸潤Tリンパ球とコルチゾールの関連

  神澤 真紀, 福岡 秀規, 蟹江 慶太郎, 志智 大成, 坂東 弘教, 山本 雅昭, 山田 正三, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, Aug. 2022, 日本内分泌学会雑誌, 98(Suppl.HPT) (Suppl.HPT), 34 - 37, Japanese


• 輸血によりゴナドトロピン単独欠損症を呈した再生不良性貧血の一例

  山本 直希, 浦井 伸, 山本 雅昭, 坂東 弘教, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Aug. 2022, 日本内分泌学会雑誌, 98(Suppl.HPT) (Suppl.HPT), 81 - 83, Japanese


• Coexistence of growth hormone, adrenocorticotropic hormone, and testosterone deficiency associated with coronavirus disease 2019: a case followed up for 15 months.

  Kai Yoshimura, Masaaki Yamamoto, Tomoya Inoue, Hidenori Fukuoka, Keiji Iida, Wataru Ogawa

  Coronavirus disease 2019 (COVID-19) is associated with endocrine disorders, but their long-term clinical course remains unclear. We here report the 15-month clinical course for an individual with multiple endocrine disorders of the pituitary gland and testis likely triggered by COVID-19. A 65-year-old man with no history of endocrinopathy was admitted for acute COVID-19 pneumonia. Although his respiratory condition improved after administration of antiviral drugs, his blood pressure dropped suddenly to a preshock level and was refractory to vasopressors. The circulating adrenocorticotropic hormone (ACTH) and cortisol concentrations were low, and secondary adrenal insufficiency was suspected. Administration of hydrocortisone rapidly ameliorated the hypotension, and the patient was discharged taking 15 mg of hydrocortisone daily. An insulin tolerance test performed 3 months later revealed impaired ACTH, cortisol, and growth hormone (GH) responses, indicative of combined hypopituitarism. The patient also manifested symptoms of hypogonadism, and a hormonal workup suggested primary hypogonadism. At 12 months after discharge, GH and ACTH responses had recovered completely and partially, respectively. After another 3 months, basal ACTH and cortisol levels had been restored to the normal range and the patient discontinued hydrocortisone replacement without exacerbation of symptoms, although his hypogonadism persisted. The patient thus developed transient GH and ACTH deficiency that lasted for more than a year as well as persistent primary hypogonadism during intensive care for COVID-19. Certain prolonged symptoms of COVID-19 might be accounted for by such hormonal disturbance.

  Jul. 2022, Endocrine journal, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics.

  Yuiko Inaba, Masaaki Yamamoto, Shin Urai, Masaki Suzuki, Seiji Nishikage, Maki Kanzawa, Yayoi Aoyama, Tomonori Kanda, Katsumi Shigemura, Hironori Bando, Genzo Iguchi, Yasuhiro Nakamura, Masato Fujisawa, Akihisa Imagawa, Hidenori Fukuoka, Wataru Ogawa

  Cases in which bilateral adrenal 123I-Metaiodobenzylguanidine (123I-MIBG) scintigraphy accumulation is sometimes shown, with mildly elevated catecholamine (CA) or metanephrine (MN) levels (within 3 times the upper reference limit) are diagnostic dilemmas. We experienced 3 cases of adrenal incidentalomas with this dilemma in the differential diagnosis. The clinical diagnosis was subclinical Cushing's syndrome in 2 cases, and primary aldosteronism in 1. Despite suspected CA excess in clinical symptoms and imaging findings, the pathological findings of all these tumors were revealed to be cytochrome P450 family 11 subfamily B member 1 (CYP11B1) positive adrenocortical adenomas. Interestingly, adrenal medullary hyperplasia (AMH) was detected in the adrenal parenchyma of all those backgrounds. To clarify the clinical features of such cases, a cross-sectional study was conducted at the Kobe University Hospital from 2014 to 2020. One-hundred sixty-four patients who had undergone 123I-MIBG scintigraphy were recruited. Among them, 10 patients (6.1%) met the above criteria, including the presented 3 cases. Plasma adrenaline, noradrenaline, urinary metanephrine, and normetanephrine had values of 0.05 ± 0.05 ng/mL, 0.63 ± 0.32 ng/mL, 0.22 ± 0.05 mg/day, and 0.35 ± 0.16 mg/day, respectively. Nine cases were complicated with hypertension, and symptoms related to CA excess were observed. Half of them (5 cases) including presented 3 cases had unilateral adrenal tumors. These suggest that in cases of bilateral adrenal uptake on 123I-MIBG, AMH needs to be considered. Adrenocortical adenomas may be associated with AMH and further larger investigation is needed for this pathology.

  Jun. 2022, Scientific reports, 12(1) (1), 9276 - 9276, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 妊娠中の副甲状腺摘出により正期産児を得た原発性副甲状腺機能亢進症合併妊娠の一例

  久保田 いろは, 今福 仁美, 益子 尚久, 福岡 秀規, 手島 直則, 谷村 憲司, 出口 雅士, 寺井 義人

  日本女性栄養・代謝学会, May 2022, 日本女性栄養・代謝学会誌, 27(2) (2), 131 - 131, Japanese


• 肺炎治療中に急激に発症し短期間で改善したSLE併発B型インスリン抵抗症の1例

  三輪 一貴, 西影 星二, 山下 真依, 白杉 郁, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 三枝 淳, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, May 2022, 糖尿病, 65(5) (5), 256 - 256, Japanese


• ニボルマブの初回投与から1988日後に劇症1型糖尿病様の糖尿病を発症した1例

  本村 悠馬, 佐々木 百合子, 上田 真莉子, 浦井 伸, 蟹江 慶太郎, 芳野 啓, 山本 雅昭, 坂東 弘教, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, May 2022, 糖尿病, 65(5) (5), 250 - 250, Japanese


• インスリン抗体の性質変化に伴いインスリン注射回数の変更を要した1型糖尿病の1例

  宮崎 裕也, 辻本 泰貴, 大井 佑夏, 芳野 啓, 坂東 弘教, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, May 2022, 糖尿病, 65(5) (5), 252 - 252, Japanese


• Relation between the insulin lowering rate and changes in bone mineral density: Analysis among subtypes of type 1 diabetes mellitus.

  Masaki Suzuki, Shin Urai, Hidenori Fukuoka, Yushi Hirota, Masaaki Yamamoto, Yuko Okada, Naoki Yamamoto, Hiroki Shichi, Yasunori Fujita, Keitaro Kanie, Genzo Iguchi, Yutaka Takahashi, Wataru Ogawa

  AIMS/INTRODUCTION: The bone mineral density in patients with type 1 diabetes mellitus is reduced due to impaired insulin secretion. However, it is unclear whether the rate of bone mineral density reduction is affected by the type 1 diabetes mellitus subtype. This study aimed to clarify the difference in bone mineral density across type 1 diabetes mellitus subtypes: slowly progressive (SP), acute-onset (AO), and fulminant (F). METHODS: This was a retrospective, single-center, cross-sectional study conducted on 98 adult type 1 diabetes mellitus patients. The main outcome included the bone mineral density Z-score (BMD-Z) measured at the lumbar spine and femoral neck. RESULTS: The lumbar spine BMD-Z was lower in the acute-onset than in the slowly progressive subtype (P = 0.03). No differences were observed when compared with the fulminant subtype. The femoral neck BMD-Z tended to be higher in the slowly progressive than in the acute-onset and fulminant subtypes. Multiple regression analyses showed that the lumbar spine BMD-Z was associated with subtypes (AO vs SP) (P = 0.01), but not subtypes (F vs SP), adjusted for sex, duration, retinopathy, and C-peptide immunoreactivity (CPR). When the patients were divided into disease duration tertiles, in the first and second tertiles, the CPR levels were lower in the acute-onset or fulminant than in the slowly progressive subtype. In contrast, the lumbar spine and femoral neck BMD-Z differed between the acute-onset and slowly progressive only in the second tertiles (both P < 0.01), with a similar tendency between the fulminant and slowly progressive subtypes. CONCLUSIONS: Among the type 1 diabetes mellitus subtypes, bone mineral density undergoes time-dependent changes, which reveals that the bone mineral density decline follows the impaired insulin secretion. These results provide novel insights into the association between the low insulin exposure duration and bone mineral density.

  Apr. 2022, Journal of diabetes investigation, 13(9) (9), 1585 - 1595, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity.

  Hiroki Shichi, Hidenori Fukuoka, Maki Kanzawa, Masaaki Yamamoto, Naoki Yamamoto, Masaki Suzuki, Shin Urai, Ryusaku Matsumoto, Keitaro Kanie, Yasunori Fujita, Hironori Bando, Genzo Iguchi, Naoko Inoshita, Shozo Yamada, Yutaka Takahashi, Wataru Ogawa

  PURPOSE: To clarify the characteristics of Cushing's disease (CD) patients who respond to the desmopressin (DDAVP) test and its underlying mechanisms. METHODS: Forty-seven patients with CD who underwent DDAVP testing were included. Patients were divided into two groups: DDAVP test (+) (adrenocorticotropic hormone [ACTH] levels increased by ≥ 1.5-fold during the DDAVP test) and DDAVP test (-) (ACTH levels increased by < 1.5-fold). AVP receptor expression levels in these tumors were quantified using quantitative RT-PCR and immunohistochemistry. AVP receptor promoter activity was analyzed using a dual-luciferase reporter assay system. RESULTS: Females (96.9%) and USP8 mutants (85.7%) were more prevalent in the DDAVP test (+) than in the DDAVP test (-). Indeed, the ACTH and cortisol responsiveness to DDAVP was greater in USP8 mutation positive tumors than that in USP8 wild type tumors (3.0-fold vs. 1.3-fold, 1.6-fold vs. 1.1-fold, respectively). Responsiveness to DDAVP was correlated with the expression levels of AVPR1B, but not with those of AVPR2. Comparably, Avpr1b promoter activity was enhanced by the overexpression of mutant USP8 compared to the wild type. CONCLUSIONS: We found that the responsiveness of ACTH to DDAVP in CD was greater in tumors with USP8 mutations. The present data suggest that USP8 mutations upregulate the AVPR1B promoter activity. Additionally, we showed that the DDAVP test can predict the presence of USP8 mutations.

  Apr. 2022, Pituitary, 25(3) (3), 496 - 507, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 末梢血FKBP5遺伝子発現はACTH非依存性に血中コルチゾールと関連する

  鈴木 正暉, 山本 雅昭, 佐々木 百合子, 大井 佑夏, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 高橋 路子, 坂東 弘教, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 315 - 315, Japanese


• 免疫チェックポイント阻害薬投与後に発症した1型糖尿病様の糖尿病の特徴と膵臓MRI所見との関連についての検討

  前田 岳志, 芳野 啓, 西山 信晴, 本村 悠馬, 鈴木 正暉, 井上 朋也, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 169, Japanese


• SGLT2阻害薬投与後のHb増加に伴うGA/HbA1c比への影響に関する検討

  芳野 啓, 本村 悠馬, 西影 星二, 山本 あかね, 坂東 弘教, 山本 雅昭, 福岡 秀規, 芳野 弘, 芳野 原, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 177, Japanese


• 肥満症における11の健康障害と長期的な体重変化との関連の検討

  影山 智子, 西影 星二, 村前 直和, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 199, Japanese


• 肥満症患者における食行動質問表の各因子スコアと減量効果予測の検討

  友藤 清爾, 西影 星二, 村前 直和, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 308, Japanese


• 肥満症患者に対する術前減量サポートの効果と周術期合併症に関する検討

  高橋 路子, 山田 倫子, 村前 直和, 尾上 弘美, 鍛冶 亜由美, 三ヶ尻 礼子, 山本 育子, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 田守 義和, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 308, Japanese


• 内科における先端巨大症管理 単一施設成績

  辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 千原 和夫, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, Japanese


• 先端巨大症患者におけるBMIで層別化した肥満関連疾患の有病率

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, Japanese


• 当院における成人成長ホルモン分泌不全症患者のGH治療による耐糖能変化に寄与する因子の検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 345 - 345, Japanese


• ダンピング症候群による低血糖のため診断に難渋したインスリノーマの一例

  藤井 研己, 蟹江 慶太郎, 山本 雅昭, 坂東 弘教, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 370 - 370, Japanese


• 先端巨大症患者におけるBMIと肥満関連疾患の有病率についての検討

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 160, Japanese


• 成人成長ホルモン分泌不全症(AGHD)患者におけるGH補充療法による耐糖能への影響に関する検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 161, Japanese


• 1型糖尿病(T1DM)患者におけるIGF-Iと自由行動下のCGM指標に関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 直希, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 169, Japanese


• 1型糖尿病患者におけるSGLT2阻害薬使用の影響に関する検討

  本村 悠馬, 芳野 啓, 山本 あかね, 上田 真莉子, 松岡 敦子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 177, Japanese


• 1型糖尿病と自己免疫性甲状腺疾患との関連についての検討

  藤井 研己, 芳野 啓, 山本 あかね, 上田 真莉子, 松岡 敦子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 197, Japanese


• Free StyleリブレLink使用者の背景および導入前後におけるスキャン回数、HbA1cの変化の検討

  花山 亜沙, 上田 真莉子, 松岡 敦子, 山本 あかね, 蟹江 慶太郎, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 208, Japanese


• 若年で糖尿病を発症した小児がん経験者の1例

  佐々木 百合子, 坂東 弘教, 藤井 研己, 西影 星二, 山本 雅昭, 芳野 啓, 蟹江 慶太郎, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 231, Japanese


• 自己免疫性下垂体炎の新たな展開 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデルの樹立

  蟹江 慶太郎, 伊藤 剛, 井口 元三, 松本 隆作, 浦井 伸, 坂東 弘教, 山本 雅昭, 福岡 秀規, 小川 渉, 金子 新, 高橋 裕

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 180 - 180, Japanese


• 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデル樹立と進展防止のための創薬への応用

  蟹江 慶太郎, 伊藤 剛, 井口 元三, 浦井 伸, 坂東 弘教, 山本 雅昭, 福岡 秀規, 小川 渉, 金子 新, 高橋 裕

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 272 - 272, Japanese


• 末梢血FKBP5遺伝子発現はACTH非依存性に血中コルチゾールと関連する

  鈴木 正暉, 山本 雅昭, 佐々木 百合子, 大井 佑夏, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 高橋 路子, 坂東 弘教, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 315 - 315, Japanese


• 内科における先端巨大症管理 単一施設成績

  辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 千原 和夫, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, Japanese


• 先端巨大症患者におけるBMIで層別化した肥満関連疾患の有病率

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, Japanese


• 当院における成人成長ホルモン分泌不全症患者のGH治療による耐糖能変化に寄与する因子の検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2022, 日本内分泌学会雑誌, 98(1) (1), 345 - 345, Japanese


• 先端巨大症患者におけるBMIと肥満関連疾患の有病率についての検討

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 160, Japanese


• 成人成長ホルモン分泌不全症(AGHD)患者におけるGH補充療法による耐糖能への影響に関する検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 161, Japanese


• 1型糖尿病(T1DM)患者におけるIGF-Iと自由行動下のCGM指標に関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 直希, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 169, Japanese


• 肥満症患者に対する術前減量サポートの効果と周術期合併症に関する検討

  高橋 路子, 山田 倫子, 村前 直和, 尾上 弘美, 鍛冶 亜由美, 三ヶ尻 礼子, 山本 育子, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 田守 義和, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2022, 糖尿病, 65(Suppl.1) (Suppl.1), S - 308, Japanese


• 間脳下垂体疾患の病態についての最新の知見 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデルの樹立

  蟹江 慶太郎, 伊藤 剛, 井口 元三, 坂東 弘教, 山本 雅昭, 福岡 秀規, 金子 新, 高橋 裕

  (一社)日本内分泌学会, Mar. 2022, 日本内分泌学会雑誌, 97(5) (5), 1236 - 1236, Japanese


• 肥満のゲノムサイエンス 減量外来受診後にパイロシークエンス法によって診断し得たPrader-Willi症候群の一例

  高橋 路子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 山田 倫子, 森貞 直哉, 松原 圭子, 鏡 雅代, 緒方 勤, 高橋 裕, 小川 渉

  (一社)日本肥満学会, Mar. 2022, 肥満研究, 27(Suppl.) (Suppl.), 176 - 176, Japanese


• 肥満のゲノムサイエンス 減量外来受診後にパイロシークエンス法によって診断し得たPrader-Willi症候群の一例

  高橋 路子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 山田 倫子, 森貞 直哉, 松原 圭子, 鏡 雅代, 緒方 勤, 高橋 裕, 小川 渉

  (一社)日本肥満学会, Mar. 2022, 肥満研究, 27(Suppl.) (Suppl.), 176 - 176, Japanese


• Adrenohepatic fusionを背景に発生した副腎皮質腺腫の1例

  井上 英軌, 宇野 礼奈, 神澤 真紀, 岡田 佳輔, 重村 克巳, 藤澤 正人, 神田 知紀, 福岡 秀規, 中村 保宏, 伊藤 智雄

  (一社)日本病理学会, Mar. 2022, 日本病理学会会誌, 111(1) (1), 308 - 308, Japanese


• Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review.

  Atsushi Ishida, Hiroki Shichi, Hidenori Fukuoka, Hideki Shiramizu, Naoko Inoshita, Shozo Yamada

  Aggressive somatotroph pituitary tumor that causes acromegaly is extremely rare and resists conventional treatments such as multiple surgeries, radiotherapies, and various types of somatostatin analogs. Here, we propose a novel treatment option for these rare cases by discussing our case and reviewing the literature. We experienced an aggressive somatotroph tumor in a 52-year-old woman with acromegaly. Not only could a complete remission of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) not be obtained, but the tumor continued to grow and eventually recurred around the brainstem despite multidisciplinary treatments. We employed immunohistochemistry and a three-dimensional (3D) spheroid ex vivo assay to determine the best treatment option for this case. Although histology showed strong O 6-methylguanine DNA methyltransferase expression and high Ki-67 labeling index (22%), temozolomide (TMZ) combined with capecitabine (CAPTEM) treatment was performed based on the results of the patient-derived 3D spheroid ex vivo assay, which predicted more effective treatment with CAPTEM than with TMZ alone. Consequently, GH and IGF-1 levels were restored to normal range with remarkable tumor shrinkage after CAPTEM treatment. To the best of our knowledge, there have been even very few reports describing successful treatment for such aggressive and refractory somatotroph tumors and this is the first report showing the effectiveness of CAPTEM on refractory somatotroph tumor both ex vivo and in vivo.

  2022, Frontiers in oncology, 12, 916982 - 916982, English, International magazine


• Case report: Late middle-aged features of FAM111A variant, Kenny-Caffey syndrome type 2-suggestive symptoms during a long follow-up.

  Yuka Ohmachi, Shin Urai, Hironori Bando, Jun Yokoi, Masaaki Yamamoto, Keitaro Kanie, Yuma Motomura, Yasutaka Tsujimoto, Yuriko Sasaki, Yuka Oi, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Genzo Iguchi, Natsumi Uehara, Hidenori Fukuoka, Wataru Ogawa

  Kenny-Caffey syndrome type 2 (KCS2) is an extremely rare skeletal disorder involving hypoparathyroidism and short stature. It has an autosomal dominant pattern of inheritance and is caused by variants in the FAM111 trypsin-like peptidase A (FAM111A) gene. This disease is often difficult to diagnose due to a wide range of more common diseases manifesting hypoparathyroidism and short stature. Herein, we present the case of a 56-year-old female patient with idiopathic hypoparathyroidism and a short stature. The patient was treated for these conditions during childhood. Upon re-evaluating the etiology of KCS2, we suspected that the patient had the disorder because of clinical manifestations, such as cortical thickening and medullary stenosis of the bones, and lack of intellectual abnormalities. Genetic testing identified a heterozygous missense variant in the FAM111A gene (p.R569H). Interestingly, the patient also had bilateral sensorineural hearing loss and vestibular dysfunction, which have been rarely described in previous reports of pediatric cases. In KCS2, inner ear dysfunction due to Eustachian tube dysfunction may progress in middle age or later. However, this disease is now being reported in younger patients. Nevertheless, our case may be instructive of how such cases emerge chronically after middle age. Herein, we also provide a literature review of KCS2.

  2022, Frontiers in endocrinology, 13, 1073173 - 1073173, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Novel genes and variants associated with congenital pituitary hormone deficiency in the era of next-generation sequencing.

  Hironori Bando, Shin Urai, Keitaro Kanie, Yuriko Sasaki, Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, Sally A Camper

  Combined pituitary hormone deficiency (CPHD) is not a rare disorder, with a frequency of approximately 1 case per 4,000 live births. However, in most cases, a genetic diagnosis is not available. Furthermore, the diagnosis is challenging because no clear correlation exists between the pituitary hormones affected and the gene(s) responsible for the disorder. Next-generation sequencing (NGS) has recently been widely used to identify novel genes that cause (or putatively cause) CPHD. This review outlines causative genes for CPHD that have been newly reported in recent years. Moreover, novel variants of known CPHD-related genes (POU1F1 and GH1 genes) that contribute to CPHD through unique mechanisms are also discussed in this review. From a clinical perspective, variants in some of the recently identified causative genes result in extra-pituitary phenotypes. Clinical research on the related symptoms and basic research on pituitary formation may help in inferring the causative gene(s) of CPHD. Future NGS analysis of a large number of CPHD cases may reveal new genes related to pituitary development. Clarifying the causative genes of CPHD may help to understand the process of pituitary development. We hope that future innovations will lead to the identification of genes responsible for CPHD and pituitary development.

  2022, Frontiers in endocrinology, 13, 1008306 - 1008306, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment.

  Naoki Yamamoto, Shin Urai, Hidenori Fukuoka, Masaaki Yamamoto, Kenichi Yoshida, Masaki Suzuki, Hiroki Shichi, Yasunori Fujita, Keitaro Kanie, Genzo Iguchi, Yutaka Takahashi, Wataru Ogawa

  Context: With the increasing number of older patients with acromegaly, it is important to understand the effects of aging on the quality of life (QoL) in acromegaly. Objective: To investigate the factors associated with the QoL of older acromegaly patients. Design: This was a single-center, retrospective, cross-sectional study conducted between 2014 and 2019. Methods: Among 90 acromegaly patients at Kobe University Hospital, 74 who had completed the QoL evaluation under treatment were enrolled (age = 62.0 [50.7-70.0], female 52%). SF-36 and the AcroQoL questionnaire were used to quantify QoL. The patients were divided into two groups: the young and middle-aged group, aged <65 years (51.0 [46.0-59.2], n =42), and the older group, aged ≥65 years (70.5 [69.0-73.0], n =32). The factors associated with the QoL scores were analyzed using univariate and multivariate regression analyses. Results: The scores for the physical component summary of SF-36 were negatively associated with age (P <0.01), while those for the mental or role/social component summary were positively associated (P <0.01, P =0.03, respectively). In contrast, AcroQoL scores were not associated with age. However, the different factors were associated with lower AcroQoL scores; arthropathy and higher BMI in the older group (P <0.01, and P =0.01, respectively), and treatment modalities and size of pituitary tumor in the young and middle-aged group (P <0.01, P =0.04, respectively). Replacement of hydrocortisone was commonly associated both in young and middle-aged group (P =0.04), and in older group (P =0.02). Conclusion: We showed that the factors associated with impaired QoL differed in the young and middle-aged, and older patients with acromegaly. In older patients, arthropathy and higher BMI were associated with poor QoL. These suggest the importance of early diagnosis and appropriate treatment in preventing arthropathy in acromegaly.

  2022, Frontiers in endocrinology, 13, 819330 - 819330, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 重症筋無力症を合併した抗PIT-1下垂体炎の1例

  大井 佑夏, 浦井 伸, 山本 雅昭, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Dec. 2021, 日本内分泌学会雑誌, 97(4) (4), 907 - 907, Japanese


• Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.

  Atsushi Ishida, Hiroki Shichi, Hidenori Fukuoka, Naoko Inoshita, Wataru Ogawa, Shozo Yamada

  PURPOSE: Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are difficult to predict, and the alternatives are limited. Recent reports suggested that TMZ combined with capecitabine (CAPTEM) can be effective for the treatment of aggressive pituitary tumors. This study sought to evaluate the effect of TMZ in an ex vivo three-dimensional (3D) spheroid culture assay and determine if this assay could be used to predict the therapeutic effect of CAPTEM in actual refractory prolactinomas. METHODS: Surgically resected tumor tissues from two patients with refractory prolactinoma were cultured as 3D spheroids. The effects of TMZ were assessed based on its suppression of cell viability and reduction of prolactin (PRL) levels. RESULTS: In Case 1, the 3D culture assay showed no effect of TMZ on cell viability or PRL suppression. Clinically, TMZ treatment did not reduce PRL levels (8870→8274 ng/mL) and the tumor progression. However, CAPTEM partially reduced PRL levels (9070→4046 ng/mL) and suppressed the tumor growth. In Case 2, TMZ in the 3D culture assay showed a 50% reduction of cell viability and 40% reduction of PRL levels. Clinically, CAPTEM was highly effective, with a considerable reduction in PRL level (17,500→210 ng/mL), and MRI showed almost no residual tumor. CONCLUSIONS: This is the first report to describe the effects of CAPTEM treatment on refractory prolactinomas. The ex vivo 3D spheroid culture assay reliably predicted TMZ sensitivity and informed the selection between TMZ or CAPTEM treatment for refractory prolactinomas.

  Nov. 2021, Pituitary, 25(2) (2), 238 - 245, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 胸腺腫術後に重症筋無力症を発症した抗PIT-1下垂体炎の1例

  大井 佑夏, 山本 雅昭, 浦井 伸, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 487 - 487, Japanese


• USP8変異はV1b受容体発現、DDAVP試験反応性亢進と関連する

  志智 大城, 福岡 秀規, 神澤 真紀, 山本 直希, 鈴木 正暉, 浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 山田 正三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 501 - 501, Japanese


• 発症36年後に抗ラブフィリン3A抗体陽性を示した尿崩症の1例

  西影 星二, 山本 雅昭, 稲葉 惟子, 坂東 弘教, 芳野 啓, 廣田 勇士, 椙村 益久, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 505 - 505, Japanese


• COVID-19治療中の高血圧クリーゼから診断した褐色細胞腫の一例

  辻本 泰貴, 西影 星二, 山本 雅昭, 西坂 まり華, 芳野 啓, 蟹江 慶太郎, 廣田 勇士, 坂東 弘教, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 528 - 528, Japanese


• ICIとTKI使用後に原発性副腎不全を生じた腎癌の2例

  西坂 まり華, 坂東 弘教, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 533 - 533, Japanese


• paragangliomaとganglioneuromaの混合腫瘍の1例

  佐々木 百合子, 山本 雅昭, 神澤 真紀, 蟹江 慶太郎, 重村 克巳, 神田 知紀, 上田 真莉子, 坂東 弘教, 芳野 啓, 廣田 勇士, 藤澤 正人, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 539 - 539, Japanese


• ALP酵素療法により効果を認めた新規ALPL A205T変異による成人発症低ホスファターゼ症の1例

  西影 星二, 福岡 秀規, 山本 雅昭, 稲葉 惟子, 廣田 勇士, 小川 渉

  (一社)日本骨粗鬆症学会, Sep. 2021, 日本骨粗鬆症学会雑誌, 7(Suppl.1) (Suppl.1), 346 - 346, Japanese


• 播種性クリプトコッカス症を含む日和見感染症の原因と考えられたACTH産生下垂体腺腫を解剖にて同定しえた一例

  菅野 天裕, 神澤 真紀, 兵頭 俊紀, 近藤 武史, 三好 園子, 尾下 寿彦, 穂積 かおり, 神田 知紀, 福岡 秀規, 伊藤 智雄, 横崎 宏

  (株)文光堂, Jun. 2021, 病理と臨床, 39(6) (6), 611 - 616, Japanese


• Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback.

  Yasutaka Tsujimoto, Hiroki Shichi, Hidenori Fukuoka, Masaaki Yamamoto, Itsuko Sato, Takamitsu Imanishi, Tomoaki Nakamura, Naoko Inoshita, Atsushi Ishida, Shozo Yamada, Yutaka Takahashi, Kazuo Chihara

  Context: Paradoxical increases in serum cortisol in the dexamethasone suppression test (DST) have been rarely observed in Cushing disease (CD). Its pathophysiology and prevalence remain unclear. Case Description: A 62-year-old woman with suspected CD showed paradoxical increases in cortisol after both 1-mg and 8-mg DST (1.95-fold and 2.52-fold, respectively). The initiation of metyrapone paradoxically decreased plasma adrenocorticotropic hormone (ACTH) levels and suppressed cortisol levels. Moreover, the pituitary tumor considerably shrank during metyrapone treatment. Ex Vivo Experiments: The resected tumor tissue was enzymatically digested, dispersed, and embedded into Matrigel as 3D cultured cells. ACTH levels in the media were measured. In this tumor culture, ACTH levels increased 1.3-fold after dexamethasone treatment (P < 0.01) while control tumor cultures exhibited no increase in ACTH levels, but rather a 20% to 40% suppression (P < 0.05). Clinical Study: A cross-sectional, retrospective, multicenter study that included 92 patients with CD who underwent both low-dose and high-dose DST from 2014 to 2020 was performed. Eight cases (8.7%) showed an increase in serum cortisol after both low-dose and high-dose DST. Conclusion: This is the first report of a patient with glucocorticoid (GC)-driven positive feedback CD who showed both ACTH suppression and tumor shrinkage by metyrapone. Our cohort study revealed that 8.7% of patients with CD patients possibly possess GC-driven positive-feedback systems, thereby suggesting the presence of a new subtype of CD that is different from the majority of CD cases. The mechanisms exhibiting GC positive feedback in CD and the therapeutic approach for these patients remain to be investigated.

  Jun. 2021, Journal of the Endocrine Society, 5(6) (6), bvab055, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.

  Keitaro Kanie, Genzo Iguchi, Hironori Bando, Shin Urai, Hiroki Shichi, Yasunori Fujita, Ryusaku Matsumoto, Kentaro Suda, Masaaki Yamamoto, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi

  BACKGROUND: Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as hypophysitis, have been associated with the use of ICIs. Most underlying mechanisms of ICI-related hypophysitis remain unclear, especially for programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors. We hypothesized that ICI-related hypophysitis is associated with paraneoplastic syndrome caused by ectopic expression of pituitary-specific antigens. METHODS: Twenty consecutive patients with ICI-related hypophysitis between 2017 and 2019 at Kobe University Hospital were retrospectively analyzed. Circulating anti-pituitary antibodies were detected using immunofluorescence staining and immunoblotting. Ectopic expression of pituitary autoantigens in tumor specimens was also examined. RESULTS: Eighteen patients were treated with PD-1/PD-L1 inhibitors, and two were treated with a combination of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and PD-1 inhibitors. All patients showed adrenocorticotropic hormone (ACTH) deficiency and additionally, three showed thyroid-stimulating hormone (TSH) deficiency, and one showed gonadotropin-releasing hormone (GnRH) deficiency. Among these patients, three exhibited anti-pituitary antibodies, two with anti-corticotroph antibody and one with anti-somatotroph antibody. Interestingly, the anti-corticotroph antibody recognized proopiomelanocortin (POMC) and those two patients exhibited ectopic ACTH expression in the tumor, while the patients without anti-corticotroph antibody did not. CONCLUSIONS: We demonstrated 10% of PD-1/PD-L1 inhibitors-related hypophysitis were associated with the autoimmunity against corticotrophs and maybe caused as a form of paraneoplastic syndrome, in which ectopic expression of ACTH in the tumor was observed. It is also suggested that the pathophysiology is heterogenous in ICI-related hypophysitis.

  May 2021, Cancer immunology, immunotherapy : CII, 70(12) (12), 3669 - 3677, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 【糖尿病・内分泌代謝疾患とGPCR update】ソマトスタチン受容体

  山本 雅昭, 福岡 秀規

  (有)科学評論社, May 2021, 糖尿病・内分泌代謝科, 52(5) (5), 453 - 458, Japanese


• 反応性低血糖により診断に至ったA型インスリン抵抗症の1例

  西影 星二, 廣田 勇士, 高吉 倫史, 竹内 健人, 浜口 哲矢, 稲葉 惟子, 芳野 啓, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, May 2021, 糖尿病, 64(Suppl.1) (Suppl.1), I - 7, Japanese


• CSII療法施行中1型糖尿病患者の朝食絶食による血中ケトン体推移に関する検討

  井上 朋也, 廣田 勇士, 松本 梨佐, 齋藤 修一郎, 新井 尚樹, 後藤 美菜子, 西影 星二, 芳野 啓, 稲葉 惟子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, May 2021, 糖尿病, 64(Suppl.1) (Suppl.1), I - 3, Japanese


• 間歇スキャンCGM(isCGM)使用中の1型糖尿病患者におけるTIR、TAR、TBRの季節性変動に関する検討

  大井 佑夏, 廣田 勇士, 西影 星二, 山本 あかね, 浦井 伸, 高吉 倫史, 中川 靖, 松岡 敦子, 芳野 啓, 稲葉 惟子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, May 2021, 糖尿病, 64(Suppl.1) (Suppl.1), III - 6, Japanese


• Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis.

  Chihiro Mimura, Motoko Tachihara, Sentaro Kusuhara, Hidenori Fukuoka, Yoshihiro Nishimura

  A 71-year-old man was diagnosed with squamous cell lung carcinoma with high expression of programmed cell death ligand 1 (PDL1) (cT4N1M1b stage IVA). He was treated with pembrolizumab, but 14 days later, he suffered from pembrolizumab-related retinal vasculitis as an immune-related adverse event (irAE). The symptoms were ameliorated by oral corticosteroids. We succeeded in switching to topical treatment as early as possible with the help of an ophthalmologist. Six months after discontinuing treatment with oral prednisolone, hypophysitis and thyroiditis occurred in six cycles of pembrolizumab. Finally, he suffered from three irAEs, but the antitumour effect resulted in a remarkable response.

  Apr. 2021, Respirology case reports, 9(4) (4), e00730, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• 内分泌研究のインパクト 自己免疫性下垂体疾患の新たな病態の解明と革新的アプローチ

  高橋 裕, 蟹江 慶太郎, 浦井 伸, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 122 - 122, Japanese


• 下垂体の疾患へのアプローチ 下垂体疾患の病態解明を目指したiPS細胞の応用

  高橋 裕, 松本 隆作, 蟹江 慶太郎, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 167 - 167, Japanese


• ACTH産生下垂体腺腫における腫瘍微小環境解析

  神澤 真紀, 福岡 秀規, 蟹江 慶太郎, 山本 雅昭, 山田 正三, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 259 - 259, Japanese


• 疾患iPS細胞/抗原特異的T細胞を用いた抗PIT-1下垂体炎疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 伊藤 剛, 喜多山 秀一, 六車 恵子, 坂東 弘教, 松本 隆作, 山本 雅昭, 福岡 秀規, 金子 新, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 262 - 262, Japanese


• 1型糖尿病におけるIGF-I低下と関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 直希, 志智 大城, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 272 - 272, Japanese


• パイロシークエンス法によって診断し得たUPD(15)matモザイクによるPrader-Willi症候群の一例

  高橋 路子, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 井口 元三, 森貞 直哉, 松原 圭子, 鏡 雅代, 緒方 勤, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 276 - 276, Japanese


• 治療抵抗性高血圧症、低カリウム血症を呈し、レニン産生が疑われた副腎皮質癌の一例

  山本 直希, 山本 雅昭, 福満 隼人, 神澤 真紀, 本間 桂子, 栗原 勲, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 286 - 286, Japanese


• メチラポン短期投与でコルチゾールを正常化できた周期性クッシング病の一例

  西影 星二, 山本 雅昭, 山本 直希, 稲葉 惟子, 廣田 勇士, 井下 尚子, 山田 正三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 296 - 296, Japanese


• 成人期診断22q11.2欠失症候群における内分泌異常の検討

  横井 愛紗, 福岡 秀規, 山本 雅昭, 穂積 かおり, 廣田 勇士, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 336 - 336, Japanese


• 当院PPGL症例におけるメチロシンの使用経験

  松本 梨佐, 山本 雅昭, 齋藤 修一郎, 西影 星二, 西山 美菜子, 大井 佑夏, 稲葉 惟子, 廣田 勇士, 江木 盛時, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 348 - 348, Japanese


• 内分泌研究のインパクト 自己免疫性下垂体疾患の新たな病態の解明と革新的アプローチ

  高橋 裕, 蟹江 慶太郎, 浦井 伸, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 122 - 122, Japanese


• 下垂体の疾患へのアプローチ 下垂体疾患の病態解明を目指したiPS細胞の応用

  高橋 裕, 松本 隆作, 蟹江 慶太郎, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 167 - 167, Japanese


• 高レニン、高アルドステロンを呈したDOC産生副腎皮質癌の一例

  福満 隼人, 山本 直希, 福岡 秀規, 山本 雅昭, 神澤 真紀, 清田 尚臣, 小松 昇平, 重村 克己, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 224 - 224, Japanese


• 自己免疫性溶血性貧血を伴った悪性胸腺腫合併抗PIT-1下垂体炎の1例

  蟹江 慶太郎, 井口 元三, 山本 雅昭, 浦井 伸, 志智 大城, 藤田 泰功, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 225 - 225, Japanese


• ACTH産生下垂体腺腫における腫瘍微小環境解析

  神澤 真紀, 福岡 秀規, 蟹江 慶太郎, 山本 雅昭, 山田 正三, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 259 - 259, Japanese


• 疾患iPS細胞/抗原特異的T細胞を用いた抗PIT-1下垂体炎疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 伊藤 剛, 喜多山 秀一, 六車 恵子, 坂東 弘教, 松本 隆作, 山本 雅昭, 福岡 秀規, 金子 新, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 262 - 262, Japanese


• 1型糖尿病におけるIGF-I低下と関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 直希, 志智 大城, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 272 - 272, Japanese


• パイロシークエンス法によって診断し得たUPD(15)matモザイクによるPrader-Willi症候群の一例

  高橋 路子, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 井口 元三, 森貞 直哉, 松原 圭子, 鏡 雅代, 緒方 勤, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 276 - 276, Japanese


• 治療抵抗性高血圧症、低カリウム血症を呈し、レニン産生が疑われた副腎皮質癌の一例

  山本 直希, 山本 雅昭, 福満 隼人, 神澤 真紀, 本間 桂子, 栗原 勲, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 286 - 286, Japanese


• メチラポン短期投与でコルチゾールを正常化できた周期性クッシング病の一例

  西影 星二, 山本 雅昭, 山本 直希, 稲葉 惟子, 廣田 勇士, 井下 尚子, 山田 正三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 296 - 296, Japanese


• 成人期診断22q11.2欠失症候群における内分泌異常の検討

  横井 愛紗, 福岡 秀規, 山本 雅昭, 穂積 かおり, 廣田 勇士, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 336 - 336, Japanese


• 当院PPGL症例におけるメチロシンの使用経験

  松本 梨佐, 山本 雅昭, 齋藤 修一郎, 西影 星二, 西山 美菜子, 大井 佑夏, 稲葉 惟子, 廣田 勇士, 江木 盛時, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 348 - 348, Japanese


• 妊娠中に高血圧と精神症状を呈した副腎皮質・髄質混合腫瘍の1例

  神澤 真紀, 福岡 秀規, 重村 克己, 青山 弥生, 中村 保宏, 原 重雄, 山本 あかね, 高橋 裕, 伊藤 智雄

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 223 - 223, Japanese


• カテコラミン軽度上昇を呈するMIBG両側副腎集積例の検討

  稲葉 惟子, 山本 雅昭, 西影 星二, 鈴木 正暉, 浦井 伸, 神澤 真紀, 青山 弥生, 神田 知紀, 中村 保宏, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 347 - 347, Japanese


• Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

  Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed

  The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.

  Mar. 2021, Journal of the Endocrine Society, 5(3) (3), bvaa205, English, International magazine

  Scientific journal


• Two Cases of anti-PIT-1 Hypophysitis Exhibited as a Form of Paraneoplastic Syndrome not Associated With Thymoma.

  Keitaro Kanie, Genzo Iguchi, Megumi Inuzuka, Kentaro Sakaki, Hironori Bando, Shin Urai, Hiroki Shichi, Yasunori Fujita, Ryusaku Matsumoto, Kentaro Suda, Masaaki Yamamoto, Hidenori Fukuoka, Takao Taniguchi, Wataru Ogawa, Yutaka Takahashi

  Anti-pituitary-specific transcription factor 1 (PIT-1) hypophysitis (anti-PIT-1 antibody syndrome) is a thymoma-associated autoimmune disease characterized by acquired growth hormone (GH), prolactin (PRL), and thyrotropin (TSH) deficiencies due to autoimmunity against PIT-1. Ectopic expression of PIT-1 in the thymoma plays a causal role in development of the disease. Here, we report 2 cases of anti-PIT-1 hypophysitis exhibiting as a form of paraneoplastic syndrome with conditions other than thymoma. A 79-year-old woman (case 1) and an 86-year-old man (case 2) were referred with a suspicion of anti-PIT-1 hypophysitis because of acquired GH, PRL, and TSH deficiencies. Case 1 was complicated by diffuse large B-cell lymphoma (DLBCL) of the bladder and case 2 was diagnosed with malignancy with multiple metastases of unknown origin. Because circulating anti-PIT-1 antibody was detected, both patients were diagnosed with anti-PIT-1 hypophysitis. Circulating PIT-1-reactive T cells were detected in case 1 via enzyme-linked immunospot (ELISPOT) assay. Interestingly, the PIT-1 protein was ectopically expressed in the DLBCL cells of case 1, whereas DLBCL tissues derived from patients without anti-PIT-1 hypophysitis were negative for PIT-1. In case 2, the materials were not available because of best supportive care was under way. These data show that anti-PIT-1 hypophysitis is associated not only with thymoma but also with other malignancies. Additionally, the ectopic expression of PIT-1 in the DLBCL tissues and presence of PIT-1-reactive T cells suggested that the underlying mechanisms were similar to those observed in thymoma. Thus, anti-PIT-1 hypophysitis is defined as a form of paraneoplastic syndrome.

  Mar. 2021, Journal of the Endocrine Society, 5(3) (3), bvaa194, English, International magazine


• Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas

  Nicholas A. Tritos, Pouneh K. Fazeli, Ann McCormack, Susana M. Mallea-Gil, Maria M. Pineyro, Mirjam Christ-Crain, Stefano Frara, Artak Labadzhyan, Adriana G. Ioachimescu, Ilan Shimon, Yutaka Takahashi, Mark Gurnell, Maria Fleseriu, Irina Bancos, Martin Bidlingmaier, Nienke Biermasz, Cesar Luiz Boguszewski, Jessica Brzana, John Carmichael, Philippe Chanson, Andjela Drincic, Yuval Eisenberg, Hidenori Fukuoka, Monica Gadelha, Luma Ghalib, Murray Gordon, Yona Greenman, Francisco Guarda, Miguel Hinojosa-Amaya, Ken Ho, Mirela-Diana Ilie, Niki Karavitaki, Larry Katznelson, Fahrettin Keleştimur, Andre Lacroix, Fabienne Langlois, Dawn Lim, Sebastian Neggers, Dan Niculescu, Stephan Petersenn, Rosario Pivonello, Gerald Raverot, Richard Ross, Roberto Salvatori, Carla Scaroni, Ismat Shafiq, Susmeeta Sharma, Antoine Tabarin, Stylianos Tsagarakis, Elena Valassi, Greisa Vila, Maggie Wierman, for the “Pituitary Society Delphi Collaborative Group”

  Springer, 2021, Pituitary, English

  Scientific journal


• Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

  Masaaki Yamamoto, Takahiro Nakao, Wataru Ogawa, Hidenori Fukuoka

  Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia. It may have a severe clinical course, including infection, psychiatric disorders, hypercoagulability, and metabolic abnormalities, despite the generally small, nonaggressive nature of the tumors. Up to 20% of ACTHomas show aggressive behavior, which is related to poor surgical outcomes, postsurgical recurrence, serious clinical course, and high mortality. Although several gene variants have been identified in both germline and somatic changes in Cushing's disease, the pathophysiology of aggressive ACTHomas is poorly understood. In this review, we focused on the aggressiveness of ACTHomas, its pathology, the current status of medical therapy, and future prospects. Crooke's cell adenoma (CCA), Nelson syndrome, and corticotroph pituitary carcinoma are representative refractory pituitary tumors that secrete superphysiological ACTH. Although clinically asymptomatic, silent corticotroph adenoma is an aggressive ACTH-producing pituitary adenoma. In this review, we summarize the current understanding of the pathophysiology of aggressive ACTHomas, including these tumors, from a molecular point of view based on genetic, pathological, and experimental evidence. The treatment of aggressive ACTHomas is clinically challenging and usually resistant to standard treatment, including surgery, radiotherapy, and established medical therapy (e.g., pasireotide and cabergoline). Temozolomide is the most prescribed pharmaceutical treatment for these tumors. Reports have shown that several treatments for patients with refractory ACTHomas include chemotherapy, such as cyclohexyl-chloroethyl-nitrosourea combined with 5-fluorouracil, or targeted therapies against several molecules including vascular endothelial growth factor receptor, cytotoxic T lymphocyte antigen 4, programmed cell death protein 1 (PD-1), and ligand for PD-1. Genetic and experimental evidence indicates that some possible therapeutic candidates are expected, such as epidermal growth factor receptor tyrosine kinase inhibitor, cyclin-dependent kinase inhibitor, and BRAF inhibitor. The development of novel treatment options for aggressive ACTHomas is an emerging task.

  2021, Frontiers in endocrinology, 12, 650791 - 650791, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Nivolumab投与開始1年半後に劇症1型糖尿病様病態で発症した糖尿病の1例

  大町 侑香, 鈴木 正暉, 伊藤 潤, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 57 - 57, Japanese


• CSII療法中1型糖尿病患者のSGLT2阻害薬服用下での絶食中血中ケトン体変化

  西山 美菜子, 鈴木 正暉, 芳野 啓, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 82 - 82, Japanese


• 複合要因により自発性低血糖を頻発したアルコール多飲習慣のあるC型肝炎合併透析患者

  西影 星二, 西山 信晴, 山本 直希, 芳野 啓, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 84 - 84, Japanese


• 下垂体腺腫摘出術後に早朝の血糖上昇が改善した先端巨大症の1例

  山本 雅昭, 廣田 勇士, 福満 隼人, 福岡 秀規, 高橋 裕, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 63 - 63, Japanese


• Clinical Heterogeneity of Acquired Idiopathic Isolated Adrenocorticotropic Hormone Deficiency.

  Yasunori Fujita, Hironori Bando, Genzo Iguchi, Keiji Iida, Hitoshi Nishizawa, Keitaro Kanie, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi

  Objective: Heterogeneous clinical characteristics are observed in acquired isolated adrenocorticotropic hormone (ACTH) deficiency (IAD); however, its classification remains to be established because of its largely unknown pathophysiology. In IAD, anti-pituitary antibodies have been detected in some patients, although their significance remains unclear. Therefore, this study aimed to classify patients with IAD and to clarify the significance of anti-pituitary antibodies. Design and Methods: We analyzed 46 consecutive patients with IAD. Serum anti-pituitary antibodies were analyzed via immunofluorescence staining using a mouse pituitary tissue. Principal component and cluster analyses were performed to classify IAD patients based on clinical characteristics and autoantibodies. Results: Immunofluorescence analysis using the sera revealed that 58% of patients showed anti-corticotroph antibodies and 6% of patients showed anti-follicular stellate cell (FSC) antibodies. Principal component analysis demonstrated that three parameters could explain 70% of the patients. Hierarchical cluster analysis showed three clusters: Groups A and B comprised patients who were positive for anti-corticotroph antibodies, and plasma ACTH levels were extremely low. Groups A and B comprised middle-aged or elderly men and middle-aged women, respectively. Group C comprised patients who were positive for the anti-FSC antibody and elderly men; plasma ACTH levels were relatively high. Conclusions: Patients with IAD were classified into three groups based on clinical characteristics and autoantibodies. The presence of anti-corticotroph antibody suggested severe injury to corticotrophs. This new classification clearly demonstrated the heterogeneity in the pathogenesis of IAD.

  2021, Frontiers in endocrinology, 12, 578802 - 578802, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease.

  Hidenori Fukuoka, Hiroki Shichi, Masaaki Yamamoto, Yutaka Takahashi

  Cushing's disease caused due to adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) leads to hypercortisolemia, resulting in increased morbidity and mortality. Autonomous ACTH secretion is attributed to the impaired glucocorticoid negative feedback (glucocorticoid resistance) response. Interestingly, other conditions, such as ectopic ACTH syndrome (EAS) and non-neoplastic hypercortisolemia (NNH, also known as pseudo-Cushing's syndrome) also exhibit glucocorticoid resistance. Therefore, to differentiate between these conditions, several dynamic tests, including those with desmopressin (DDAVP), corticotrophin-releasing hormone (CRH), and Dex/CRH have been developed. In normal pituitary corticotrophs, ACTH synthesis and secretion are regulated mainly by CRH and glucocorticoids, which are the ACTH secretion-stimulating and -suppressing factors, respectively. These factors regulate ACTH synthesis and secretion through genomic and non-genomic mechanisms. Conversely, glucocorticoid negative feedback is impaired in ACTHomas, which could be due to the overexpression of 11β-HSD2, HSP90, or TR4, or loss of expression of CABLES1 or nuclear BRG1 proteins. Genetic analysis has indicated the involvement of several genes in the etiology of ACTHomas, including USP8, USP48, BRAF, and TP53. However, the association between glucocorticoid resistance and these genes remains unclear. Here, we review the clinical aspects and molecular mechanisms of ACTHomas and compare them to those of other related conditions.

  Nov. 2020, International journal of molecular sciences, 21(23) (23), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A case of Luscan-Lumish syndrome: Possible involvement of enhanced GH signaling.

  Kentaro Suda, Hidenori Fukuoka, Genzo Iguchi, Keitaro Kanie, Yasunori Fujita, Yukiko Odake, Ryusaku Matsumoto, Hironori Bando, Hiroki Ito, Michiko Takahashi, Kazuo Chihara, Hiroshi Nagai, Satoshi Narumi, Tomonobu Hasegawa, Wataru Ogawa, Yutaka Takahashi

  CONTEXT: Luscan-Lumish syndrome (LLS) is characterized by postnatal overgrowth, obesity, Chiari I malformation, seizures, and intellectual disability. SET domain-containing protein 2 (SETD2) is a histone methyltransferase, where mutations in the gene are associated with the development of LLS. However, mechanisms underlying LLS remain unclear. CASE DESCRIPTION: A 20-year-old man was referred to our hospital because of tall stature. His body height was 188.2 cm (+3.18 SD) and he showed obesity with a body mass index of 28.4 kg/m 2. He exhibited acral overgrowth, jaw malocclusion, and prognathism, but no history of seizures, intellectual disability, or speech delay. Serum growth hormone (GH), insulin-like growth factor 1 (IGF-1), and nadir GH levels after administration of 75 g oral glucose were within normal range. Pituitary magnetic resonance imaging showed no pituitary adenoma, but Chiari I malformation. Whole exome sequencing analysis of the proband revealed a de novo heterozygous germline mutation in SETD2 (c.236T>A, p.L79H). Skin fibroblasts derived from the patient grew faster than those from his father and the control subject. In addition, these cells showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH. CONCLUSION: This is a mild case of LLS with a novel mutation in SETD2 without neurological symptoms. LLS should be differentiated in a patient with gigantism without pituitary tumors. Although further investigation is necessary, this is the first study to suggest the involvement of aberrant GH signaling in the development of LLS.

  Nov. 2020, The Journal of clinical endocrinology and metabolism, 106(3) (3), 718 - 723, English, International magazine

  Scientific journal


• Response to Letter to the Editor from Berthon: "Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patients With Cortisol-Secreting Adrenocortical Adenoma".

  Kentaro Suda, Hidenori Fukuoka

  Nov. 2020, The Journal of clinical endocrinology and metabolism, 105(11) (11), English, International magazine

  Scientific journal


• 心肺停止に偽性アルドステロン症の関与が疑われた副腎腫瘍の一例

  齋藤 修一郎, 穂積 かおり, 稲葉 惟子, 山本 雅昭, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 561 - 561, Japanese


• Pazopanibにより改善を認めた非膵島細胞腫瘍性低血糖症の一例

  山本 直希, 山本 雅昭, 稲葉 惟子, 清田 尚臣, 西山 信晴, 西影 星二, 福田 いずみ, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 564 - 564, Japanese


• TSHの周期性分泌が示唆されたGH・TSH産生下垂体腺腫の1例

  大井 佑夏, 山本 雅昭, 稲葉 惟子, 穂積 かおり, 志智 大城, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 502 - 502, Japanese


• クッシング病術後に精神症状を生じた1例

  鈴木 正暉, 山本 雅昭, 堀本 誠也, 木村 敦, 石田 敦士, 山田 正三, 辻本 泰貴, 千原 和夫, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 506 - 506, Japanese


• AVP持続点滴後に一過性DDAVP抵抗性を生じた中枢性尿崩症の3例

  西影 星二, 山本 雅昭, 稲葉 惟子, 松本 梨佐, 大町 侑香, 山本 直希, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 499 - 499, Japanese


• 免疫チェックポイント阻害薬関連下垂体炎の新たな発症機序の解明

  蟹江 慶太郎, 井口 元三, 浦井 伸, 志智 大城, 藤田 泰功, 山本 雅昭, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 495 - 495, Japanese


• AVP持続点滴後に一過性DDAVP抵抗性を生じた中枢性尿崩症の3例

  西影 星二, 山本 雅昭, 稲葉 惟子, 松本 梨佐, 大町 侑香, 山本 直希, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 499 - 499, Japanese


• 血中遊離メタネフリン分画が鑑別に有用であった副腎腺腫の1例

  大町 侑香, 山本 雅昭, 稲葉 惟子, 鈴木 正暉, 神澤 真紀, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 542 - 542, Japanese


• 心肺停止に偽性アルドステロン症の関与が疑われた副腎腫瘍の一例

  齋藤 修一郎, 穂積 かおり, 稲葉 惟子, 山本 雅昭, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 561 - 561, Japanese


• Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports.

  Tomoko Yamada, Hidenori Fukuoka, Yusei Hosokawa, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Yuko Okada, Yushi Hirota, Genzo Iguchi, Wataru Ogawa, Yutaka Takahashi

  BACKGROUND: Plasma renin activity (PRA) is generally increased in patients with pheochromocytoma (PCC) due to low circulating plasma volume and activation of β-1 adrenergic receptor signaling. However, there has been no study on the aldosterone renin ratio (ARR) in patients with PCC. To elucidate the issue, this study aimed to determine the PRA, plasma aldosterone concentration (PAC), and ARR in patients with PCC and compare them with those in patients with subclinical Cushing's syndrome (SCS) and non-functioning adrenal adenoma (NFA). METHODS: In this retrospective single-center, cross-sectional study, 67 consecutive patients with adrenal tumors (PCC (n = 18), SCS (n = 18), and NFA (n = 31)) diagnosed at Kobe University Hospital between 2008 and 2014 were enrolled. RESULTS: PRA was significantly higher in patients with PCC than in those with SCS and NFA (2.1 (1.3 ~ 2.8) vs. 0.7 (0.5 ~ 1.8) and 0.9 (0.6 ~ 1.4) ng/mL/h; p = 0.018 and p = 0.025). Although PACs were comparable among the three groups, ARR was significantly lower in patients with PCC than in those with SCS and NFA (70.5 (45.5 ~ 79.5) vs. 156.0 (92.9 ~ 194.5) and 114.9 (90.1 ~ 153.4); p = 0.001 and p < 0.001). Receiver operating characteristic curve analysis demonstrated that, in differentiating PCC from NFA, PRA > 1.55 ng/mL/h showed a sensitivity of 70.0% and specificity of 80.6%. Interestingly, ARR < 95.4 showed a sensitivity of 83.3% and specificity of 86.7%, which were higher than those in PRA. CONCLUSIONS: ARR decreased in patients with PCC, which was a more sensitive marker than PRA. Further study is necessary to understand the usefulness of this convenient marker in the detection of PCC. TRIAL REGISTRATION: This study was not registered because of the retrospective analysis.

  Sep. 2020, BMC endocrine disorders, 20(1) (1), 140 - 140, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 【内分泌腺腫瘍(第2版)-基礎・臨床研究のアップデート-】間脳・下垂体腫瘍 間脳・下垂体腫瘍の病理生理と臨床像 視床下部腫瘍

  福岡 秀規, 高橋 裕

  (株)日本臨床社, Sep. 2020, 日本臨床, 78(増刊4 内分泌腺腫瘍) (増刊4 内分泌腺腫瘍), 146 - 149, Japanese


• The impact of adrenal tumor multidisciplinary team meetings on clinical outcomes.

  Hidenori Fukuoka, Katsumi Shigemura, Maki Kanzawa, Tomonori Kanda, Masaaki Yamamoto, Koichi Kitagawa, Mariko Sakamoto, Genzo Iguchi, Wataru Ogawa, Masato Fujisawa, Yutaka Takahashi

  PURPOSE: Multidisciplinary team meetings (MDMs) to address various clinical problems have become common, especially for cancer care. However, the impact of MDMs on adrenal tumor care has rarely been reported. We organized an endocrine tumor MDM including adrenal tumors in August 2014. The objective of this study was to assess the impact of our adrenal tumor MDMs on patient clinical outcomes. We compared several parameters measuring clinical outcomes before and after MDMs were instituted. METHODS: The adrenal tumor MDMs included an endocrinologists, urologists, radiologists, pathologists, and residents. We analyzed 128 consecutive cases of functioning adrenal tumors (primary aldosteronism (PA), n = 53; Cushing's syndrome (CS), n = 24; pheochromocytoma (PCC), n = 51) who underwent surgery in Kobe University Hospital from 2008 to 2019, and compared clinical parameters before (n = 68) and after (n = 60) MDMs were instituted. RESULTS: Twenty-one selected cases including PA, CS, PCC, adrenocortical carcinoma, and metastatic adrenal tumor were discussed in the MDM. In the analysis of 128 cases, the difference between pre- and postoperative systolic BP (ΔBP) in patients with PA after MDMs were instituted was smaller compared with those before (p = 0.02). In CS, preoperative steroid synthesis inhibitors were used more often (33 vs. 100%, p < 0.01), postoperative plasma ACTH levels were higher (29.1 vs. 84.5 pg/mL, p < 0.01), and postoperative decrease in systolic BP was milder (p < 0.01) after MDMs were instituted. In PCC, doses of preoperative doxazosin were higher (p < 0.01) after MDMs institution. Operating time, bleeding volume, and cure rate did not differ between each tumor type. CONCLUSIONS: These data suggest that instituting MDMs improved the perioperative management of functioning adrenal tumors.

  Sep. 2020, Endocrine, 69(3) (3), 519 - 525, English, International magazine

  [Refereed]

  Scientific journal


• Adrenal Corticomedullary Mixed Tumor Associated With the FGFR4-G388R Variant.

  Maki Kanzawa, Hidenori Fukuoka, Akane Yamamoto, Kentaro Suda, Katsumi Shigemura, Shigeo Hara, Naoko Imagawa, Ryuko Tsukamoto, Yayoi Aoyama, Yasuhiro Nakamura, Masato Fujisawa, Wataru Ogawa, Yutaka Takahashi, Tomoo Itoh

  Adrenal corticomedullary mixed tumors (CMMTs) are extremely rare; with only 20 cases being reported to date, the pathogenesis has remained elusive. A 31-year-old woman developed gestational hypertension with psychiatric disturbances persistent to postpartum and was diagnosed with pheochromocytoma, for which adrenalectomy was performed. Histological findings showed mixed adrenocortical adenoma and pheochromocytoma. Double immunostaining of inhibin and INSM1 (insulinoma-associated protein 1) showed that the 2 tumor components had distinct functional properties. Exome analysis of peripheral leukocytes and tumor (singular, as anatomically it is only 1 mass) revealed a homozygous germline FGFR4-G388R variant. As a readout of the variant, serine phosphorylation of signal transducer and activator of transcription 3 (STAT3) was detected only in the nucleus of adrenocortical adenoma component but not in the pheochromocytoma component. No tyrosine phosphorylation of STAT3 was detected. We report a case of CMMT with the germline FGFR4-G388R variant. Although additional studies are required, our immunohistochemical analysis suggests that the variant may play a role in the development of the adrenocortical component within the pheochromocytoma, leading to CMMT.

  The Endocrine Society, Sep. 2020, Journal of the Endocrine Society, 4(9) (9), bvaa101, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 1型糖尿病患者における発症様式の違いは骨密度に影響を与える

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 雅昭, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本糖尿病学会, Aug. 2020, 糖尿病, 63(Suppl.1) (Suppl.1), S - 219, Japanese


• 糖質コルチコイドによる正のフィードバック機構の関与が想定されるクッシング病

  辻本 泰貴, 志智 大城, 福岡 秀規, 中村 友昭, 神澤 真紀, 石田 敦士, 山田 正三, 小川 渉, 高橋 裕, 千原 和夫

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 249 - 249, Japanese


• 妊娠中に高血圧と精神症状を呈した副腎皮質・髄質混合腫瘍の1例

  神澤 真紀, 福岡 秀規, 重村 克己, 青山 弥生, 中村 保宏, 原 重雄, 山本 あかね, 高橋 裕, 伊藤 智雄

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 372 - 372, Japanese


• 高レニン、高アルドステロンを呈したDOC産生副腎皮質癌の一例

  福満 隼人, 山本 直希, 福岡 秀規, 山本 雅昭, 神澤 真紀, 清田 尚臣, 小松 昇平, 重村 克己, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 374 - 374, Japanese


• 1型糖尿病ではインスリン分泌能が骨密度に影響を与える

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 雅昭, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 246 - 246, Japanese


• 自己免疫性溶血性貧血を伴った悪性胸腺腫合併抗PIT-1下垂体炎の1例

  蟹江 慶太郎, 井口 元三, 山本 雅昭, 浦井 伸, 志智 大城, 藤田 泰功, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 250 - 250, Japanese


• QT延長、致死性不整脈を呈したACTH分泌不全症の3例

  浦井 伸, 山本 雅昭, 福岡 秀規, 桂 由佳梨, 内山 奏, 西本 祐希, 金谷 雅之, 志智 大城, 蟹江 慶太郎, 藤田 泰功, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 251 - 251, Japanese


• Cushing病におけるCRH試験の反応性と関連する臨床的特徴の検討

  志智 大城, 福岡 秀規, 浦井 伸, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 290 - 290, Japanese


• ICI関連下垂体炎、1型糖尿病を同時期に発症した一例

  藤田 泰功, 合田 菜穂, 浦井 伸, 志智 大城, 蟹江 慶太郎, 山本 雅昭, 岡田 裕子, 廣田 勇士, 福岡 秀規, 井口 元三, 清田 尚臣, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 307 - 307, Japanese


• ゴナドトロピン単独分泌不全症をきたした再生不良性貧血の一例

  山本 直希, 浦井 伸, 福岡 秀規, 山本 雅昭, 福満 隼人, 清家 雅子, 高吉 倫史, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 360 - 360, Japanese


• 1型糖尿病患者における心エコー図を用いた左室拡張機能の検討

  浦井 伸, 山本 雅昭, 福岡 秀規, 岡田 裕子, 田中 秀和, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 475 - 475, Japanese


• 高結合能・低親和性インスリン抗体の性質の改善を認めた1型糖尿病の1例

  小畠 正樹, 金子 景弘, 苛原 彩, 岡田 裕子, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 481 - 481, Japanese


• SAP療法中1型糖尿病患者におけるカニューレ交換後の血糖推移に関する検討

  穂積 かおり, 浦井 伸, 山本 雅昭, 岡田 裕子, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 505 - 505, Japanese


• SAP療法中の1型糖尿病患者におけるPLGS機能導入半年後の効果についての検討

  山本 あかね, 廣田 勇士, 山本 雅昭, 福岡 秀規, 岡田 裕子, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 505 - 505, Japanese


• 1型糖尿病患者における心エコー図を用いた左室拡張機能の検討

  浦井 伸, 山本 雅昭, 福岡 秀規, 岡田 裕子, 田中 秀和, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 475 - 475, Japanese


• SAP療法中1型糖尿病患者におけるカニューレ交換後の血糖推移に関する検討

  穂積 かおり, 浦井 伸, 山本 雅昭, 岡田 裕子, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 505 - 505, Japanese


• SAP療法中の1型糖尿病患者におけるPLGS機能導入半年後の効果についての検討

  山本 あかね, 廣田 勇士, 山本 雅昭, 福岡 秀規, 岡田 裕子, 小川 渉

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 505 - 505, Japanese


• Insulin secretion and sensitivity before and after surgical treatment for aldosterone-producing adenoma

  H. Komada, Y. Hirota, A. So, T. Nakamura, Y. Okuno, H. Fukuoka, G. Iguchi, Y. Takahashi, K. Sakaguchi, W. Ogawa

  Elsevier Masson SAS, Jun. 2020, Diabetes and Metabolism, 46(3) (3), 236 - 242, English

  Scientific journal


• Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma.

  Kentaro Suda, Hidenori Fukuoka, Yuto Yamazaki, Katsumi Shigemura, Miki Mukai, Yukiko Odake, Ryusaku Matsumoto, Hironori Bando, Michiko Takahashi, Genzo Iguchi, Masato Fujisawa, Masahiro Oka, Katsuhiko Ono, Kazuo Chihara, Hironobu Sasano, Wataru Ogawa, Yutaka Takahashi

  CONTEXT: Germline mutations in fumarate hydratase (FH) gene are known to cause hereditary leiomyomatosis and renal cell carcinoma (HLRCC) and are occasionally accompanied with cutaneous and uterine leiomyoma or cortisol-producing adrenocortical hyperplasia. However, the association between FH mutations and cardiac or adrenocortical tumors has remained unknown. Here, we identified a novel deletion in FH, exhibiting cardiac myxoma and subclinical Cushing syndrome due to adrenocortical tumor. CASE DESCRIPTION: A 44-year-old man was referred to our hospital for cardiac and adrenal tumor evaluation. He had a history of multiple painful, dermal papules and nodules diagnosed as cutaneous leiomyoma. The surgically resected cardiac tumor was diagnosed as myxoma. The adrenal tumor was clinically diagnosed as subclinical Cushing syndrome. Laparoscopically resected adrenal tumor was pathologically diagnosed as adrenocortical adenoma harboring unique histological findings similar to primary pigmented nodular adrenocortical disease (PPNAD). DNA analysis revealed a germline deletion in FH c0.737delT (p. Phe225Leufs*31) and loss of heterozygosity (LOH) in cardiac myxoma. As a functional analysis of FH in cardiac myxoma, low FH protein expression with elevated 2-succinocysteine (2SC), a marker of FH dysfunction, was immunohistochemically detected. However, in adrenocortical tumor, LOH of FH was not detected, and FH or 2SC expression was not altered. CONCLUSIONS: This is the first case of HLRCC complicated by cardiac myxoma. LOH of FH deletion and its dysfunction were identified in cardiac myxoma. The association between FH deletion and adrenocortical lesion, however, needs to be further clarified.

  Jun. 2020, The Journal of clinical endocrinology and metabolism, 105(6) (6), English, International magazine

  [Refereed]

  Scientific journal


• 疾患iPS細胞/抗原特異的T細胞を用いた抗PIT-1下垂体炎疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 伊藤 剛, 喜多山 秀一, 坂東 弘教, 六車 恵子, 松本 隆作, 山本 雅昭, 福岡 秀規, 金子 新, 小川 渉, 高橋 裕

  日本臨床分子医学会, Apr. 2020, 日本臨床分子医学会学術総会プログラム・抄録集, 57回(1) (1), 78 - 78, Japanese

  [Refereed]


• Cushing病におけるCRH試験反応性に関連する病態の解明

  志智 大城, 福岡 秀規, 浦井 伸, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 井下 尚子, 山田 正三, 小川 渉, 高橋 裕

  日本臨床分子医学会, Apr. 2020, 日本臨床分子医学会学術総会プログラム・抄録集, 57回, 79 - 79, Japanese

  [Refereed]


• 疾患iPS細胞/抗原特異的T細胞を用いた抗PIT-1下垂体炎疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 伊藤 剛, 喜多山 秀一, 坂東 弘教, 六車 恵子, 松本 隆作, 山本 雅昭, 福岡 秀規, 金子 新, 小川 渉, 高橋 裕

  日本臨床分子医学会, Apr. 2020, 日本臨床分子医学会学術総会プログラム・抄録集, 57回, 78 - 78, Japanese

  [Refereed]


• Cushing病におけるCRH試験反応性に関連する病態の解明

  志智 大城, 福岡 秀規, 浦井 伸, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 井下 尚子, 山田 正三, 小川 渉, 高橋 裕

  日本臨床分子医学会, Apr. 2020, 日本臨床分子医学会学術総会プログラム・抄録集, 57回, 79 - 79, Japanese

  [Refereed]


• Autoimmune Pituitary Disease: New Concepts With Clinical Implications.

  Masaaki Yamamoto, Genzo Iguchi, Hironori Bando, Keitaro Kanie, Ryoko Hidaka-Takeno, Hidenori Fukuoka, Yutaka Takahashi

  Some endocrine disorders, including hypophysitis and isolated adrenocorticotropic hormone (ACTH) deficiency, are caused by an autoimmune response to endocrine organs. Although the pathogenesis of some autoimmune endocrine diseases has been elucidated, it remains obscure for most. Anti-PIT-1 hypophysitis (anti-PIT-1 antibody syndrome) is a newly described pituitary autoimmune disease characterized by acquired and specific growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiencies. This disorder is associated with a thymoma or neoplasm that ectopically expresses pituitary-specific transcription factor 1 (PIT-1) protein. Circulating anti-PIT-1 antibody is a disease marker, and PIT-1-reactive cytotoxic T cells (CTLs) play a pivotal role in disease development. In addition, isolated ACTH deficiency appears to be caused by autoimmunity to corticotrophs; however, the pathogenesis remains unclear. A recently described case of isolated ACTH deficiency with large cell neuroendocrine carcinoma (LCNEC) showed ectopically expressed proopiomelanocortin (POMC), and circulating anti-POMC antibody and POMC-reactive CTLs were also detected. As CTL infiltrations around corticotrophs were also observed, isolated ACTH deficiency may be associated at least in part with a paraneoplastic syndrome. Although several underlying mechanisms for pituitary autoimmunity have been proposed, these observations highlight the importance of paraneoplastic syndrome as a cause of pituitary autoimmune disease. In this review, we focus on the pathophysiology and connection of anti-PIT-1 hypophysitis and isolated ACTH deficiency and discuss the state-of-art knowledge for understanding pituitary autoimmunity.

  Apr. 2020, Endocrine reviews, 41(2) (2), English, International magazine

  [Refereed]

  Scientific journal


• Congenital pituitary hypoplasia model demonstrates hypothalamic OTX2 regulation of pituitary progenitor cells.

  Ryusaku Matsumoto, Hidetaka Suga, Takashi Aoi, Hironori Bando, Hidenori Fukuoka, Genzo Iguchi, Satoshi Narumi, Tomonobu Hasegawa, Keiko Muguruma, Wataru Ogawa, Yutaka Takahashi

  Pituitary develops from oral ectoderm in contact with adjacent ventral hypothalamus. Impairment in this process results in congenital pituitary hypoplasia (CPH); however, there have been no human disease models for CPH thus far, prohibiting the elucidation of the underlying mechanisms. In this study, we established a disease model of CPH using patient-derived induced pluripotent stem cells (iPSCs) and 3D organoid technique, in which oral ectoderm and hypothalamus develop simultaneously. Interestingly, patient iPSCs with a heterozygous mutation in the orthodenticle homeobox 2 (OTX2) gene showed increased apoptosis in the pituitary progenitor cells, and the differentiation into pituitary hormone-producing cells was severely impaired. As an underlying mechanism, OTX2 in hypothalamus, not in oral ectoderm, was essential for progenitor cell maintenance by regulating LHX3 expression in oral ectoderm via FGF10 expression in the hypothalamus. Convincingly, the phenotype was reversed by the correction of the mutation, and the haploinsufficiency of OTX2 in control iPSCs revealed a similar phenotype, demonstrating that this mutation was responsible. Thus, we established an iPSC-based congenital pituitary disease model, which recapitulated interaction between hypothalamus and oral ectoderm and demonstrated the essential role of hypothalamic OTX2.

  Feb. 2020, The Journal of clinical investigation, 130(2) (2), 641 - 654, English, International magazine

  [Refereed]

  Scientific journal


• 特発性アルドステロン症を合併したサブクリニカルクッシング症候群の1例

  神澤 真紀, 瀬尾 あかね, 福岡 秀規, 岡田 佳輔, 藤沢 正人, 青山 弥生, 中村 保宏, 高橋 裕, 伊藤 智雄

  (一社)日本内分泌学会, Feb. 2020, 日本内分泌学会雑誌, 95(4) (4), 1693 - 1693, Japanese


• 高齢先端巨大症患者におけるQOLの特徴とその低下に寄与する因子の検討

  山本 直希, 浦井 伸, 福岡 秀規, 高吉 倫史, 山本 雅昭, 吉田 健一, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Jan. 2020, 日本内分泌学会雑誌, 95(3) (3), 1139 - 1139, Japanese

  [Refereed]


• 2年間以上形態学的変化のなかった肺腫瘤が原因であった異所性ACTH症候群の一例

  辻本 泰貴, 中村 友昭, 山本 直希, 高吉 倫史, 山本 雅昭, 福岡 秀規, 佐藤 伊都子, 大橋 千裕, 田中 雄悟, 眞庭 謙昌, 稲葉 礼奈, 神保 直江, 小川 渉, 高橋 裕, 千原 和夫

  (一社)日本内分泌学会, Jan. 2020, 日本内分泌学会雑誌, 95(3) (3), 1142 - 1142, Japanese

  [Refereed]


• 大腿部にFreeStyleリブレのセンサーを装着し、壊死性筋膜炎を発症した血液透析中の1型糖尿病患者の1例

  吉田 舞, 岡田 裕子, 坂本 洋一, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  日本先進糖尿病治療研究会, Nov. 2019, 日本先進糖尿病治療研究会雑誌, 15, 35 - 35, Japanese


• FGM(Flash Glucose Monitoring)使用が1型糖尿病患者の血糖コントロールに与える影響についての検討

  瀬尾 あかね, 岡田 裕子, 藤原 えり, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  日本先進糖尿病治療研究会, Nov. 2019, 日本先進糖尿病治療研究会雑誌, 15, 45 - 45, Japanese


• Pathogenesis of Anti-PIT-1 Antibody Syndrome: PIT-1 Presentation by HLA Class I on Anterior Pituitary Cells.

  Keitaro Kanie, Hironori Bando, Genzo Iguchi, Keiko Muguruma, Ryusaku Matsumoto, Ryoko Hidaka-Takeno, Yasuhiko Okimura, Masaaki Yamamoto, Yasunori Fujita, Hidenori Fukuoka, Kenichi Yoshida, Kentaro Suda, Hitoshi Nishizawa, Wataru Ogawa, Yutaka Takahashi

  Context: Anti-pituitary-specific transcriptional factor-1 (anti-PIT-1) antibody syndrome is characterized by acquired and specific deficiencies in growth hormone, prolactin, and thyroid-stimulating hormone. Although PIT-1-reactive cytotoxic T lymphocytes (CTLs) have been speculated to recognize anterior pituitary cells and to cause the injury in the pathogenesis of the syndrome, it remains unclear whether endogenous PIT-1 protein is processed through the proteolytic pathway and presented as an antigen on anterior pituitary cells. Objective: To examine how PIT-1 protein is processed and whether its epitope is presented by major histocompatibility complex (MHC)/HLA class I on anterior pituitary cells. Materials and Methods: Immunofluorescence staining and proximity ligation assay (PLA) were performed using anti-PIT-1 antibody and patients' sera on PIT-1-expressing cell line GH3 cells and human induced pluripotent stem cell (iPSC)-derived pituitary tissues. Results: PIT-1 was colocalized with MHC class I molecules, calnexin, and GM130 in the cytosol. PLA results showed that PIT-1 epitope was presented by MHC/HLA class I molecules on the cell surface of GH3 cells and iPSC-derived pituitary cells. The number of PIT-1/HLA complexes on the cell surface of pituitary cells in the patient was comparable with that in the control subject. Conclusions: Our data indicate that PIT-1 protein is processed in the antigen presentation pathway and that its epitopes are presented by in MHC/HLA class I on anterior pituitary cells, supporting the hypothesis that PIT-1-reactive CTLs caused the cell-specific damage. It is also suggested that number of epitope presentation was not associated with the pathogenesis of anti-PIT-1 antibody syndrome.

  Nov. 2019, Journal of the Endocrine Society, 3(11) (11), 1969 - 1978, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.

  Kaori Hozumi, Hidenori Fukuoka, Yukiko Odake, Takehito Takeuchi, Tomoko Uehara, Takeshi Sato, Naoko Inoshita, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Yushi Hirota, Genzo Iguchi, Masaaki Taniguchi, Naoki Otsuki, Chikako Nishigori, Kenjiro Kosaki, Tomonobu Hasegawa, Wataru Ogawa, Yutaka Takahashi

  Although acromegaly has been reported in patients with Neurofibromatosis type 1 (NF1), these cases have not been associated with growth hormone (GH)-producing somatotroph adenoma, but with optic pathway glioma. A 68 year-old Japanese woman, who had been clinically diagnosed with NF1, was referred to our hospital due to a thyroid tumor and hypercalcemia. Acromegaly was suspected due to her facial features, and subsequent examinations revealed the presence of GH excess with a pituitary tumor, leading to the diagnosis of acromegaly. Histological and immunohistochemical analysis demonstrated an eosinophilic pituitary adenoma with diffuse positivity for GH, indicating typical somatotroph adenoma. In addition, her thyroid tumor was diagnosed histologically as follicular thyroid carcinoma (FTC) with primary hyperparathyroidism (PHPT). To investigate the pathogenesis of this untypical multiple endocrine tumor case of NF1, genetic analysis was performed using peripheral leukocytes and tissue of resected tumors. A heterozygous novel germline nonsense mutation (p.Arg1534*) in exon 35 of the NF1 gene was detected from peripheral leukocytes, which results in a truncated protein lacking the critical domain for GTPase activity, strongly suggesting its causal role in NF1. The loss of heterozygosity (LOH) in exon 35 of the NF1 gene was not detected in the somatotroph adenoma, parathyroid adenoma, and FTC. Although any mutations of the following genes; MEN1, CDKN1B, and PAX8-PPARγ were not detected, a heterozygous GNAS R201C mutation was detected in the somatotroph adenoma. To our knowledge, this is the first rare MEN1-like case of genetically diagnosed NF1 complicated with acromegaly caused by a somatotroph adenoma.

  Oct. 2019, Endocrine journal, 66(10) (10), 853 - 857, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 原発性大結節性副腎過形成症の多くは遺伝性疾患である

  姜 知佳, 臼井 健, 小杉 理英子, 鳥居 みずき, 米本 崇子, 小川 達雄, 小谷 仁人, 田村 尚久, 方波見 卓之, 齋藤 洸平, 栗原 勲, 金本 巨哲, 福岡 秀規, 村部 浩之, 井上 達秀

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 705 - 705, Japanese


• 高用量DEX抵抗性サブクリニカルクッシング病in vitroでの検証

  臼谷 真理, 高安 忍, 志智 大城, 福岡 秀規, 山田 正三, 山形 聡, 杉山 綾, 照井 健, 川嶋 詳子, 蔭山 和則, 高橋 裕, 大門 眞

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 763 - 763, Japanese


• 造血幹細胞移植10年後に部分性脂肪萎縮症を発症したと考えられた1例

  淺原 俊一郎, 穂積 かおり, 廣田 勇士, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本肥満学会, Oct. 2019, 肥満研究, 25(Suppl.) (Suppl.), 312 - 312, Japanese

  [Refereed]


• ARMC5 Alterations in Primary Macronodular Adrenal Hyperplasia (PMAH) and the Clinical State of Variant Carriers.

  Chika Kyo, Takeshi Usui, Rieko Kosugi, Mizuki Torii, Takako Yonemoto, Tatsuo Ogawa, Masato Kotani, Naohisa Tamura, Yutaro Yamamoto, Takuyuki Katabami, Isao Kurihara, Kohei Saito, Naotetsu Kanamoto, Hidenori Fukuoka, Norio Wada, Hiroyuki Murabe, Tatsuhide Inoue

  Context: Primary macronodular adrenal hyperplasia (PMAH) is a rare type of Cushing or subclinical Cushing syndrome and is associated with bilateral multinodular formation. ARMC5 is one of the responsible genes for PMAH. Objectives: This study was performed to identify the genotype-phenotype correlation of ARMC5 in a cohort of Japanese patients. Patients and Methods: Fourteen patients with clinically diagnosed PMAH and family members of selected patients were studied for ARMC5 gene alteration and clinical phenotype. The associated nonadrenal tumor tissues were also studied. Results: Of fourteen patients with PMAH, 10 had pathogenic or likely pathogenic variants of ARMC5. We found two variants. Five unrelated patients had identical variants (p.R619*). In two patients, the variant was found in offspring with the asymptomatic or presymptomatic state. Six of ten patients who tested positive for the ARMC5 pathogenic or likely pathogenic variant carried nonadrenal tumors; however, no loss of heterozygosity (LOH) or second hit of the ARMC5 gene was evident. The ARMC5 variant-positive group showed a significantly higher basal cortisol level. Furthermore, age-dependent cortisol hypersecretion was seen in the ARMC5 variant-positive group. Conclusions: ARMC5 pathogenic variants are common (71%) in Japanese patients with PMAH. p.R619* might be a hot spot in Japanese patients with PMAH. Asymptomatic or presymptomatic pathogenic variant carriers were found among the family members of the patients. Although 50% of ARMC5 variant carriers had nonadrenal neoplastic lesions, no LOH or second hit of ARMC5 in the tumor tissues was evident. The ARMC5 variant-positive mutant group showed a higher basal cortisol level than the negative group.

  Oct. 2019, Journal of the Endocrine Society, 3(10) (10), 1837 - 1846, English, International magazine

  [Refereed]

  Scientific journal


• パミドロン酸の効果を認めた閉経後骨形成不全症V型の一例

  福岡 秀規, 浦井 伸, 伊賀 真紀子, 中島 進介, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本骨粗鬆症学会, Sep. 2019, 日本骨粗鬆症学会雑誌, 5(Suppl.1) (Suppl.1), 437 - 437, Japanese


• Phenotypic differences and similarities of monozygotic twins with maturity-onset diabetes of the young type 5.

  Yasuko Ohara, Yuko Okada, Tomoko Yamada, Kenji Sugawara, Masayuki Kanatani, Hidenori Fukuoka, Yushi Hirota, Takaki Maeda, Naoya Morisada, Kazumoto Iijima, Wataru Ogawa

  Here, we report phenotypic differences and similarities of monozygotic twins with maturity-onset diabetes of the young type 5 harboring a partial deletion of chromosome 17q12. The proband and her twin sister manifested complete aplasia and marked hypoplasia, respectively, of the body and tail of the pancreas. Whereas both twins showed marked hypoplasia of the right kidney and multiple cysts in both kidneys, only the proband's sister showed hydronephrosis in the left kidney. The proband had profound defects in insulin and glucagon secretion, as well as mild renal dysfunction, whereas her sister had pronounced renal dysfunction accompanied by mild defects in insulin and glucagon secretion. Both twins manifested hypomagnesemia and hyperuricemia, but no apparent liver dysfunction or intellectual disability. The severity of renal and pancreatic defects differed between monozygotic twins with maturity-onset diabetes of the young type 5, suggesting that the phenotypes of this condition are determined not solely by genetic factors.

  Jul. 2019, Journal of diabetes investigation, 10(4) (4), 1112 - 1115, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 6年間の糖質制限食により、低栄養、やせを来した1型糖尿病の1例

  鈴木 宏隆, 中谷 早希, 岡田 裕子, 土橋 一生, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Apr. 2019, 糖尿病, 62(4) (4), 251 - 251, Japanese


• FGM使用が1型糖尿病患者の血糖コントロールに与える影響についての検討

  瀬尾 あかね, 岡田 裕子, 藤原 えり, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2019, 糖尿病, 62(4) (4), 260 - 261, Japanese


• FreeStyleリブレセンサーを装着し壊死性筋膜炎を発症した血液透析中の1型糖尿病患者の1例

  吉田 舞, 岡田 裕子, 坂本 洋一, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2019, 糖尿病, 62(4) (4), 293 - 293, Japanese


• SAP療法中の1型糖尿病患者における低グルコース前一時停止(predictive low glucose suspend: PLGS)機能の効果についての検討

  瀬尾 あかね, 廣田 勇士, 岡田 裕子, 福岡 秀規, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2019, 糖尿病, 62(Suppl.1) (Suppl.1), S - 292, Japanese


• 暁現象に対する早朝超速効型インスリン投与がもたらす血糖変動の変化の検討

  高吉 倫史, 廣田 勇士, 岡田 裕子, 福岡 秀規, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2019, 糖尿病, 62(Suppl.1) (Suppl.1), S - 293, Japanese


• Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey.

  Lisa B Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V Syro, Daniel Kelly, Maria Fleseriu

  PURPOSE: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. METHODS: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. RESULTS: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. CONCLUSIONS: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.

  Feb. 2019, Pituitary, 22(1) (1), 37 - 45, English, International magazine

  [Refereed]

  Scientific journal


• IgG4-related hypophysitis in patients with autoimmune pancreatitis.

  Keitaro Kanie, Hironori Bando, Genzo Iguchi, Hideyuki Shiomi, Atsuhiro Masuda, Hidenori Fukuoka, Hitoshi Nishizawa, Yasunori Fujita, Arata Sakai, Takashi Kobayashi, Yuuki Shiomi, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Yuzo Kodama, Wataru Ogawa, Yutaka Takahashi

  PURPOSE: IgG4-related disease involves various organs including the pituitary and pancreas. The prevalence of IgG4-related hypophysitis is relatively rare compared with IgG4-related pancreatitis (autoimmune pancreatitis). Although several cases demonstrating both autoimmune pancreatitis and hypophysitis have been reported, the prevalence of IgG4-related hypophysitis in patients with autoimmune pancreatitis remains unknown. This study aimed at screening for IgG4-related hypophysitis to accurately determine its prevalence in patients with autoimmune pancreatitis. METHODS: In this cohort study, we screened IgG4-related hypophysitis via pituitary magnetic resonance imaging (MRI) and endocrinological examination in 27 patients who were undergoing follow-up for autoimmune pancreatitis at Kobe University Hospital between 2014 and 2018. RESULTS: Among 27 patients with autoimmune pancreatitis, 5 patients exhibited morphological abnormalities in the pituitary (18.5%). Among them, one patient (3.7%) met the criteria for hypophysitis with an enlarged pituitary and stalk concomitant with hypopituitarism. After glucocorticoid treatment, the enlarged pituitary shrank and became empty sella during the clinical course. Four patients (14.8%) revealed empty sella without obvious pituitary dysfunction. Four of 5 patients with morphological pituitary abnormalities showed multiple organ involvement in addition to pancreatic and pituitary involvement. Accordingly, multiple organ involvement was more prevalent in patients with morphological pituitary abnormalities (80%) compared to those without (48%). CONCLUSIONS: Although a large-scale study is necessary to validate these results, these data suggest that the prevalence of hypophysitis in patients with autoimmune pancreatitis may be underestimated. Based on our findings, we recommend screening for hypophysitis, especially in patients with multiple organ involvement.

  Feb. 2019, Pituitary, 22(1) (1), 54 - 61, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Editorial: Targeted Therapy for Pituitary Adenomas.

  Takako Araki, Odelia Cooper, Hidenori Fukuoka

  2019, Frontiers in endocrinology, 10, 358 - 358, English, International magazine

  [Refereed]

  Link to Kobe Univ. Repository (Kernel)


• 当院における副腎腫瘍マネージメントにおける術後多科合同カンファレンスについて

  重村 克巳, 寺川 智章, 千葉 公嗣, 古川 順也, 原田 健一, 日向 信之, 福岡 秀規, 高橋 裕, 中野 雄造, 藤澤 正人

  (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2018, 日本泌尿器内視鏡学会総会, 32回, ADP - 4, Japanese


• Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.

  Reina Yamamoto, Kosuke Robert Shima, Hirobumi Igawa, Yuka Kaikoi, Yasuo Sasagawa, Yasuhiko Hayashi, Naoko Inoshita, Hidenori Fukuoka, Yutaka Takahashi, Toshinari Takamura

  A 43-year-old woman with an 8-year history of diabetes, hypertension, and dyslipidemia presented with amenorrhea and convulsion. Her MRI scan revealed a 3.5-cm T2-hyperintense pituitary macroadenoma with suprasellar extension to the frontal lobe and bilateral cavernous sinus invasion. Her serum levels of GH and insulin-like growth factor-I (IGF-I) were elevated to 9.08 ng/mL (normal range: <2.1 ng/mL) and 1,000 ng/mL (normal range: 90-233 ng/mL, SD score +10.6), respectively. Bromocriptine insufficiently suppressed her GH levels, while octreotide paradoxically increased her GH levels. Together with her characteristic features, she was diagnosed with acromegaly caused by an invasive GH-producing pituitary macroadenoma. As performing a one-stage operation would have been extremely difficult, she was first treated with pasireotide long-acting release (40 mg monthly) for 5 months followed by a successful transsphenoidal surgery. One month after the first injection, biochemical control was achieved (IGF-I, 220 ng/mL; GH, 1.26 ng/mL), and tumor shrinkage of approximately 50% was observed. The resected tumor was histologically diagnosed as a sparsely granulated somatotroph adenoma, with higher expression of somatostatin receptor subtype 5 (SSTR5) than that of SSTR2A. The germline aryl hydrocarbon receptor interacting protein (AIP) mutation was negative, and several tumor cells were weakly immunoreactive for AIP. Despite the presence of a residual tumor postoperatively, biochemical control was achieved 6 months after the final injection of pasireotide. In conclusion, this case suggests that pasireotide may be an option for preoperative first-line therapy in invasive and octreotide-resistant sparsely granulated somatotroph adenomas.

  Oct. 2018, Endocrine journal, 65(10) (10), 1061 - 1067, English, Domestic magazine

  [Refereed]

  Scientific journal


• Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function.

  Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed

  Pituitary corticotroph somatostatin receptor subtype 5 (SSTR5) signals to inhibit adrenocorticotrophin (ACTH) secretion. As ACTH deficiency results in attenuated adrenal cortisol production and an impaired stress response, we sought to clarify the role of SSTR5 in modifying the hypothalamic/pituitary/adrenal (HPA) axis. We generated Tg HP5 mice overexpressing SSTR5 in pituitary corticotrophs that produce the ACTH precursor proopiomelanocortin (POMC). Basal ACTH and corticosterone were similar in HP5 and WT mice, while HP5 mice showed attenuated ACTH and corticosterone responses to corticotrophin releasing hormone (CRH). HP5 mice exhibited attenuated corticosterone responses upon a restraint stress test and inflammatory stress following LPS injection, as well as increased anxiety-like and depressive-like behavior on open field and forced swim tests. Pituitary corticotroph CRH receptor subtype 1 (CRHR1) mRNA expression and ACTH responses to CRH were also attenuated in HP5 mice. In AtT20 cells stably overexpressing SSTR5, CRHR1 expression and cAMP response to CRH were reduced, whereas both were increased after SSTR5 KO. In elucidating mechanisms for these observations, we show that SSTR5-induced miR-449c suppresses both CRHR1 expression and function. We conclude that corticotroph SSTR5 attenuates HPA axis responses via CRHR1 downregulation, suggesting a role for SSTR5 in the pathogenesis of secondary adrenal insufficiency.

  Oct. 2018, JCI insight, 3(19) (19), English, International magazine

  [Refereed]

  Scientific journal


• Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome.

  Hironori Bando, Genzo Iguchi, Keitaro Kanie, Hitoshi Nishizawa, Ryusaku Matsumoto, Yasunori Fujita, Yukiko Odake, Kenichi Yoshida, Kentaro Suda, Hidenori Fukuoka, Keiko Tanaka, Wataru Ogawa, Yutaka Takahashi

  PURPOSE: In isolated adrenocorticoropic hormone (ACTH) deficiency (IAD), autoimmunity against corticotrophs has been suggested; however, the pathogenesis remains largely unknown. Large cell neuroendocrine carcinoma (LCNEC) of the lung is a pulmonary tumor of high-grade malignant neuroendocrine tumor and it reportedly caused paraneoplastic syndrome by autoimmunity in several cases. METHODS: A 42-year-old woman with isolated adrenocorticotropic (ACTH) hormone deficiency (IAD) was diagnosed with large cell neuroendocrine carcinoma (LCNEC) 3 years after being diagnosed with IAD. We hypothesized that the LCNEC played a causal role in the development of IAD as a paraneoplastic syndrome and analyzed the autoimmunity. We also analyzed another case of ectopic ACTH syndrome to prove this hypothesis. RESULTS: The LCNEC tissue revealed an ectopic ACTH expression and lymphocyte infiltration. Interestingly, autoantibody against the proopiomelanocortin (POMC) protein was detected in the peripheral blood. Although, patient's serum did not show any effects on cell viability, proliferation, nor pomc expression in a corticotroph cell line, AtT20 cells, patient's lymphocytes in the peripheral blood specifically reacted toward POMC protein, indicating a presence of cytotoxic T lymphocytes (CTLs). In addition, the analysis of another case of ectopic ACTH syndrome showed lymphocyte infiltration not only in the metastatic liver tumors but also in the pituitary. Moreover, most CD8-positive cells resided adjacent to corticotrophs. CONCLUSIONS: These data indicate that the ectopic ACTH expression in the tumor evoked the autoimmunity to corticotrophs and caused IAD as a form of paraneoplastic syndrome.

  Oct. 2018, Pituitary, 21(5) (5), 480 - 489, English, International magazine

  [Refereed]

  Scientific journal


• GH分泌不全症患者に対するGH補充療法がサルコペニアに与える影響の検討

  Fukuoka Hidenori

  (公財)成長科学協会, Oct. 2018, 成長科学協会研究年報, (41号) (41号), 181 - 181, Japanese

  [Invited]


• 免疫チェックポイント阻害薬関連下垂体炎における自己抗体の同定

  蟹江慶太郎, 井口元三, 坂東弘教, 志智大城, 藤田泰功, 小武由紀子, 松本隆作, 隅田健太郎, Fukuoka Hidenori, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 607 - 607, Japanese

  [Invited]

  Research society


• 本邦におけるPMAHの遺伝的背景とその臨床的特徴

  姜知佳, 小杉理英子, 臼井健, 鳥居みずき, 米本崇子, 小川達雄, 田村尚久, 金本巨哲, 村部浩之, 菱田吉明, 方波見卓行, 坂東弘教, Fukuoka Hidenori, 井上達秀

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2号) (2号), 712 - 712, Japanese

  [Invited]


• 部分的甲状腺ホルモン不応症を呈したTSH産生下垂体腫瘍の一例

  合田菜穂, Fukuoka Hidenori, 谷口理章, 西原永潤, 宮内昭, 岡田裕子, 廣田勇士, 井口元三, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 671 - 671, Japanese

  [Invited]

  Research society


• 非機能性副腎腫瘍の不均一性から見る機能性腫瘍診断基準の問題点

  松本隆作, 山田倫子, Fukuoka Hidenori, 井口元三, 藤田奏功, 蟹江慶太郎, 坂東弘教, 隅田健太郎, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 714 - 714, Japanese

  [Invited]

  Research society


• 妊娠中に認められたコルチゾール産生腫瘍と褐色細胞腫1例

  瀬尾あかね, Fukuoka Hidenori, 坂本洋一, 岡田裕子, 廣田勇士, 井口元三, 小川渉, 高橋裕

  (一社)日本肥満学会, Sep. 2018, 肥満研究, 24(Suppl.) (Suppl.), 194 - 194, Japanese

  [Invited]

  Research society


• 診断に難渋したTSH単独分泌不全症の一例

  隅田健太郎, 千原和夫, 志智大城, 蟹江慶太郎, 藤田泰功, 小武由紀子, 坂東弘教, 高橋路子, Fukuoka Hidenori, 井口元三, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 681 - 681, Japanese

  [Invited]

  Research society


• 若年性高血圧、体重増加を契機にクッシング病の診断に至った1例

  鈴木宏隆, Fukuoka Hidenori, 志智大城, 廣田勇士, 岡田裕子, 井口元三, 小川渉, 高橋裕

  (一社)日本肥満学会, Sep. 2018, 肥満研究, 24(Suppl.) (Suppl.), 194 - 194, Japanese

  Research society


• 機能性下垂体腺腫の薬物療法

  Fukuoka Hidenori, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 584 - 584, Japanese

  [Invited]

  Research society


• 褐色細胞腫とコルチゾール産生副腎腺腫が混在した妊婦の一例

  瀬尾あかね, Fukuoka Hidenori, 神澤真紀, 重村克己, 中村保宏, 森實真由美, 坂本洋一, 岡田裕子, 廣田勇士, 井口元三, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 704 - 704, Japanese

  [Invited]

  Research society


• 下垂体腺腫発生に関わる分子学的異常の理解と診療への応用

  Fukuoka Hidenori, 吉田健一, 小武由紀子, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(Suppl.HPT) (Suppl.HPT), 16 - 17, Japanese

  Research society


• 鞍上部海綿状血管腫術後に高度肥満を含む視床下部症候群を呈し治療に難渋した一例

  藤田泰功, 金谷雅之, 浦井伸, 蟹江慶太郎, 小武由紀子, 松本隆作, 坂東弘教, 隅田健太郎, 岡田裕子, Fukuoka Hidenori, 廣田勇士, 井口元三, 小川渉, 高橋裕

  (一社)日本肥満学会, Sep. 2018, 肥満研究, 24(Suppl.) (Suppl.), 194 - 194, Japanese

  [Invited]

  Research society


• パラガングリオーマと原発性アルドステロン症を合併した1例

  芳村魁, Fukuoka Hidenori, 志智大城, 小松正人, 神澤真紀, 寺川智章, 重村克己, 岡田裕子, 廣田勇士, 井口元三, 藤澤正人, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 704 - 704, Japanese

  [Invited]

  Research society


• Cushing病におけるDDAVP試験の反応性とその臨床的特徴の検討

  志智大城, Fukuoka Hidenori, 松本隆作, 蟹江慶太郎, 藤田泰功, 井口元三, 隅田健太郎, 坂東弘教, 井下尚子, 山田正三, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 607 - 607, Japanese

  [Invited]

  Research society


• ARMC5変異を認めたPBMAHと異所性副甲状腺腫によるPHPTの合併例

  苛原彩, Fukuoka Hidenori, 吉田健一, 土橋一生, 坂東弘教, 岡田裕子, 井口元三, 小川裕行, 神澤真紀, 坂井誠, 臼井健, 小川渉, 高橋裕

  (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2号) (2号), 713 - 713, Japanese

  [Invited]


• A Body Shape Indexと頸動脈プラークスコアとの関連についての検討

  芳村魁, 岡田裕子, Fukuoka Hidenori, 廣田勇士, 坂口一彦, 小川渉

  (一社)日本肥満学会, Sep. 2018, 肥満研究, 24(Suppl.) (Suppl.), 174 - 174, Japanese

  [Invited]

  Research society


• 1型糖尿病患者におけるFGMの使用が血糖コントロールおよび体重に与える影響についての検討

  藤原えり, 岡田裕子, 瀬尾あかね, Fukuoka Hidenori, 廣田勇士, 坂口一彦, 小川渉

  (一社)日本肥満学会, Sep. 2018, 肥満研究, 24(Suppl.) (Suppl.), 173 - 173, Japanese

  Research society


• Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects.

  Ryusaku Matsumoto, Masafumi Koga, Soji Kasayama, Hidenori Fukuoka, Genzo Iguchi, Yukiko Odake, Kenichi Yoshida, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Wataru Ogawa, Yutaka Takahashi

  BACKGROUND: Most of circulating IGF-I is derived from the liver and circulating IGF-I levels are decreased in several pathological conditions, such as liver cirrhosis, uncontrolled diabetes, renal failure, and malnutrition. However, it has not fully been elucidated which factors modify IGF-I level in a physiological condition. OBJECTIVE: To identify the factors which are associated with circulating IGF-I levels. DESIGN: Cross-sectional study. METHODS: This study included 428 subjects who undertook health check-up. Subjects diagnosed with non-alcoholic fatty liver disease (NAFLD) by ultrasonography were analyzed separately. Univariate and multivariate regression analyses were conducted to identify the factors associated with circulating IGF-I levels. RESULTS: Regression analyses revealed that serum albumin levels, total-bilirubin levels, calcium levels, and HOMA-IR were positively correlated with IGF-I levels. Serum transaminase levels and habitual drinking (ethanol intake >20 g/day) were negatively correlated with serum IGF-I levels. Although serum IGF-I standard deviation scores (SDS) in subjects with and without NAFLD were comparable, after adjusting confounding factors clarified by multivariate regression analysis, IGF-I SDS negatively correlated with the presence of NAFLD. CONCLUSION: In this study, we demonstrated that serum bilirubin and calcium levels are correlated with serum IGF-I levels. Although further study is necessary, these data suggest a presence of interaction between GH-IGF-I axis and bilirubin and calcium metabolism.

  Jun. 2018, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 40, 55 - 60, English, International magazine

  [Refereed]

  Scientific journal


• 自己免疫性溶血性貧血と偽性副甲状腺機能低下症を合併した一例

  坂本洋一, Fukuoka Hidenori, 野崎高史, 藤田泰功, 蟹江慶太郎, 小武由紀子, 吉田健一, 松本隆作, 坂東弘教, Hirota Yushi, 岡田裕子, Iguchi Genzo, Ogawa Wataru, 高橋裕

  (一社)日本内分泌学会, Jun. 2018, 日本内分泌学会雑誌, 94(Suppl.Update) (Suppl.Update), 32 - 34, Japanese

  [Refereed]


• 持効型インスリンが不要となったインスリン抗体陽性1型糖尿病の1例

  苛原彩, 岡田裕子, 坂本洋一, 菅原健二, Fukuoka Hidenori, 廣田勇士, 坂口一彦, 小川渉

  (一社)日本糖尿病学会, Jun. 2018, 糖尿病, 61(6号) (6号), 421 - 421, Japanese

  [Invited]


• インスリン分泌不全を基盤としてケトーシス発症しMODY5の診断に至った一卵性双生児の例

  小原靖子, 山田倫子, 岡田裕子, 坂本洋一, 菅原健二, Fukuoka Hidenori, 廣田勇士, 坂口一彦, 森貞直哉, 飯島一誠, 小川渉

  (一社)日本糖尿病学会, Jun. 2018, 糖尿病, 61(6) (6), 456 - 456, Japanese

  [Invited]

  Research society


• 2型糖尿病患者の血中IGF-I値に影響を与える因子の検討

  隅田健太郎, Fukuoka Hidenori, 廣田勇士, 坂東弘教, 高橋路子, 井口元三, 木南佐織, 坂口一彦, 千原和夫, 小川渉, 高橋裕

  (一社)日本糖尿病学会, Jun. 2018, 糖尿病, 61(6号) (6号), 401 - 401, Japanese

  [Invited]


• 下垂体SSTR5はmicroRNAを介してHPA軸を抑制する

  山本 雅昭, Ben-Shlomo Anat, 亀田 啓, 福岡 秀規, Melmed Shlomo

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 290 - 290, Japanese

  [Refereed]


• 発症前からの経時的な内分泌学的評価が可能であったニボルマブ関連下垂体炎の一例

  藤田泰功, Fukuoka Hidenori, 中野温子, 友藤清爾, 蟹江慶太郎, 小武由紀子, 吉田健一, 松本隆作, 坂東弘教, 岡田裕子, 井口元三, 小川渉, 高橋裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 386 - 386, Japanese

  [Invited]

  Research society


• 特発性中枢性尿崩症とPRL単独欠損症を合併した1例

  蟹江慶太郎, 井口元三, 坂東弘教, 藤原えり, 藤田泰功, 小武由紀子, 吉田健一, 松本隆作, Fukuoka Hidenori, 小川渉, 高橋裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 342 - 342, Japanese

  [Invited]

  Research society


• 糖尿病患者におけるビタミンD欠乏に関連する因子についての検討

  合田菜穂, 岡田裕子, 苛原彩, 瀬尾あかね, 小原靖子, 松山温子, 藤原えり, 坂本洋一, 菅原健二, Fukuoka Hidenori, 廣田勇士, 坂口一彦, 小川渉

  (一社)日本糖尿病学会, Apr. 2018, 糖尿病, 61(Suppl.1) (Suppl.1), S - 147, Japanese

  [Invited]

  Research society


• 中枢性副腎不全を呈した偽性副甲状腺機能低下症の一例

  坂本洋一, 林佳菜恵, Fukuoka Hidenori, 池田真理子, 岡田裕子, 廣田勇士, 井口元三, 飯島誠, 小川渉, 高橋裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 328 - 328, Japanese

  [Invited]

  Research society


• メトホルミン内服患者におけるビタミンB12欠乏の実態調査

  菅原健二, 岡田裕子, 野村和弘, 山田倫子, 中川靖, Fukuoka Hidenori, 廣田勇士, 細岡哲也, 坂口一彦, 木戸良明, 小川渉

  (一社)日本糖尿病学会, Apr. 2018, 糖尿病, 61(Suppl.1) (Suppl.1), S - 238, Japanese

  [Invited]

  Research society


• ACTH単独欠損症の新たな成因 腫瘍随伴症候群

  坂東弘教, 井口元三, 蟹江慶太郎, 藤田泰功, 小武由紀子, 吉田健一, 松本隆作, 隅田健太郎, Fukuoka Hidenori, 小川渉, 高橋裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 341 - 341, Japanese

  [Invited]

  Research society


• ACTH産生下垂体腫瘍におけるErbB4受容体の役割の解明

  小武由紀子, Fukuoka Hidenori, 吉田健一, 山田正三, 井口元三, 小川渉, 高橋裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 403 - 403, Japanese

  [Invited]

  Research society


• 下垂体-副腎の分子生物学 Long noncoding RNA、CRNDEはACTH産生下垂体腺腫の増殖、浸潤性に関連する

  Fukuoka Hidenori, 吉田健一, 小武由紀子, 松本隆作, 坂東弘教, 隅田健太郎, 藤田泰功, 蟹江慶太郎, 井口元三, 山田正三, 小川渉, 高橋裕

  間脳・下垂体・副腎系研究会, Mar. 2018, ACTH RELATED PEPTIDES, 29, 42 - 43, Japanese

  [Refereed][Invited]

  Scientific journal


• Two Cases of Atezolizumab-Induced Hypophysitis.

  Keitaro Kanie, Genzo Iguchi, Hironori Bando, Yasunori Fujita, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi

  Cancer immunotherapy has emerged as treatment of multiple advanced cancer types. Immune checkpoint inhibitors, namely anticytotoxic T-lymphocyte antigen-4 (CTLA-4), antiprogrammed cell death-1 (PD-1), and antiprogrammed cell death-1 ligand 1 (PD-L1) antibodies, have been used for treatment of various cancers. Classified as immune-related adverse events, several endocrinopathies, including hypophysitis, are associated with these agents. Although anti-CTLA-4-induced hypophysitis has been frequently observed, hypophysitis upon use of anti-PD-1 and anti-PD-L1 antibodies is rare. Case 1 is a 65-year-old man presented with a stage IV non-small cell lung cancer (NSCLC) treated with atezolizumab (an anti-PD-L1 antibody) following several inefficacious chemotherapies. After 56 weeks of the treatment, he complained of general malaise and appetite loss, and was diagnosed with adrenal insufficiency. Endocrinological examination revealed isolated adrenocorticotropic hormone (ACTH) deficiency; pituitary magnetic resonance imaging (MRI) showed anterior pituitary atrophy. Hydrocortisone replacement therapy rapidly improved his symptoms and enabled him to continue atezolizumab therapy. Case 2 is a 70-year-old man with a stage IV NSCLC treated with atezolizumab. After 52 weeks of treatment, he was diagnosed with isolated ACTH deficiency. Pituitary MRI revealed no obvious abnormalities in the anterior pituitary. Hydrocortisone replacement therapy was also efficacious. We report two cases of atezolizumab-induced hypophysitis. Both showed isolated ACTH deficiency, suggesting similar clinical characteristics of hypophysitis associated with the use of anti-PD-1 antibodies. These results suggest a caution for the late-onset central adrenal insufficiency associated with hypophysitis in patients treated with anti-PD-L1 antibodies.

  Jan. 2018, Journal of the Endocrine Society, 2(1) (1), 91 - 95, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience.

  Yukiko Odake, Hidenori Fukuoka, Masaaki Yamamoto, Yoshifumi Arisaka, Junya Konishi, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Genzo Iguchi, Shozo Yamada, Wataru Ogawa, Yutaka Takahashi

  Oct. 2017, Pituitary, 20(5) (5), 509 - 514, English, International magazine

  [Refereed]

  Scientific journal


• Insulin Secretion and Insulin Sensitivity Before and After Surgical Treatment of Pheochromocytoma or Paraganglioma.

  Hisako Komada, Yushi Hirota, Anna So, Tomoaki Nakamura, Yoko Okuno, Hidenori Fukuoka, Genzo Iguchi, Yutaka Takahashi, Kazuhiko Sakaguchi, Wataru Ogawa

  Sep. 2017, The Journal of clinical endocrinology and metabolism, 102(9) (9), 3400 - 3405, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A case of fatal heart and liver failure accompanied by thyroid storm treated with prompt plasma exchange.

  Feibi Zeng, Tomofumi Takaya, Naofumi Yoshida, Tatsuro Ito, Makiko Suto, Yu Hatani, Hiroyuki Sano, Jun Ito, Hidenori Fukuoka, Tomoya Yamashita, Ken-Ichi Hirata

  A 36-year-old man with a history of Graves' disease was admitted complaining of dyspnea. He was diagnosed with acute heart failure and severe liver dysfunction accompanied by thyroid storm. Left ventricular ejection fraction was 19%, and liver enzyme levels were markedly elevated followed with coagulation disorders. In addition to the conventional therapy, we performed plasma exchange emergently. Thyroid hormone levels promptly normalized, then his clinical condition improved. Finally, his cardiac and liver function almost normalized from a fatal condition without serious complications. Hyperthyroidism can cause myocardial and liver injury, hence thyroid hormone removal in acute phase is important. Prompt plasma exchange is effective in the acute phase for heart and liver failure accompanied by thyroid storm. .

  Mar. 2017, Journal of cardiology cases, 15(3) (3), 100 - 103, English, Domestic magazine

  [Refereed]


• A novel thymoma-associated autoimmune disease: Anti-PIT-1 antibody syndrome.

  Hironori Bando, Genzo Iguchi, Yasuhiko Okimura, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Hidenori Fukuoka, Atsuko Mokubo, Katsuyoshi Tojo, Yoshimasa Maniwa, Wataru Ogawa, Yutaka Takahashi

  Feb. 2017, Scientific reports, 7, 43060 - 43060, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.

  Takako Araki, Xiaohai Liu, Hiraku Kameda, Yukiko Tone, Hidenori Fukuoka, Masahide Tone, Shlomo Melmed

  The epidermal growth factor receptor (EGFR), expressed in adrenocorticotrophic hormone (ACTH)-secreting pituitary adenomas causing Cushing disease, regulates ACTH production and corticotroph proliferation. To elucidate the utility of EGFR as a therapeutic target for Cushing disease, we generated transgenic (Tg) mice with corticotroph-specific human EGFR expression (corti-EGFR-Tg) using a newly constructed corticotroph-specific promoter. Pituitary-specific EGFR expression was observed by 2.5 months, and aggressive ACTH-secreting pituitary adenomas with features of Crooke's cells developed by 8 months with 65% penetrance observed. Features consistent with the Cushing phenotype included elevated plasma ACTH and corticosterone levels, increased body weight, glucose intolerance, and enlarged adrenal cortex. Gefitinib, an EGFR tyrosine kinase inhibitor, suppressed tumor POMC expression and downstream EGFR tumor signaling, and ACTH and corticosterone levels were attenuated by 80% and 78%, respectively. Both E2F1 and phosphorylated Ser-337 E2F1 were increased in corti-EGFR-Tg mice and also colocalized with human POMC (hPOMC) in human pituitary corticotroph tumor samples. EGFR inhibition reversed E2F1 activity in vivo, whereas E2F1 inhibition suppressed POMC and ACTH in cultured human pituitary tumor cells. The corti-EGFR-Tg phenotype recapitulates ACTH-secreting pituitary adenomas and Cushing disease, validating the relevance of EGFR to corticotroph tumorigenesis. E2F1 is identified as a promising corticotroph-specific target for ACTH-dependent Cushing disease.

  Feb. 2017, Journal of the Endocrine Society, 1(2) (2), 127 - 143, English, International magazine

  [Refereed]

  Scientific journal


• 5 Years Follow-up of Diabetic Polyneuropathy with Type 1 Diabetes after Simultaneous Pancreas-kidney Transplantation

  Inoue Seiya, Okada Yuko, Miura Hiroshi, Nakamura Tomoaki, Fukuoka Hidenori, Hirota Yushi, Sakaguchi Kazuhiko, Ogawa Wataru

  The Japanese Society of Internal Medicine, 2017, Nihon Naika Gakkai Zasshi, 106(8) (8), 1640 - 1645, Japanese


• Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing's Syndromes Treatment: Case Presentations.

  Kenichi Yoshida, Hidenori Fukuoka, Yukiko Odake, Shinsuke Nakajima, Mariko Tachibana, Jun Ito, Yusei Hosokawa, Tomoko Yamada, Hiroshi Miura, Natsu Suematsu, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Genzo Iguchi, Wataru Ogawa, Yutaka Takahashi

  Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulness as a marker for monitoring medical therapy has not yet been established. The aim of this study was to assess the utility of multiple salivary cortisol measurements in patients with Cushing's syndrome (CS) during medical therapy. Six patients with CS (three with cortisol-secreting adrenocortical adenoma and three with ACTH-secreting pituitary adenoma) were recruited. Samples for morning serum cortisol, urinary free cortisol (UFC), and multiple salivary cortisol levels were collected before and during metyrapone treatment. The area under the curve (AUC) and mean value (MV) of daily salivary cortisol levels were calculated. In five out of six patients, UFC were normalized; however, multiple salivary cortisol measurements revealed an impaired diurnal cortisol rhythm in these patients. To verify the usefulness of multiple salivary cortisol measurements, we performed a prospective case study of a patient in whom the excess secretion of cortisol was not controlled (UFC 211 μg/day) with 2,250 mg/day in four divided doses of metyrapone. Multiple measurements of salivary cortisol revealed that cortisol levels elevated before the next administration. Accordingly, we shortened the interval by increasing the number of administration from four to five times per day, with a slight increment of daily dose of 2,500 mg. These optimizations resulted in a drastic improvement of diurnal pattern as well as UFC level (101 μg/day). Changes in both the MV and AUC of salivary cortisol levels were more correlated with those in UFC levels (Correlation coefficient 0.75, p = 0.007, and 0.70, p = 0.017) than those in the morning serum cortisol levels (0.42, p = 0.200), indicating that multiple salivary cortisol measurements reflect more precisely the excess secretion of cortisol. Our preliminary data suggest that multiple salivary cortisol measurements can be a useful tool to visualize the diurnal cortisol rhythm and to determine the dose and timing of metyrapone during the treatment in patients with CS.

  2017, Frontiers in endocrinology, 8, 375 - 375, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma.

  Ryusaku Matsumoto, Masako Izawa, Hidenori Fukuoka, Genzo Iguchi, Yukiko Odake, Kenichi Yoshida, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Naoko Inoshita, Shozo Yamada, Wataru Ogawa, Yutaka Takahashi

  Nov. 2016, Endocrine journal, 63(11) (11), 953 - 963, English, Domestic magazine

  [Refereed]

  Scientific journal


• IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner.

  Hitoshi Nishizawa, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Kentaro Suda, Hironori Bando, Ryusaku Matsumoto, Kenichi Yoshida, Yukiko Odake, Wataru Ogawa, Yutaka Takahashi

  Oct. 2016, Scientific reports, 6, 34605 - 34605, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients.

  Kentaro Suda, Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Yushi Hirota, Hitoshi Nishizawa, Hironori Bando, Kenichi Yoshida, Yukiko Odake, Michiko Takahashi, Kazuhiko Sakaguchi, Wataru Ogawa, Yutaka Takahashi

  Aug. 2016, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 29, 4 - 10, English, International magazine

  [Refereed]

  Scientific journal


• Prevalence of Simple Renal Cysts in Acromegaly.

  Masaaki Yamamoto, Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Michiko Takahashi, Hitoshi Nishizawa, Kentaro Suda, Hironori Bando, Yutaka Takahashi

  2016, Internal medicine (Tokyo, Japan), 55(13) (13), 1685 - 90, English, Domestic magazine

  [Refereed]

  Scientific journal


• The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.

  Kenichi Yoshida, Hidenori Fukuoka, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Genzo Iguchi, Wataru Ogawa, Susan M Webb, Yutaka Takahashi

  PURPOSE: To develop a Japanese version of the acromegaly quality of life (QoL) questionnaire (AcroQoL) and investigate the factors associated with impaired QoL in patients with acromegaly. METHODS: We developed a Japanese version of the AcroQoL by a forward-backward method and evaluated QoL in 38 patients with acromegaly who had been followed up at an outpatient clinic at Kobe University Hospital. Its reliability was examined with Cronbach's alpha and item-total correlations. Second examination was performed for concurrent validity by assessment of correlations with the Short Form-36 (SF-36) and longitudinal analysis of the AcroQoL in 25 patients. RESULTS: Cronbach's alpha and item-total correlations showed a range of 0.76-0.93 and 0.20-0.84, respectively, and significant correlations were found between the AcroQoL and the SF-36. Younger age and a history of radiotherapy were associated with worse total score by the multivariate linear regression analysis (p = 0.020 and p = 0.042, respectively). Intriguingly, in the biochemically-controlled group after the exclusion of patients who received radiotherapy, patients who underwent surgery alone exhibited a higher psychological (75.0 vs. 65.7 %, p = 0.036) and appearance (64.3 vs. 53.6 %, p = 0.036) score than those who are treating with pharmaceutical therapy. CONCLUSIONS: The reliability of the Japanese version of the AcroQoL was satisfactory. Younger age and a history of radiotherapy were associated with lower QoL in patients with acromegaly. In biochemically-controlled acromegaly, patients who underwent surgery alone exhibited better QoL than those under pharmaceutical therapy.

  Dec. 2015, Pituitary, 18(6) (6), 876 - 83, English, International magazine

  [Refereed]

  Scientific journal


• A diagnostic pitfall in IgG4-related hypophysitis: infiltration of IgG4-positive cells in the pituitary of granulomatosis with polyangiitis.

  Hironori Bando, Genzo Iguchi, Hidenori Fukuoka, Masaaki Taniguchi, Seiji Kawano, Miki Saitoh, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Akio Morinobu, Eiji Kohmura, Wataru Ogawa, Yutaka Takahashi

  INTRODUCTION: Immunoglobulin (Ig) G4-related hypophysitis is an emerging clinical entity, which is characterized by an elevated serum IgG4 concentration and infiltration of IgG4-positive plasma cells in the pituitary. Although some criteria for its diagnosis have been proposed, they have not been fully established. In particular, differential diagnosis from secondary chronic inflammation including granulomatosis with polyangiitis (GPA) is difficult in some cases. We describe central diabetes insipidus with pituitary swelling exhibiting infiltration of IgG4-positive cells. PATIENT: A 43-year-old woman in the remission stage of GPA presented with sudden-onset polyuria and polydipsia. Pituitary magnetic resonance imaging revealed swelling of the anterior and posterior pituitary and stalk, with heterogeneous gadolinium enhancement and disappearance of the high signal intensity of the posterior pituitary. Evaluation of biochemical markers for GPA suggested that the disease activity was well-controlled. Endocrinological examination revealed the presence of central diabetes insipidus and growth hormone deficiency. Pituitary biopsy specimen showed IgG4-positive cells, with a 43% IgG4(+)/IgG(+) ratio, which met the criteria for IgG4-related hypophysitis. However, substantial infiltration of polymorphonuclear neutrophils with giant cells was also noted, resulting in a final diagnosis of pituitary involvement of GPA. CONCLUSION: These results suggest that pituitary involvement of GPA should be taken into account for the differential diagnosis of IgG4-related hypophysitis.

  Oct. 2015, Pituitary, 18(5) (5), 722 - 30, English, International magazine

  [Refereed]

  Scientific journal


• Median-lower normal levels of serum thyroxine are associated with low triiodothyronine levels and body temperature in patients with central hypothyroidism.

  Yu Hirata, Hidenori Fukuoka, Genzo Iguchi, Yasuyuki Iwahashi, Yasunori Fujita, Yusuke Hari, Makiko Iga, Shinsuke Nakajima, Yuki Nishimoto, Miki Mukai, Yushi Hirota, Kazuhiko Sakaguchi, Wataru Ogawa, Yutaka Takahashi

  OBJECTIVE: Although it has been recommended that serum free thyroxine (FT4) levels should be targeted to middle-upper normal levels during levothyroxine (l-T4) replacement therapy in patients with central hypothyroidism (CeH), the rationale has not been clarified. METHODS: A retrospective single-center study enrolled 116 patients with hypothyroidism (CeH, n=32; total thyroidectomy (Tx), n=22; primary hypothyroidism (PH), n=33; and control benign thyroid nodule (C), n=29). The patients had received L-T4 therapy at the Kobe University Hospital between 2003 and 2013. They were stratified according to serum FT4 level (≥ 1.10 or <1.10 ng/dl), and body temperature (BT), serum free triiodothyronine (FT3) levels, FT3/FT4 ratio, and lipid profiles were compared. The effect of GH replacement therapy on thyroid function was also analyzed. RESULTS: FT3 levels and FT3/FT4 ratios were significantly lower in patients with CeH than in patients with PH (P<0.05) or C (P<0.05). In patients with FT4 <1.10 ng/dl, BT was significantly lower in patients with CeH (P=0.002) and Tx (P=0.005) than in patients with PH, whereas no differences were found in patients with FT4 ≥ 1.10 ng/dl. In patients with CeH, FT3 levels were higher in those with GH replacement therapy (P=0.018). CONCLUSION: In CeH, patients with median-lower normal levels of serum FT4 exhibited lower serum FT3 levels and lower BT. These results support the target levels of serum FT4 as middle-upper normal levels during l-T4 replacement therapy in patients with CeH.

  Aug. 2015, European journal of endocrinology, 173(2) (2), 247 - 56, English, International magazine

  [Refereed]

  Scientific journal


• Turner症候群とCAHの合併を認めた副腎偶発腫の一例

  岩橋泰幸, Fukuoka Hidenori, 中島進介, 井口元三, 本間桂子, 長谷川奉延, Ogawa Wataru, 高橋裕

  (一社)日本内分泌学会, Jul. 2015, 日本内分泌学会雑誌, 91(Suppl.Update) (Suppl.Update), 44 - 46, Japanese

  [Refereed]


• The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study

  Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, Ryusaku Matsumoto, Michiko Takahashi, Hitoshi Nishizawa, Kentaro Suda, Hironori Bando, Yutaka Takahashi

  Jun. 2015, PITUITARY, 18(3) (3), 343 - 351, English

  [Refereed]

  Scientific journal


• ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice

  Xiaohai Liu, Maya Kano, Takako Araki, Odelia Cooper, Hidenori Fukuoka, Yukiko Tone, Masahide Tone, Shlomo Melmed

  Jan. 2015, ENDOCRINOLOGY, 156(1) (1), 71 - 79, English

  [Refereed]

  Scientific journal


• The prevalence of acromegaly in hospitalized patients with type 2 diabetes

  Kentaro Suda, Hidenori Fukuoka, Genzo Iguchi, Yushi Hirota, Hitoshi Nishizawa, Hironori Bando, Ryusaku Matsumoto, Michiko Takahashi, Kazuhiko Sakaguchi, Yutaka Takahashi

  Jan. 2015, ENDOCRINE JOURNAL, 62(1) (1), 53 - 59, English

  [Refereed]

  Scientific journal


• Accelerated Telomere Shortening in Acromegaly; IGF-I Induces Telomere Shortening and Cellular Senescence.

  Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Yukiko Odake, Kenichi Yoshida, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Shozo Yamada, Wataru Ogawa, Yutaka Takahashi

  OBJECTIVE: Patients with acromegaly exhibit reduced life expectancy and increased prevalence of age-related diseases, such as diabetes, hypertension, and cardiovascular disease. However, the underlying mechanism has not been fully elucidated. Telomere shortening is reportedly associated with reduced life expectancy and increased prevalence of these age-related diseases. METHODS: We measured telomere length in patients with acromegaly using quantitative PCR method. The effect of GH and IGF-I on telomere length and cellular senescence was examined in human skin fibroblasts. RESULTS: Patients with acromegaly exhibited shorter telomere length than age-, sex-, smoking-, and diabetes-matched control patients with non-functioning pituitary adenoma (0.62 ± 0.23 vs. 0.75 ± 0.35, respectively, P = 0.047). In addition, telomere length in acromegaly was negatively correlated with the disease duration (R2 = 0.210, P = 0.003). In vitro analysis revealed that not GH but IGF-I induced telomere shortening in human skin fibroblasts. Furthermore, IGF-I-treated cells showed increased senescence-associated β-galactosidase activity and expression of p53 and p21 protein. IGF-I-treated cells reached the Hayflick limit earlier than GH- or vehicle-treated cells, indicating that IGF-I induces cellular senescence. CONCLUSION: Shortened telomeres in acromegaly and cellular senescence induced by IGF-I can explain, in part, the underlying mechanisms by which acromegaly exhibits an increased morbidity and mortality in association with the excess secretion of IGF-I.

  2015, PloS one, 10(10) (10), e0140189, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 原発性副甲状腺機能亢進症におけるシナカルセトの効果の検討

  末松 那都, 福岡 秀規, 播 悠介, 平田 悠, 中島 進介, 山田 佳子, 志智 大樹, 浦井 伸, 加藤 慶太郎, 三浦 洋, 廣田 勇士, Iguchi Genzo, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 947 - 947, Japanese


• 異所性ACTH産生腫瘍症例におけるACTH測定試薬の比較

  福住 典子, 佐藤 伊都子, 林 伸英, 三枝 淳, 福岡 秀規, Takahashi Yutaka, 河野 誠司

  日本臨床検査医学会, Oct. 2014, 臨床病理, 62(補冊) (補冊), 174 - 174, Japanese


• クッシング病の薬物療法 現況と今後の展望

  福岡 秀規, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 874 - 874, Japanese


• Turner症候群とCAHの合併を認めた副腎偶発腫の一例

  岩橋 泰幸, 福岡 秀規, 中島 進介, Iguchi Genzo, 本間 桂子, 長谷川 奉延, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 941 - 941, Japanese


• 肝生検を施行した小児期発症GH分泌不全症5例の検討

  志智 大城, 福岡 秀規, 松本 隆作, 西澤 衡, Iguchi Genzo, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 920 - 920, Japanese


• 原発性副甲状腺機能亢進症におけるデノスマブの効果の検討

  山田 佳子, 福岡 秀規, 末松 那都, 平田 悠, 吉田 健一, 廣田 勇士, Iguchi Genzo, 坂口 一彦, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 947 - 947, Japanese


• 術後に心機能が改善したサブクリニカルクッシング症候群の1例

  隅田 健太郎, Iguchi Genzo, 福岡 秀規, 廣田 勇士, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, Takahashi Michiko, 坂口 一彦, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 931 - 931, Japanese


• 先端巨大症においては末梢血テロメア長が短縮している

  松本 隆作, 福岡 秀規, Iguchi Genzo, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, Takahashi Michiko, 山田 正三, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 912 - 912, Japanese


• 日本人先端巨大症患者におけるAcroQoL日本語版の信頼性と有用性

  吉田 健一, 福岡 秀規, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, Iguchi Genzo, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 917 - 917, Japanese


• 補充療法で多血症が改善した21水酸化酵素欠損症の一男性例

  西澤 衡, 福岡 秀規, Iguchi Genzo, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 豊田 有子, 本間 桂子, 長谷川 泰延, 臼井 健, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 968 - 968, Japanese


• D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing's syndrome

  Hidenori Fukuoka, Takehito Takeuchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Yushi Hirota, Genzo Iguchi, Yutaka Takahashi

  Oct. 2014, ENDOCRINE JOURNAL, 61(10) (10), 1003 - 1010, English

  [Refereed]

  Scientific journal


• Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency

  Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Hitoshi Nishizawa, Hironori Bando, Kentaro Suda, Michiko Takahashi, Yutaka Takahashi

  Oct. 2014, GROWTH HORMONE & IGF RESEARCH, 24(5) (5), 174 - 179, English

  [Refereed]

  Scientific journal


• 下肢関節拘縮を呈し補充療法によって改善した汎下垂体機能低下症

  中島 進介, 福岡 秀規, Sekiguchi Kenji, 廣田 勇士, Iguchi Genzo, 坂口 一彦, Ogawa Wataru, Takahashi Yutaka

  (一社)日本内分泌学会, Sep. 2014, 日本内分泌学会雑誌, 90(Suppl.Update) (Suppl.Update), 16 - 18, Japanese


• 播種状黄色腫による中枢性尿崩症と考えられた一例

  伊賀 真紀子, 福岡 秀規, 西本 祐希, 岩橋 泰幸, 藤田 泰功, 播 悠介, 平田 悠, 中島 進介, 向井 美希, 廣田 勇士, Iguchi Genzo, Ogawa Wataru, 岡 昌宏, Takahashi Yutaka

  (一社)日本内分泌学会, Sep. 2014, 日本内分泌学会雑誌, 90(Suppl.HPT) (Suppl.HPT), 83 - 85, Japanese


• Involvement of PIT-1-Reactive Cytotoxic T Lymphocytes in Anti-PIT-1 Antibody Syndrome

  Hironori Bando, Genzo Iguchi, Hidenori Fukuoka, Masaaki Yamamoto, Ryoko Hidaka-Takeno, Yasuhiko Okimura, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Katsuyoshi Tojo, Yutaka Takahashi

  Sep. 2014, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 99(9) (9), E1744 - E1749, English

  [Refereed]

  Scientific journal


• ErbB Mediate ACTH Suppression By Canertinib in Human Pituitary Corticotroph Adenoma Cells

  Hidenori Fukuoka, Genzo Iguchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Naoko Inoshita, Song-Guang Ren, Shozo Yamada, Yutaka Takahashi

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3), English

  [Refereed]


• ErbB Mediate ACTH Suppression By Canertinib in Human Pituitary Corticotroph Adenoma Cells

  Hidenori Fukuoka, Genzo Iguchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Naoko Inoshita, Song-Guang Ren, Shozo Yamada, Yutaka Takahashi

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3), English

  [Refereed]


• IGF-I Ameliorates Hepatic Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis and Cirrhosis By Inhibiting the Hepatic Stellate Cell Activity

  Hitoshi Nishizawa, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Kentaro Suda, Hironori Bando, Ryusaku Matsumoto, Yutaka Takahashi

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3), English

  [Refereed]


• Acromegaly Is Associated with a Shortened Telomere Length

  Matsumoto Ryusaku, Fukuoka Hidenori, Iguchi Genzo, Bando Hironori, Suda Kentaro, Nishizawa Hitoshi, Takahashi Michiko, Yamada Shozo, Takahashi Yutaka

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3)

  [Refereed]


• The Increased Area Under the Growth Hormone Concentration-Time Curve during Oral Glucose Tolerance Test Is Associated with Colorectal Adenocarcinoma in Acromegaly

  Yamamoto Masaaki, Fukuoka Hidenori, Iguchi Genzo, Matsumoto Ryusaku, Takahashi Michiko, Nishizawa Hitoshi, Suda Kentaro, Bando Hironori, Takahashi Yutaka

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3)

  [Refereed]


• The Characteristics of IgG4-Related Hypophysitis; A Comparison with Autoimmune Hypophysitis

  Bando Hironori, Iguchi Genzo, Fukuoka Hidenori, Matsumoto Ryusaku, Suda Kentaro, Nishizawa Hitoshi, Takahashi Michiko, Takahashi Yutaka

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3)

  [Refereed]


• A Case of Androgen- and Fibroblast Growth Factor 23-Producing Ovarian Tumor

  Iguchi Genzo, Matsumoto Ryusaku, Bando Hironori, Suda Kentaro, Nishizawa Hitoshi, Takahashi Michiko, Fukuoka Hidenori, Imanishi Yasuo, Sasano Hironobu, Takahashi Yutaka

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3)

  [Refereed]


• A missense single-nucleotide polymorphism in the sialic acid acetylesterase (SIAE) gene is associated with anti-PIT-1 antibody syndrome

  Masaaki Yamamoto, Genzo Iguchi, Hironori Bando, Hidenori Fukuoka, Kentaro Suda, Michiko Takahashi, Hitoshi Nishizawa, Ryusaku Matsumoto, Katsuyoshi Tojo, Atsuko Mokubo, Tsutomu Ogata, Yutaka Takahashi

  Jun. 2014, ENDOCRINE JOURNAL, 61(6) (6), 641 - 644, English

  [Refereed]

  Scientific journal


• ACTH産生下垂体腫瘍におけるカネルチニブのPOMC発現抑制効果とEGF受容体ファミリー発現量との関連

  福岡 秀規, Iguchi Genzo, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, Takahashi Michiko, 井下 尚子, 山田 正三, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 264 - 264, Japanese


• GHシグナルの亢進を認めたGH産生下垂体腺腫によらない巨人症の一例

  隅田 健太郎, 福岡 秀規, Iguchi Genzo, 松本 隆作, 坂東 弘教, 西澤 衡, Takahashi Michiko, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 277 - 277, Japanese


• IGF-Iの新たな作用 星細胞の細胞老化を介した肝線維化抑制作用

  西澤 衡, Iguchi Genzo, 松本 隆作, 坂東 弘教, 隅田 健太郎, Takahashi Michiko, 福岡 秀規, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 289 - 289, Japanese


• Subclinical Cushing症候群を合併した遺伝性平滑筋腫症 腎細胞がん症候群の一例

  向井 美希, 福岡 秀規, 中島 進介, 杉立 有弥, 藤田 泰功, 隅田 健太郎, 岩橋 泰幸, 平田 悠, 播 悠介, 伊賀 真紀子, 西本 祐希, 廣田 勇士, Iguchi Genzo, 坂口 一彦, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 284 - 284, Japanese


• SunitinibによってACTHの低下を認めた異所性ACTH産生腫瘍の一例

  小武 由紀子, 福岡 秀規, 向原 徹, Iguchi Genzo, 福住 典子, 佐藤 伊都子, 林 伸英, 廣田 勇士, 坂口 一彦, 小川 渉, 河野 誠司, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 333 - 333, Japanese


• デスモプレシン経鼻から経口製剤への外来での切り替えについての検討

  松本 隆作, 福岡 秀規, Iguchi Genzo, 坂東 弘教, 隅田 健太郎, 西澤 衡, Takahashi Michiko, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 293 - 293, Japanese


• 下垂体と自己免疫 多腺性自己免疫症候群に伴う下垂体炎と抗PIT-1抗体症候群のトピックス

  Takahashi Yutaka, 坂東 弘教, 山本 雅昭, 福岡 秀規, Iguchi Genzo

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 211 - 211, Japanese


• 抗PIT-1抗体症候群においてはPIT-1に対する細胞障害性T細胞が存在する

  坂東 弘教, Iguchi Genzo, 福岡 秀規, 山本 雅昭, 竹野 亮子, 松本 隆作, 隅田 健太郎, 西澤 衡, Takahashi Michiko, 東條 克能, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 257 - 257, Japanese


• 酢酸オクトレオチド投与後に低血糖を生じる患者背景についての検討

  西本 祐希, 福岡 秀規, 岩橋 泰幸, 藤田 泰功, 播 悠介, 平田 悠, 伊賀 真紀子, 中島 進介, 向井 美希, 廣田 勇士, Iguchi Genzo, 坂口 一彦, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Apr. 2014, 日本内分泌学会雑誌, 90(1) (1), 364 - 364, Japanese


• The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature

  Hironori Bando, Genzo Iguchi, Hidenori Fukuoka, Masaaki Taniguchi, Masaaki Yamamoto, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Eiji Kohmura, Yutaka Takahashi

  Feb. 2014, EUROPEAN JOURNAL OF ENDOCRINOLOGY, 170(2) (2), 161 - 172, English

  [Refereed]

  Scientific journal


• パーキンソニズムを呈した22q11.2欠失症候群の1例

  赤谷 律, Fukuoka Hidenori, 本岡 里英子, 千原 典夫, 佐竹 渉, 関口 兼司, 濱口 浩敏, 古和 久朋, Kanda Fumio, 戸田 達史

  (一社)日本神経学会, Jan. 2014, 臨床神経学, 54(1) (1), 65 - 65, Japanese

  Research society


• 栄養介入・ステロイド補充にて全身状態が著明に改善した相対的副腎不全の一例

  高橋 路子, 永濱 郁代, 生田 智子, 堀川 真由美, 脇田 久美子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 福岡 秀規, Iguchi Genzo, 戸田 明代, 濱田 康弘, 高橋 裕, 宇佐美 眞

  (一社)日本病態栄養学会, Dec. 2013, 日本病態栄養学会誌, 17(Suppl.) (Suppl.), S - 106, Japanese

  [Refereed]


• 頭部外傷後に発症し失神発作をきたしたACTH単独欠損症の一例

  西澤 衡, Iguchi Genzo, 松本 隆作, 坂東 弘教, 隅田 健太郎, Fukuoka Hidenori, 廣田 勇士, 坂口 一彦, Ogawa Wataru, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 933 - 933, Japanese


• 中枢性甲状腺機能低下症に対するT4製剤補充時の指標に関する検討

  平田 悠, Fukuoka Hidenori, 岩橋 泰幸, 藤田 泰功, 播 悠介, 伊賀 真紀子, 中島 進介, 西本 祐希, 向井 美希, 廣田 勇士, Iguchi Genzo, 坂口 一彦, Ogawa Wataru, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 994 - 994, Japanese


• 成人GH分泌不全症に対するGH補充療法 肝機能に関する長期成績

  松本 隆作, Fukuoka Hidenori, Iguchi Genzo, 西沢 衡, 坂東 弘教, 隅田 健太郎, Takahashi Michiko, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 974 - 974, Japanese


• 顕性、不顕性クッシング症候群における骨折と糖脂質代謝の関連

  播 悠介, Fukuoka Hidenori, 竹内 健人, 岩橋 泰幸, 藤田 泰功, 平田 悠, 伊賀 真紀子, 中島 進介, 西本 祐希, 向井 美希, 廣田 勇士, Iguchi Genzo, 坂口 一彦, Ogawa Wataru, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 980 - 980, Japanese


• 下垂体機能低下症、中枢性尿崩症におけるIgG4関連下垂体炎の頻度

  坂東 弘教, Iguchi Genzo, Fukuoka Hidenori, 隅田 健太郎, 松本 隆作, 西澤 衡, Takahashi Michiko, 谷口 理章, Kohmura Eiji, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 988 - 988, Japanese


• 下肢関節拘縮を呈し補充療法によって改善した汎下垂体機能低下症

  中島 進介, Fukuoka Hidenori, 関口 兼司, 廣田 勇士, Iguchi Genzo, 坂口 一彦, Ogawa Wataru, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 950 - 950, Japanese


• ステロイド補充が著効した重症患者における相対的副腎不全の一例

  Takahashi Michiko, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, Fukuoka Hidenori, Iguchi Genzo, 宇佐美 眞, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 999 - 999, Japanese


• 75gOGTTのGH高値は先端巨大症における大腸癌合併と関連している

  山本 雅昭, Fukuoka Hidenori, Iguchi Genzo, Takahashi Michiko, 西澤 衡, 隅田 健太郎, 坂東 弘教, 松本 隆作, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 937 - 937, Japanese


• 2型糖尿病による血中GH、IGF-I値への影響の検討

  隅田 健太郎, 松本 隆作, Fukuoka Hidenori, Iguchi Genzo, 廣田 勇士, 坂東 弘教, 西澤 衡, Takahashi Michiko, 坂口 一彦, 高橋 裕

  (一社)日本内分泌学会, Dec. 2013, 日本内分泌学会雑誌, 89(3) (3), 975 - 975, Japanese


• SOCS2遺伝子変異により引き起こされた巨人症

  隅田 健太郎, 松本 隆作, Fukuoka Hidenori, Iguchi Genzo, 坂東 弘教, 西沢 衡, Takahashi Michiko, Takahashi Yutaka

  (一社)日本内分泌学会, Sep. 2013, 日本内分泌学会雑誌, 89(2) (2), 578 - 578, Japanese


• SIRT1 regulates adaptive response of the growth hormone-insulin-like growth factor-I axis under fasting conditions in liver

  Masaaki Yamamoto, Genzo Iguchi, Hidenori Fukuoka, Kentaro Suda, Hironori Bando, Michiko Takahashi, Hitoshi Nishizawa, Susumu Seino, Yutaka Takahashi

  Sep. 2013, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(37) (37), 14948 - 14953, English

  [Refereed]

  Scientific journal


• リンパ球性下垂体炎の合併が疑われた水疱性類天疱瘡の一例

  西澤 衡, Iguchi Genzo, 坂東 弘教, 隅田 健太郎, 山本 雅昭, Takahashi Michiko, Fukuoka Hidenori, 村西 浩二, Takahashi Yutaka

  (一社)日本内分泌学会, Jun. 2013, 日本内分泌学会雑誌, 89(Suppl.Update) (Suppl.Update), 30 - 32, Japanese


• クランプ法を用いた内分泌疾患における耐糖能の検討

  駒田 久子, 廣田 勇士, 坂口 一彦, 中村 友昭, Fukuoka Hidenori, 橋本 尚子, Iguchi Genzo, Takahashi Yutaka, Ogawa Wataru, Seino Susumu

  (一社)日本内分泌学会, Jun. 2013, 日本内分泌学会雑誌, 89(Suppl.Update) (Suppl.Update), 92 - 94, Japanese

  [Refereed]


• 2型糖尿病における先端巨大症の頻度についての検討

  隅田 健太郎, Iguchi Genzo, Fukuoka Hidenori, 廣田 勇士, 坂東 弘教, 山本 雅昭, 西沢 衡, Takahashi Michiko, 坂口 一彦, 高橋 裕

  (一社)日本内分泌学会, Jun. 2013, 日本内分泌学会雑誌, 89(Suppl.Update) (Suppl.Update), 5 - 7, Japanese

  [Refereed]


• 副甲状腺機能低下症をきっかけに成人期に診断された22q11.2欠失症候群の3例

  小武 由紀子, Fukuoka Hidenori, 吉岡 奈美, 廣田 勇士, Iguchi Genzo, 坂口 一彦, Ogawa Wataru, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2013, 日本内分泌学会雑誌, 89(1) (1), 308 - 308, Japanese


• 腎嚢胞は先端巨大症における脳動脈瘤合併の危険因子である

  山本 雅昭, Fukuoka Hidenori, Iguchi Genzo, 中島 進介, Takahashi Michiko, 西沢 衡, 隅田 健太郎, 坂東 弘教, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2013, 日本内分泌学会雑誌, 89(1) (1), 320 - 320, Japanese


• 新規TRβ遺伝子変異(A234D)を同定した甲状腺ホルモン不応症の1家系

  吉岡 奈美, Fukuoka Hidenori, 西原 永潤, 宮内 昭, Iguchi Genzo, 廣田 勇士, 坂口 一彦, Ogawa Wataru, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2013, 日本内分泌学会雑誌, 89(1) (1), 245 - 245, Japanese


• 下垂体腫瘍を認めない巨人症におけるSOCS2、IGF-IRの遺伝子解析

  隅田 健太郎, Fukuoka Hidenori, Iguchi Genzo, 坂東 弘教, 山本 雅昭, 西澤 衡, Takahashi Michiko, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2013, 日本内分泌学会雑誌, 89(1) (1), 254 - 254, Japanese


• IgG4陽性細胞が認められた肉芽腫性下垂体炎の1例

  坂東 弘教, Iguchi Genzo, Fukuoka Hidenori, 隅田 健太郎, 山本 雅昭, 西澤 衡, Takahashi Michiko, 谷口 理章, Kohmura Eiji, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2013, 日本内分泌学会雑誌, 89(1) (1), 324 - 324, Japanese

  [Refereed]


• IGF-IはNASHにおける線維化進展を防止する

  西澤 衡, Iguchi Genzo, 坂東 弘教, 隅田 健太郎, 山本 雅昭, Takahashi Michiko, Fukuoka Hidenori, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2013, 日本内分泌学会雑誌, 89(1) (1), 240 - 240, Japanese


• or central diabetes insipidus and review of the literature.

  Bando H, Iguchi G, Fukuoka H, Taniguchi M, Yamamoto M, Matsumoto R, Suda K, Nishizawa H, Takahashi M, Kohmura E, Takahashi Yutaka

  2013, Eur J Endocrinol., Oct 28. [Epub ahead of print], English

  [Refereed]

  Scientific journal


• Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: A retrospective clinical study and review of the literature

  Kentaro Suda, Naoko Inoshita, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Hitoshi Nishizawa, Masaaki Yamamoto, Shozo Yamada, Yutaka Takahashi

  2013, Endocrine Journal, 60(4) (4), 507 - 515, English

  [Refereed]

  Scientific journal


• Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: Sex dimorphism

  Michiko Takahashi, Sumie Inomata, Yasuhiko Okimura, Genzo Iguchi, Hidenori Fukuoka, Kazuaki Miyake, Daisuke Koga, Suguru Akamatsu, Masato Kasuga, Yutaka Takahashi

  2013, Endocrine Journal, 60(1) (1), 37 - 44, English

  [Refereed]

  Scientific journal


• AIP mutation identified in a patient with acromegaly caused by pituitary somatotroph adenoma with neuronal choristoma

  H. Nishizawa, H. Fukuoka, G. Iguchi, N. Inoshita, S. Yamada, Y. Takahashi

  2013, Experimental and Clinical Endocrinology and Diabetes, 121(5) (5), 295 - 299, English

  [Refereed]

  Scientific journal


• 両側精巣腫瘍を契機に発見された21水酸化酵素欠損症の一例

  小武 由紀子, Fukuoka Hidenori, 臼井 健, 長谷川 奉延, 本間 桂子, 中村 友昭, 廣田 勇士, Iguchi Genzo, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1004 - 1004, Japanese


• 慢性甲状腺炎を呈した22q11.2 microdeletion症候群の一例

  吉岡 奈美, Fukuoka Hidenori, Iguchi Genzo, 廣田 勇士, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1025 - 1025, Japanese


• 妊娠、出産に成功した先端巨大症の1例

  Takahashi Michiko, Fukuoka Hidenori, Iguchi Genzo, 西澤 衡, 山本 雅昭, 隅田 健太郎, 坂東 弘教, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1047 - 1047, Japanese


• リンパ球性下垂体炎を合併したと考えられる水疱性類天疱瘡の一例

  西澤 衡, 中村 友昭, Iguchi Genzo, 坂東 弘教, 隅田 健太郎, 山本 雅昭, Takahashi Michiko, Fukuoka Hidenori, 橋本 尚子, 廣田 勇士, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1014 - 1014, Japanese


• グルコースクランプ法を用いた内分泌疾患における耐糖能の検討

  駒田 久子, 廣田 勇士, 坂口 一彦, 中村 友昭, Fukuoka Hidenori, 橋本 尚子, Iguchi Genzo, 高橋 裕, 小川 渉, 清野 進

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1073 - 1073, Japanese


• クッシング症候群における深部静脈血栓症に関連する因子の検討

  竹内 健人, Fukuoka Hidenori, Iguchi Genzo, 廣田 勇士, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1032 - 1032, Japanese


• オクトレオチドによって低血糖を生じたMEN-1ガストリノーマの1例

  西本 祐希, Fukuoka Hidenori, 廣田 勇士, Iguchi Genzo, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1035 - 1035, Japanese


• IgG4関連下垂体炎5例の臨床的検討

  坂東 弘教, Iguchi Genzo, Fukuoka Hidenori, 隅田 健太郎, 山本 雅昭, 西澤 衡, Takahashi Michiko, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1050 - 1050, Japanese


• 2型糖尿病における先端巨大症の頻度についての検討

  隅田 健太郎, Iguchi Genzo, 橋本 尚子, 廣田 勇士, 坂東 弘教, 山本 雅昭, 西澤 衡, Fukuoka Hidenori, Takahashi Michiko, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Dec. 2012, 日本内分泌学会雑誌, 88(3) (3), 1013 - 1013, Japanese


• 成人GH分泌不全症におけるNAFLD/NASH発症を防止するためのGH補充療法

  高橋 裕, 村脇 あゆみ, 西沢 衡, Fukuoka Hidenori, Iguchi Genzo, 千原 和夫

  (一社)日本内分泌学会, Aug. 2012, 日本内分泌学会雑誌, 88(Suppl.) (Suppl.), 79 - 81, Japanese

  [Refereed]


• IGF-I enhances cellular senescence via the reactive oxygen species-p53 pathway

  Anastasia-Evi Handayaningsih, Michiko Takahashi, Hidenori Fukuoka, Genzo Iguchi, Hitoshi Nishizawa, Masaaki Yamamoto, Kentaro Suda, Yutaka Takahashi

  Aug. 2012, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 425(2) (2), 478 - 484, English

  [Refereed]

  Scientific journal


• Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy

  Hitoshi Nishizawa, Genzo Iguchi, Ayumi Murawaki, Hidenori Fukuoka, Yoshitake Hayashi, Hidesuke Kaji, Masaaki Yamamoto, Kentaro Suda, Michiko Takahashi, Yasushi Seo, Yoshihiko Yano, Riko Kitazawa, Sohei Kitazawa, Masafumi Koga, Yasuhiko Okimura, Kazuo Chihara, Yutaka Takahashi

  Jul. 2012, EUROPEAN JOURNAL OF ENDOCRINOLOGY, 167(1) (1), 67 - 74, English

  [Refereed]

  Scientific journal


• 静脈サンプリングにて腫瘍局在を同定できた腫瘍性骨軟化症の一例

  吉岡 奈美, Iguchi Genzo, 福岡 秀規, 高部 倫敬, 松田 友和, 橋本 尚子, 廣田 勇士, 坂口 一彦, 小川 渉, Seino Susumu, 高橋 裕

  (一社)日本内分泌学会, Jun. 2012, 日本内分泌学会雑誌, 88(Suppl.) (Suppl.), 87 - 89, Japanese

  [Refereed]


• GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model

  Hitoshi Nishizawa, Michiko Takahashi, Hidenori Fukuoka, Genzo Iguchi, Riko Kitazawa, Yutaka Takahashi

  Jun. 2012, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 423(2) (2), 295 - 300, English

  [Refereed]

  Scientific journal


• Growth Hormone Deficiency in 2 Siblings Associated with Combined GH1 Gene Polymorphisms

  M. Yamamoto, G. Iguchi, H. Fukuoka, K. Miyako, Y. Takahashi

  May 2012, EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 120(5) (5), 308 - 310, English

  [Refereed]

  Scientific journal


• EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

  Hidenori Fukuoka, Odelia Cooper, Anat Ben-Shlomo, Adam Mamelak, Song-Guang Ren, Dave Bruyette, Shlomo Melmed

  Dec. 2011, JOURNAL OF CLINICAL INVESTIGATION, 121(12) (12), 4712 - 4721, English

  [Refereed]

  Scientific journal


• CEBPD Suppresses Prolactin Expression and Prolactinoma Cell Proliferation

  Yunguang Tong, Jin Zhou, Jun Mizutani, Hidenori Fukuoka, Song-Guang Ren, Arthur Gutierrez-Hartmann, H. Phillip Koeffler, Shlomo Melmed

  Nov. 2011, MOLECULAR ENDOCRINOLOGY, 25(11) (11), 1880 - 1891, English

  [Refereed]

  Scientific journal


• Sirt1は肝臓におけるGHシグナルおよびIGF-I産生を調節する

  Fukuoka Hidenori

  (一社)日本内分泌学会, Apr. 2011, 日本内分泌学会雑誌, 87(1) (1), 258 - 258, Japanese


• ACTH産生腫瘍におけるEGF受容体(EGFR)の役割 クッシング病の治療標的としての意義

  Fukuoka Hidenori

  (一社)日本内分泌学会, Apr. 2011, 日本内分泌学会雑誌, 87巻, 1号, pp. 259-259(1) (1), 259 - 259, Japanese


• Reactive oxygen species play an essential role in IGF-I signaling and IGF-I-induced myocyte hypertrophy in C2C12 myocytes.

  Anastasia-Evi Handayaningsih, Genzo Iguchi, Hidenori Fukuoka, Hitoshi Nishizawa, Michiko Takahashi, Masaaki Yamamoto, Elizabeth-Henny Herningtyas, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara, Susumu Seino, Yutaka Takahashi

  IGF-I induces skeletal muscle hypertrophy by stimulating protein synthesis and suppressing the protein degradation pathway; the downstream signaling pathways Akt-mammalian target of rapamycin (mTOR)-p70-kDA-S6-kinase (p70S6K), and Forkhead box O1 (FoxO1) play essential roles in this regulation. Reactive oxygen species (ROS) modulate the signaling of various growth factors via redox regulation. However, the role of ROS in IGF-I signaling is not fully understood. In this study, we investigated whether ROS regulate the signaling and biological action of IGF-I in C2C12 myocytes. We found that IGF-I induces ROS in C2C12 myocytes. While treatment with H(2)O(2) significantly enhanced IGF-I-induced phosphorylation of the IGF-I receptor (IGF-IR), IGF-IR phosphorylation was markedly attenuated when cells were treated with antioxidants. The downstream signaling pathway, Akt-mTOR-p70S6K was subsequently down-regulated. Furthermore, the phosphorylation of FoxO1 by IGF-I decreased concomitantly with the restoration of the expression of its target genes, Atrogin-1 and muscle RING finger 1, which are related to muscle atrophy. Nox4 knockdown, which is reportedly to produce ROS in insulin signaling, attenuated IGF-I-induced IGF-IR phosphorylation, indicating that Nox4 is involved in the regulation of IGF-I signaling. Importantly, antioxidant treatments inhibited IGF-I-induced myocyte hypertrophy, demonstrating that ROS are necessary for IGF-I-induced myocyte hypertrophy in vitro. These results indicate that ROS play an essential role in the signaling and biological action of IGF-I in C2C12 myocytes.

  Mar. 2011, Endocrinology, 152(3) (3), 912 - 21, English, International magazine

  [Refereed]


• Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans

  Masaaki Yamamoto, Genzo Iguchi, Ryoko Takeno, Yasuhiko Okimura, Toshiaki Sano, Michiko Takahashi, Hitoshi Nishizawa, Anastasia Evi Handayaningshi, Hidenori Fukuoka, Maya Tobita, Takatoshi Saitoh, Katsuyoshi Tojo, Atsuko Mokubo, Akio Morinobu, Keiji Iida, Hidesuke Kaji, Susumu Seino, Kazuo Chihara, Yutaka Takahashi

  Jan. 2011, Journal of Clinical Investigation, 121(1) (1), 113 - 119, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy

  Hidenori Fukuoka, Odelia Cooper, Jun Mizutani, Yunguang Tong, Song-Guang Ren, Serguei Bannykh, Shlomo Melmed

  Jan. 2011, MOLECULAR ENDOCRINOLOGY, 25(1) (1), 92 - 103, English

  Scientific journal


• IGF-I stimulates reactive oxygen species (ROS) production and inhibits insulin-dependent glucose uptake via ROS in 3T3-L1 adipocytes

  Hidenori Fukuoka, Keiji Iida, Hitoshi Nishizawa, Mari Imanaka, Ryoko Takeno, Genzo Iguchi, Michiko Takahashi, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara, Yutaka Takahashi

  Jun. 2010, GROWTH HORMONE & IGF RESEARCH, 20(3) (3), 212 - 219, English

  [Refereed]

  Scientific journal


• Pathophysiology of acromegaly: Progression of aging process by IGF-I excess?

  Kazuo Chihara, Anastasia Evi Handayaningsih, Hidenori Fukuoka, Hitoshi Nishizawa, Michiko Takahashi, Masaaki Yamamoto, Genzo Iguchi, Yasuhiko Okimura, Hidesuke Kaji, Yutaka Takahashi

  Mar. 2010, ENDOCRINE JOURNAL, 57, S249 - S249, English

  [Refereed]


• Sirt1 negatively regulates IGF-I production by growth hormone in hepatocytes

  Masaaki Yamamoto, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Hitoshi Nishizawa, Anastasia-Evi Handayaningsih, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara, Susumu Seino, Yutaka Takahashi

  Mar. 2010, ENDOCRINE JOURNAL, 57, S538 - S538, English

  [Refereed]


• IGF-1 induces cellular senescence via reactive oxygen species in vascular smooth muscle cells

  Anastasia Evi Handayaningsih, Genzo Iguchi, Hidenori Fukuoka, Hitoshi Nishizawa, Michiko Takahashi, Masaaki Yamamoto, Elizabeth-Henny Herningtyas, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara, Susumu Seino, Yutaka Takahashi

  Mar. 2010, ENDOCRINE JOURNAL, 57, S625 - S625, English

  [Refereed]


• ミトタンの使用中に甲状腺機能低下症の増悪を認めた周期性クッシング病の一例

  Fukuoka Hidenori

  (一社)日本内分泌学会, Mar. 2008, 日本内分泌学会雑誌, 83(4) (4), 889 - 889, Japanese


• Growth hormone stimulates mechano growth factor expression and activates myoblast transformation in C2C12 cells

  Mari Imanaka, Keiji Iida, Ayumi Murawaki, Hitoshi Nishizawa, Hidenori Fukuoka, Ryoko Takeno, Yutaka Takahashi, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara

  2008, Kobe Journal of Medical Sciences, 54(1) (1), 46 - 54, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly

  Hidenori Fukuoka, Yutaka Takahashi, Keiji Iida, Takumi Kudo, Hitoshi Nishizawa, Mari Imanaka, Ryoko Takeno, Genzo Iguchi, Kentaro Takahashi, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara

  2008, HORMONE RESEARCH, 69(3) (3), 165 - 171, English

  [Refereed]

  Scientific journal


• 妊娠中毒症、糖尿病を契機に診断されたクッシング症候群の一例

  Fukuoka Hidenori

  (一社)日本内分泌学会, Dec. 2007, 日本内分泌学会雑誌, 83(3) (3), 785 - 785, Japanese


• 先端巨大症においてIGF-I/GH比の低下は耐糖能異常と関連する

  TAKAHASHI YUTAKA, Takahashi Kentaro, IIDA KEIJI, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Jun. 2007, 日本内分泌学会雑誌, 83(Suppl.) (Suppl.), 96 - 98, Japanese


• プレクリニカルクッシング症候群を伴った副腎皮質癌の一例

  IIDA KEIJI, Takahashi Kentaro, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Jun. 2007, 日本内分泌学会雑誌, 83(Suppl.) (Suppl.), 158 - 160, Japanese


• 2A型VHL病の一家系におけるVHL遺伝子解析

  IIDA KEIJI, Takahashi Kentaro, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Jun. 2007, 日本内分泌学会雑誌, 83(Suppl.) (Suppl.), 174 - 177, Japanese


• Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency

  Yutaka Takahashi, Keiji Iida, Kentaro Takahashi, Shiro Yoshioka, Hidenori Fukuoka, Ryoko Takeno, Mari Imanaka, Hitoshi Nishizawa, Michiko Takahashi, Yasushi Seo, Yoshitake Hayashi, Takuma Kondo, Yasuhiko Okimura, Hidesuke Kaji, Riko Kitazawa, Sohei Kitazawa, Kazuo Chihara

  Mar. 2007, GASTROENTEROLOGY, 132(3) (3), 938 - 943, English

  [Refereed]

  Scientific journal


• 稀なVHL遺伝子異常を認めた2型VHL病の1家系

  IIDA KEIJI, Takahashi Kentaro, TAKAHASHI YUTAKA, CHIHARA KAZUO

  (一社)日本内科学会, Feb. 2007, 日本内科学会雑誌, 96(Suppl.) (Suppl.), 137 - 137, Japanese


• McCune-Albright Syndrome with Acromegaly and Fibrous Dysplasia Associated with the GNAS Gene Mutation Identified by Sensitive PNA-clamping Method

  Mari Imanaka, Keiji Iida, Hitoshi Nishizawa, Hidenori Fukuoka, Ryoko Takeno, Kentaro Takahashi, Hiroshi Kaji, Yutaka Takahashi, Yasuhiko Okimura, Hidesuke Kaji, Yasuo Imanishi, Kazuo Chihara

  2007, INTERNAL MEDICINE, 46(18) (18), 1577 - 1583, English

  [Refereed]

  Scientific journal


• オクトレオチド徐放剤で低血糖が改善した悪性インスリノーマ症例

  IIDA KEIJI, Takahashi Kentaro, KAJI HIROSHI, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Dec. 2006, 日本内分泌学会雑誌, 82(3) (3), 697 - 697, Japanese


• The N131S mutation in the von Hippel-Lindau gene in a Japanese family with pheochromocytoma and hemangioblastomas

  Mari Imanaka, Keiji Iida, Kentaro Takahashi, Kazuo Tsuji, Hitoshi Nishizawa, Hidenori Fukuoka, Ryoko Takeno, Yutaka Takahashi, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara

  Dec. 2006, ENDOCRINE JOURNAL, 53(6) (6), 819 - 827, English

  [Refereed]

  Scientific journal


• 幼少時のGH補充療法後に先端巨大症を呈したTurner症候群の一例

  Takahashi Kentaro, IIDA KEIJI, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Sep. 2006, 日本内分泌学会雑誌, 82(2) (2), 369 - 369, Japanese


• GH産生巨大下垂体腺腫によるPreclinical Acromegalyの一例

  TAKAHASHI YUTAKA, Takahashi Kentaro, IIDA KEIJI, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Jun. 2006, 日本内分泌学会雑誌, 82(Suppl.) (Suppl.), 69 - 71, Japanese


• 28年の経過中に脳幹浸潤,脊髄播種をきたした浸潤性プロラクチノーマの1例

  Takahashi Kentaro, IIDA KEIJI, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Jun. 2006, 日本内分泌学会雑誌, 82(Suppl.) (Suppl.), 75 - 78, Japanese


• 褐色細胞腫摘除術により著明な耐糖能の改善を認めた1例

  Takahashi Kentaro, IIDA KEIJI, KAJI HIROSHI, TAKAHASHI YUTAKA, CHIHARA KAZUO

  (一社)日本糖尿病学会, Jun. 2006, 糖尿病, 49(6) (6), 483 - 483, Japanese


• cDNAマイクロアレイを用いた骨格筋,骨における成長ホルモン標的遺伝子の解析

  TAKAHASHI YUTAKA, Takahashi Kentaro, IIDA KEIJI, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Apr. 2006, 日本内分泌学会雑誌, 82(1) (1), 153 - 153, Japanese


• 成長ホルモンは,脂肪細胞においてFOXO1の蛋白量,インスリンによるリン酸化を調節する

  TAKAHASHI YUTAKA, Nakae Jun, Takahashi Kentaro, IIDA KEIJI, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本糖尿病学会, Apr. 2006, 糖尿病, 49(Suppl.1) (Suppl.1), S113 - S113, Japanese


• GH,PRL.TSH欠乏を特徴とする後天性複合下垂体機能低下症 血中PIT1自己抗体の検出

  TAKAHASHI YUTAKA, Takahashi Kentaro, IIDA KEIJI, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Apr. 2006, 日本内分泌学会雑誌, 82(1) (1), 95 - 95, Japanese


• 両側副腎の皮質腺腫とPPNAD様の病理組織像を呈する結節を伴ったCushing症候群の一例

  IIDA KEIJI, Takahashi Kentaro, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Apr. 2006, 日本内分泌学会雑誌, 82(1) (1), 141 - 141, Japanese


• GnRHスーパーアゴニスト治療中,視野障害と頭痛が出現したゴナドトロピン産生下垂体腫瘍の1例

  Takahashi Kentaro, IIDA KEIJI, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Apr. 2006, 日本内分泌学会雑誌, 82(1) (1), 150 - 150, Japanese


• 成長ホルモンは,脂肪,肝細胞においてFOXO1の蛋白量,インスリンによるリン酸化を調節する

  TAKAHASHI YUTAKA, Nakae Jun, Takahashi Kentaro, IIDA KEIJI, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Apr. 2006, 日本内分泌学会雑誌, 82(1) (1), 185 - 185, Japanese


• 部分的11βhydroxylase欠損症の合併が疑われた巨大副腎腫瘍の一例

  Takahashi Kentaro, IIDA KEIJI, TAKAHASHI YUTAKA, OKIMURA YASUHIKO, CHIHARA KAZUO

  (一社)日本内分泌学会, Apr. 2006, 日本内分泌学会雑誌, 82(1) (1), 190 - 190, Japanese


• 両側副腎腫大を伴うsubclinical Cushing症候群の一例

  今中真理, IIDA, Keiji, 板倉崇泰, 福岡秀規, 竹野亮子, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  間脳・下垂体・副腎系研究会, Dec. 2005, ACTH Related Peptides, 16, 131 - 139, Japanese

  [Refereed]

  Scientific journal


• 先端巨大症を合併し線維性骨異形成が著明であったMcCune-Albright症候群の1例

  今中真理, IIDA, Keiji, 西沢衡, 本多久子, 福岡秀規, 竹野亮子, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Dec. 2005, 日本内分泌学会雑誌, 81(3) (3), 727 - 727, Japanese


• 先端巨大症に多発性骨異形成症様画像所見を合併し,その一部が特発性骨髄炎を示した一例

  竹野亮子, IIDA, Keiji, 本多久子, 西沢衡, 今中真理, 福岡秀規, TAKAHASHI, Kentaro, OKIMURA, Yasuhiko, 加治秀介, TAKAHASHI, Yutaka, CHIHARA, Kazuo

  (一社)日本内分泌学会, Dec. 2005, 日本内分泌学会雑誌, 81(3) (3), 726 - 726, Japanese


• オクトレオタイドが奏功したPreclinical Acromegalyの一例

  福岡秀規, TAKAHASHI, Yutaka, 西沢衡, 本多久子, 今中真理, 竹野亮子, TAKAHASHI, Kentaro, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Dec. 2005, 日本内分泌学会雑誌, 81(3) (3), 717 - 717, Japanese


• 先端巨大症に多発性特発性骨髄炎を合併した一例

  竹野亮子, IIDA, Keiji, 板倉崇泰, 今中真理, 福岡秀規, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Sep. 2005, 日本内分泌学会雑誌, 81(2) (2), 400 - 400, Japanese


• Prader-Willi症候群2例の代謝異常についての検討

  福岡秀規, TAKAHASHI, Yutaka, 今中真理, 板倉崇泰, 竹野亮子, 工藤工, TAKAHASHI, Kentaro, IGUCHI,Genzo, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Jun. 2005, 日本内分泌学会雑誌, 81(Suppl.) (Suppl.), 16 - 19, Japanese


• 両側副腎腫大を伴うsubclinical Cushing症候群の一例

  今中真理, IIDA, Keiji, 板倉崇泰, 福岡秀規, 竹野亮子, TAKAHASHI, Kentaro, OKIMURA, Yasuhiko, 加治秀介, TAKAHASHI, Yutaka, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2005, 日本内分泌学会雑誌, 81(1) (1), 178 - 178, Japanese


• von Hippel-Lindau病患者の遺伝子異常と表現型の検討

  TAKAHASHI, Kentaro, IIDA, Keiji, 今中真理, 板倉崇泰, 福岡秀規, 竹野亮子, 工藤工, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, 猪俣純枝, 門脇誠三, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2005, 日本内分泌学会雑誌, 81(1) (1), 169 - 169, Japanese


• cDNAマイクロアレイを用いた肝臓における成長ホルモン標的遺伝子の解析

  吉岡嗣朗, TAKAHASHI, Yutaka, 福岡秀規, 工藤工, TAKAHASHI, Kentaro, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo, 柳澤夕佳, 伊藤恵美, 本間玲子, 今井順一, 渡辺慎哉

  (一社)日本内分泌学会, Apr. 2005, 日本内分泌学会雑誌, 81(1) (1), 159 - 159, Japanese


• オクトレオチド徐放性注射剤による先端巨大症の治療について

  竹野亮子, TAKAHASHI, Yutaka, 今中真理, 板倉崇泰, 福岡秀規, 工藤工, TAKAHASHI, Kentaro, IGUCHI,Genzo, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2005, 日本内分泌学会雑誌, 81(1) (1), 161 - 161, Japanese


• 先端巨大症における耐糖能異常の発症を規定する要素の解析(第2報)

  福岡秀規, TAKAHASHI, Yutaka, 工藤工, 今中真理, 板倉崇泰, 竹野亮子, TAKAHASHI, Kentaro, IGUCHI,Genzo, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2005, 日本内分泌学会雑誌, 81(1) (1), 160 - 160, Japanese


• ピオグリタゾンが著効したステロイド糖尿病の1例

  TAKAHASHI, Yutaka, 竹野亮子, 福岡秀規, IIDA, Keiji, TAKAHASHI, Kentaro, 工藤工, 板倉崇泰, 今中真理, CHIHARA, Kazuo

  (一社)日本内科学会, Feb. 2005, 日本内科学会雑誌, 94(Suppl.) (Suppl.), 191 - 191, Japanese

  International conference proceedings


• Prader-Willi症候群2例の代謝異常についての検討

  福岡秀規, TAKAHASHI, Yutaka, 今中真理, 板倉崇泰, 竹野亮子, 工藤工, TAKAHASHI, Kentaro, IGUCHI,Genzo, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Dec. 2004, 日本内分泌学会雑誌, 80(3) (3), 647 - 647, Japanese


• 洞不全症候群,肺梗塞を合併したSheehan症候群の一例

  竹野亮子, TAKAHASHI, Yutaka, 今中真理, 板倉崇泰, 福岡秀規, 工藤工, TAKAHASHI, Kentaro, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Dec. 2004, 日本内分泌学会雑誌, 80(3) (3), 618 - 618, Japanese


• 妊娠後期発症,一過性リンパ球性漏斗下垂体後葉炎を疑った一例

  板倉崇泰, TAKAHASHI, Yutaka, IGUCHI,Genzo, 今中真理, 福岡秀規, 竹野亮子, 工藤工, TAKAHASHI, Kentaro, IIDA, Keiji, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Dec. 2004, 日本内分泌学会雑誌, 80(3) (3), 643 - 643, Japanese


• 27年の経過中に脳幹浸潤,脊髄播種をきたした浸潤性プロラクチノーマの1例

  TAKAHASHI, Kentaro, IGUCHI,Genzo, TAKAHASHI, Yutaka, 今中真理, 板倉崇泰, 福岡秀規, 竹野亮子, 工藤工, OKIMURA, Yasuhiko, 加治秀介, 垰本勝司, 松本悟, CHIHARA, Kazuo

  (一社)日本内分泌学会, Sep. 2004, 日本内分泌学会雑誌, 80(2) (2), 365 - 365, Japanese


• BMI 54.6の高度な肥満と重症睡眠時無呼吸症候群を合併したPrader-Willi症候群の1例

  福岡秀規, TAKAHASHI, Yutaka, 比佐伊都子, 飛松崇子, 竹野亮子, 工藤工, TAKAHASHI, Kentaro, IGUCHI,Genzo, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Sep. 2004, 日本内分泌学会雑誌, 80(2) (2), 365 - 365, Japanese


• ES細胞由来GH産生細胞の分離

  工藤工, IGUCHI,Genzo, 福岡秀規, 竹野亮子, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Sep. 2004, 日本内分泌学会雑誌, 80(2) (2), 366 - 366, Japanese


• ラトケ嚢胞に自己免疫性視床下部下垂体炎を発症したと考えられた一例

  竹野亮子, IGUCHI,Genzo, 飛松崇子, 福岡秀規, 工藤工, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Sep. 2004, 日本内分泌学会雑誌, 80(2) (2), 365 - 365, Japanese


• 特異な経過を辿っている周期性クッシング病の一例

  工藤工, IGUCHI,Genzo, 竹野亮子, 福岡秀規, TAKAHASHI, Kentaro, 吉岡嗣朗, TAKAHASHI, Yutaka, 長谷川吉昭, 北野則和, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Jun. 2004, 日本内分泌学会雑誌, 80(Suppl.) (Suppl.), 84 - 87, Japanese


• 先端巨大症における耐糖能異常の発症を規定する因子の解析

  福岡 秀規, 高橋 裕, 工藤 工, 竹野 亮子, 高橋 健太郎, 井口 元三, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本糖尿病学会, Apr. 2004, 糖尿病, 47(Suppl.1) (Suppl.1), S129 - S129, Japanese

  [Refereed]


• 先端巨大症における耐糖能異常の発症を規定する因子の解析

  福岡秀規, TAKAHASHI, Yutaka, 工藤工, 竹野亮子, TAKAHASHI, Kentaro, IGUCHI,Genzo, OKIMURA, Yasuhiko, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2004, 糖尿病, 80(1) (1), 149 - 149, Japanese


• 健常高齢者及び軽症疾患罹患高齢者におけるGH分泌反応

  OKIMURA, Yasuhiko, 工藤工, 竹野亮子, 福岡秀規, TAKAHASHI, Kentaro, 吉岡嗣朗, 高橋路子, 麓万里子, IGUCHI,Genzo, TAKAHASHI, Yutaka, 加治秀介, 佐藤倫明, 喜多哲也, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2004, 日本内分泌学会雑誌, 80(1) (1), 103 - 103, Japanese


• ES細胞から下垂体細胞への分化誘導の試み

  工藤工, IGUCHI,Genzo, OKIMURA, Yasuhiko, 福岡秀規, 竹野亮子, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Apr. 2004, 日本内分泌学会雑誌, 80(1) (1), 102 - 102, Japanese


• 糖尿病,肺梗塞,大腿骨頸部骨折を合併した副腎腺腫によるクッシング症候群の1例

  TAKAHASHI, Yutaka, 内藤純子, 福岡秀規, TAKAHASHI, Kentaro, 工藤工, 竹野亮子, 高橋路子, IGUCHI,Genzo, CHIHARA, Kazuo

  (一社)日本糖尿病学会, Feb. 2004, 糖尿病, 47(2) (2), 164 - 164, Japanese


• 当院の末端肥大症手術例における耐糖能変化

  福岡秀規, TAKAHASHI, Yutaka, 工藤工, 竹野亮子, TAKAHASHI, Kentaro, 高橋路子, OKIMURA, Yasuhiko, 加治秀介, IGUCHI,Genzo, CHIHARA, Kazuo

  (一社)日本糖尿病学会, Feb. 2004, 糖尿病, 47(2) (2), 164 - 164, Japanese


• 後天性の複合型下垂体ホルモン欠損症と考えられた一例

  竹野亮子, IGUCHI,Genzo, 福岡秀規, 工藤工, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, OKIMURA, Yasuhiko, 加治秀介, 片山秀喜, CHIHARA, Kazuo

  (一社)日本内科学会, Feb. 2004, 日本内科学会雑誌, 93(Suppl.) (Suppl.), 223 - 223, Japanese


• 特異な経過を辿っている周期性クッシング病の一例

  工藤 工, 井口 元三, 竹野 亮子, 福岡 秀規, 高橋 健太郎, 吉岡 嗣朗, 高橋 裕, 長谷川 吉昭, 北野 則和, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Dec. 2003, 日本内分泌学会雑誌, 79, 85 - 85, Japanese

  [Refereed]


• ES細胞から下垂体細胞への分化誘導の試み

  工藤工, IGUCHI,Genzo, OKIMURA, Yasuhiko, 福岡秀規, 竹野亮子, TAKAHASHI, Kentaro, TAKAHASHI, Yutaka, 加治秀介, CHIHARA, Kazuo

  (一社)日本内分泌学会, Sep. 2003, 日本内分泌学会雑誌, 79(2) (2), 373 - 373, Japanese


• 急性心筋梗塞症のリハビリテーション

  呉 昌憙, 末松 正邦, 向田 善之, 福岡 秀規, 青山 大輔, 飛松(西海)崇子, 岡田 学, 藤原 恵, 宮田 陽子, 井ノ上 竜一, 山本 篤, 前川 透, 西山 勝人, 黒木 康雄, 島田 隆男, 上羽 康之

  神戸百年記念病院, Mar. 2002, 鐘紡記念病院誌, 17(17) (17), 7 - 11, Japanese


• A biphasic regulation of receptor mRNA expressions for growth hormone, glucocorticoid and mineralocorticoid in the rat dentate gyrus during acute stress.

  T Fujikawa, H Soya, H Fukuoka, K S Alam, H Yoshizato, B S McEwen, K Nakashima

  Acute stress increases circulating ACTH and glucocorticoid levels. The hippocampus (HIP) is a target of such stress hormones as glucocorticoid and it also expresses receptors for growth hormone (GH), particularly in the dentate gyms (DG). In order to understand the interactions between glucocorticoids and functions of GH in HIP during acute stress, the mRNA levels for GH receptor (GHR), glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) were investigated in DG in rats exposed to restraint stress in the water (RSW). Using in situ hybridization histochemistry (ISHH), high level expressions of GHR mRNA were detected in DG. These were down-regulated by 14% after 0.5 h of RSW and then up-regulated by 38% over the initial level after 4 h of RSW. This biphasic enhancement of GHR mRNA expression in DG followed the elevation of plasma glucocorticoid levels and paralleled with biphasic expressions of mRNAs for GR and MR in DG. Although circulating GH levels did not show any correlation with the hippocampal GHR mRNA expression, adrenalectomy (ADX) decreased GHR mRNA expression in DG, and the dexamethasone treatment (DEX; 20 microg/100 microl, i.p.) of ADX rats rapidly increased the GHR mRNA expression in DG. These results have suggested that the GHR mRNA expression in the DG is regulated, at least in part, by glucocorticoids and that GH may be involved in responses of the DG to acute stress.

  Aug. 2000, Brain research, 874(2) (2), 186 - 93, English, International magazine

  [Refereed]


• Subcutaneously administered prolactin and 20K hGH, but not rGH or 22K hGH, prevent restraint stress-induced gastric ulcers in rats.

  K Fujikawa, H Fukuoka, K S Alam, H Yoshizato, S Higashimoto, H Soya, M Tanaka, K Nakashima

  Stress causes gastric ulcer in vertebrates. In humans, growth hormone (hGH) and prolactin (hRPL) are promptly released into the circulation under the stress conditions, while in rats exposed to stress, the circulating levels of GH (rGH) are decreased and the circulating PRL (rPRL) levels are rapidly increased as in humans during stress. However, the roles of the circulating rGH and rPRL during stress are still unclear. Here we analyzed whether 22K hGH, 20K hGH or rGH, when compared to rPRL, can affect restraint stress in water (RSW)-induced gastric ulcers. Pretreatments of rats with subcutaneously (s.c.) administered rPRL or 20K hGH clearly prevented the development of the gastric injuries in rats subjected to 7 h RSW. The s.c. pretreatment with 22K hGH resulted in little cytoprotection in the rats exposed to RSW, while s.c. pretreatment with rGH showed no such protective effect against RSW-induced gastric injuries. Results suggested that rPRL and 20K hGH were acting on PRL receptor, but not on GH receptor, to prevent RSW-induced gastric injuries.

  Mar. 2000, Endocrine journal, 47 Suppl, S49-52, English, Domestic magazine

  [Refereed]

• コルチゾール暴露環境がコルチコトロフ腫瘍における免疫細胞浸潤に与える影響

  神澤真紀, 志智大城, 蟹江慶太郎, 山本雅昭, 山本直希, 辻本泰貴, 坂東弘教, 井口元三, 北野滋久, 井下尚子, 山田正三, 小川渉, 伊藤智雄, 福岡秀規

  2024, ACTH Related Peptides (CD-ROM), 35


• コルチゾール暴露環境がコルチコトロフ腫瘍における免疫細胞浸潤に与える影響

  神澤真紀, 志智大成, 蟹江慶太郎, 山本雅昭, 山本直希, 辻本泰貴, 坂東弘教, 井口元三, 北野滋久, 井下尚子, 山田正三, 小川渉, 伊藤智雄, 福岡秀規

  2024, 間脳・下垂体・副腎系研究会プログラム・抄録集(Web), 35th


• Down症候群に合併したACTH単独欠損症の一例

  渡邊美季, 浦井伸, 坂東弘教, 山本雅昭, 福岡秀規, 小川渉, 井口元三, 井口元三

  2024, 日本内分泌学会雑誌, 100(1) (1)


• ACTH産生下垂体腫瘍におけるWW-like領域を含めたUSP8体細胞変異の解析

  辻本泰貴, 山本直希, 福嶋俊明, 柿原慧遵, 大町侑香, 本村悠馬, 大井佑夏, 佐々木百合子, 鈴木正暉, 浦井伸, 坂東弘教, 山本雅昭, 井口元三, 駒田雅之, 西岡宏, 山田正三, 小川渉, 福岡秀規

  2024, 日本内分泌学会雑誌, 100(1) (1)


• GH,PRL完全欠損に至る過程を観察し得た抗PIT-1下垂体炎

  友藤清爾, 浦井伸, 坂東弘教, 神澤真紀, 山本雅昭, 福岡秀規, 津田政広, 井口元三, 井口元三, 小川渉

  2024, 日本内分泌学会雑誌, 100(1) (1)


• BMAHにおけるアルドステロン自律性分泌とその病理学的検討

  合田菜穂, 神澤真紀, 辻本泰貴, 蟹江慶太郎, 山本雅昭, 臼井健, 臼井健, 高橋裕, 小川渉, 福岡秀規

  2023, 日本臨床内分泌病理学会学術総会プログラム・抄録集, 27th


• 偽性Cushing症候群を契機に同定に至ったNR3C1新規変異の一例

  山本直希, 木戸希, 坂東弘教, 山本雅昭, 浦井伸, 辻本泰貴, 大町侑香, 本村悠馬, 大井佑夏, 佐々木百合子, 鈴木正暉, 高橋路子, 井口元三, 井口元三, 小川渉, 福岡秀規

  2023, 日本神経内分泌学会学術集会プログラム・抄録集, 49th


• Adult growth hormone deficiency.

  山本雅昭, 福岡秀規

  2023, 月刊糖尿病・内分泌代謝科, 57(3) (3)


• ODP329 Long-term Effect of Daily Growth Hormone Replacement Therapy on Glucose Tolerance in Adult growth Hormone Deficiency

  Hironori Bando, Hidenori Fukuoka, Genzo Iguchi, Keitaro Kanie, Wataru Ogawa, Hiroki Shichi, Masaki Suzuki, Michiko Takahashi, Yutaka Takahashi, Shin Urai, Naoki Yamamoto, Yuka Oi, Masaaki Yamamoto, Yuriko Sasaki

  The Endocrine Society, 01 Nov. 2022, Journal of the Endocrine Society, 6(Supplement{\_}1) (Supplement{\_}1), A499 - A500


• Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review

  Atsushi Ishida, Hiroki Shichi, Hidenori Fukuoka, Hideki Shiramizu, Naoko Inoshita, Shozo Yamada

  May 2022, FRONTIERS IN ONCOLOGY, 12, English

  Book review


• 間脳下垂体疾患の病態についての最新の知見 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデルの樹立

  蟹江 慶太郎, 伊藤 剛, 井口 元三, 坂東 弘教, 山本 雅昭, 福岡 秀規, 金子 新, 高橋 裕

  (一社)日本内分泌学会, Mar. 2022, 日本内分泌学会雑誌, 97(5) (5), 1236 - 1236, Japanese


• 下垂体副腎系腫瘍の病態解明と分子標的薬の開発

  福岡 秀規

  (一社)日本内分泌学会, Mar. 2022, 日本内分泌学会雑誌, 97(5) (5), 1583 - 1583, Japanese


• 両側副腎での123I-MIBG陽性例における臨床的、病理学的検討

  稲葉 惟子, 山本 雅昭, 神澤 真紀, 青山 弥生, 神田 知紀, 中村 保宏, 坂東 弘教, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Mar. 2022, 日本内分泌学会雑誌, 97(5) (5), 1603 - 1603, Japanese


• Corticotroph adenomaにおける腫瘍微小環境は非炎症性を呈する

  神澤 真紀, 福岡 秀規, 蟹江 慶太郎, 山本 雅昭, 山田 正三, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, Mar. 2022, 日本内分泌学会雑誌, 97(5) (5), 1608 - 1608, Japanese


• paragangliomaとganglioneuromaの混合腫瘍の1例

  佐々木 百合子, 神澤 真紀, 山本 雅昭, 蟹江 慶太郎, 重村 克巳, 神田 知紀, 上田 真莉子, 坂東 弘教, 芳野 啓, 廣田 勇士, 藤澤 正人, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Mar. 2022, 日本内分泌学会雑誌, 97(5) (5), 1622 - 1622, Japanese


• Gonadotroph tumorとsomatotroph tumorのcollisionと考えられた一例

  神澤真紀, 辻本泰貴, 山本雅昭, 蟹江慶太郎, 坂東弘教, 坂東弘教, 中井友昭, 篠山隆司, 井下尚子, 福岡秀規, 小川渉, 伊藤智雄

  2022, 日本臨床内分泌病理学会学術総会プログラム・抄録集, 26th


• 先端巨大症患者におけるBMIと肥満関連疾患の有病率についての検討

  山本直希, 浦井伸, 鈴木正暉, 佐々木百合子, 大井佑夏, 志智大城, 蟹江慶太郎, 坂東弘教, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 1型糖尿病(T1DM)患者におけるIGF-Iと自由行動下のCGM指標に関連する因子の検討

  鈴木正暉, 浦井伸, 福岡秀規, 廣田勇士, 山本直希, 志智大城, 蟹江慶太郎, 坂東弘教, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 肥満症患者における食行動質問表の各因子スコアと減量効果予測の検討

  友藤清爾, 西影星二, 村前直和, 芳野啓, 坂東弘教, 山本雅昭, 福岡秀規, 高橋路子, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• Free StyleリブレLink使用者の背景および導入前後におけるスキャン回数,HbA1cの変化の検討

  芳野啓, 花山亜沙, 上田真莉子, 松岡敦子, 山本あかね, 蟹江慶太郎, 坂東弘教, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 肥満症における11の健康障害と長期的な体重変化との関連の検討

  影山智子, 西影星二, 村前直和, 芳野啓, 坂東弘教, 山本雅昭, 福岡秀規, 高橋路子, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• SGLT2阻害薬投与後のHb増加に伴うGA/HbA1c比への影響に関する検討

  芳野啓, 本村悠馬, 西影星二, 西影星二, 山本あかね, 坂東弘教, 山本雅昭, 福岡秀規, 芳野弘, 芳野原, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• インスリン抗体の性質変化に伴いインスリン注射回数の変更を要した1型糖尿病の1例

  宮崎裕也, 辻本泰貴, 大井佑夏, 芳野啓, 坂東弘教, 蟹江慶太郎, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(5) (5)


• 成人成長ホルモン分泌不全症(AGHD)患者におけるGH補充療法による耐糖能への影響に関する検討

  大井佑夏, 山本雅昭, 佐々木百合子, 鈴木正暉, 山本直希, 浦井伸, 志智大城, 蟹江慶太郎, 坂東弘教, 高橋路子, 高橋路子, 井口元三, 井口元三, 高橋裕, 福岡秀規, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 肺炎治療中に急激に発症し短期間で改善したSLE併発B型インスリン抵抗症の1例

  三輪一貴, 西影星二, 山下真依, 白杉郁, 芳野啓, 坂東弘教, 山本雅昭, 福岡秀規, 三枝淳, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(5) (5)


• 免疫チェックポイント阻害薬投与後に発症した1型糖尿病様の糖尿病の特徴と膵臓MRI所見との関連についての検討

  前田岳志, 芳野啓, 西山信晴, 本村悠馬, 鈴木正暉, 井上朋也, 坂東弘教, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 肥満症患者に対する術前減量サポートの効果と周術期合併症に関する検討

  高橋路子, 高橋路子, 山田倫子, 山田倫子, 村前直和, 尾上弘美, 鍛冶亜由美, 三ヶ尻礼子, 山本育子, 坂東弘教, 山本雅昭, 福岡秀規, 井口元三, 井口元三, 田守義和, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 1型糖尿病患者におけるSGLT2阻害薬使用の影響に関する検討

  本村悠馬, 芳野啓, 山本あかね, 上田真莉子, 松岡敦子, 蟹江慶太郎, 坂東弘教, 坂東弘教, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• 若年で糖尿病を発症した小児がん経験者の1例

  佐々木百合子, 坂東弘教, 藤井研己, 西影星二, 山本雅昭, 芳野啓, 蟹江慶太郎, 廣田勇士, 福岡秀規, 小川渉

  2022, 糖尿病(Web), 65(Suppl) (Suppl)


• Cushing症候群診断時における自覚症状と他覚所見の乖離について

  本村悠馬, 浦井伸, 坂東弘教, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022, 日本内分泌学会雑誌, 98(1) (1)


• 甲状腺刺激ホルモン(TSH)の測定系のハーモナイゼーションから探る測定系に不安定性を与える因子の検討

  生戸健一, 坂東弘教, 福岡秀規, 山本雅昭, 小笠原綾子, 佐藤伊都子, 今西孝充, 岡野隆一, 小川渉, 矢野嘉彦

  2022, 日本内分泌学会雑誌, 98(1) (1)


• グルココルチコイド補充中患者におけるCOVID-19ワクチン接種後のステロイドカバーに関する実態調査

  友藤清爾, 坂東弘教, 山本雅昭, 高橋路子, 高橋路子, 佐々木百合子, 大井佑夏, 穂積かおり, 西影星二, 浦井伸, 志智大城, 山本直希, 鈴木正暉, 蟹江慶太郎, 井口元三, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022, 日本内分泌学会雑誌, 98(1) (1)


• Cushing症候群診断時における自覚症状と他覚所見の乖離について

  本村悠馬, 浦井伸, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022, 間脳・下垂体・副腎系研究会プログラム・抄録集(Web), 33rd


• 輸血によりゴナドトロピン単独欠損症をきたした再生不良性貧血の一例

  山本直希, 浦井伸, 山本雅昭, 坂東弘教, 坂東弘教, 鈴木正暉, 佐々木百合子, 大井佑夏, 志智大城, 蟹江慶太郎, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• グルココルチコイド補充療法患者におけるCOVID-19ワクチン接種後のステロイドカバーに関する実態調査

  坂東弘教, 坂東弘教, 山本雅昭, 高橋路子, 高橋路子, 佐々木百合子, 大井佑夏, 穂積かおり, 西影星二, 浦井伸, 志智大城, 山本直希, 鈴木正暉, 蟹江慶太郎, 福岡秀規, 井口元三, 井口元三, 井口元三, 小川渉

  2022, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• Corticotroph adenomaにおける腫瘍微小環境とコルチゾールの関連性

  神澤真紀, 福岡秀規, 蟹江慶太郎, 山本雅昭, 山田正三, 小川渉, 伊藤智雄

  2022, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• 重症筋無力症を合併した抗PIT-1下垂体炎の新規症例

  浦井伸, 大井佑夏, 蟹江慶太郎, 山本雅昭, 坂東弘教, 坂東弘教, 山本直希, 鈴木正暉, 志智大城, 福岡秀規, 井口元三, 井口元三, 井口元三, 小川渉

  2022, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• 神戸大学医学部附属病院におけるクッシング病の診療実態

  福岡秀規, 山本雅昭, 坂東弘教, 蟹江慶太郎, 志智大城, 浦井伸, 山本直希, 鈴木正暉, 大井佑夏, 佐々木百合子, 高橋路子, 井口元三, 井口元三, 谷口理章, 西岡宏, 山田正三, 山田正三, 高橋裕, 高橋裕, 小川渉

  2022, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• USP8変異はAVPR1b受容体高発現を介してクッシング病のDDAVP試験反応性と関連する

  志智大城, 福岡秀規, 神澤真紀, 山本直希, 鈴木正暉, 浦井伸, 蟹江慶太郎, 坂東弘教, 山本雅昭, 井口元三, 井下尚子, 山田正三, 高橋裕, 高橋裕, 小川渉

  2022, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• 【内分泌疾患・病歴聴取と説明の要点とコツ】先端巨大症

  浦井 伸, 福岡 秀規

  (有)科学評論社, Dec. 2021, 糖尿病・内分泌代謝科, 53(6) (6), 600 - 604, Japanese


• 重症筋無力症を合併した抗PIT-1下垂体炎の1例

  大井 佑夏, 浦井 伸, 山本 雅昭, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Dec. 2021, 日本内分泌学会雑誌, 97(4) (4), 907 - 907, Japanese


• 【内分泌疾患・糖尿病・代謝疾患-診療のエッセンス】(I章)内分泌疾患 主要内分泌疾患 視床下部・下垂体疾患 成長ホルモン分泌不全性低身長症、成人成長ホルモン分泌不全症

  福岡 秀規

  (公社)日本医師会, Oct. 2021, 日本医師会雑誌, 150(特別2) (特別2), S71 - S72, Japanese


• 胸腺腫術後に重症筋無力症を発症した抗PIT-1下垂体炎の1例

  大井 佑夏, 山本 雅昭, 浦井 伸, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 487 - 487, Japanese


• 成人GH分泌不全症患者におけるソマプシタンの耐糖能への影響

  高橋 裕, Biller Beverly M.K., Rasmussen Michael Hojby, Johannsson Gudmundur, Nedjatian Navid, Sverke Claus, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 496 - 496, Japanese


• USP8変異はV1b受容体発現、DDAVP試験反応性亢進と関連する

  志智 大城, 福岡 秀規, 神澤 真紀, 山本 直希, 鈴木 正暉, 浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 山田 正三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 501 - 501, Japanese


• 発症36年後に抗ラブフィリン3A抗体陽性を示した尿崩症の1例

  西影 星二, 山本 雅昭, 稲葉 惟子, 坂東 弘教, 芳野 啓, 廣田 勇士, 椙村 益久, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 505 - 505, Japanese


• COVID-19治療中の高血圧クリーゼから診断した褐色細胞腫の一例

  辻本 泰貴, 西影 星二, 山本 雅昭, 西坂 まり華, 芳野 啓, 蟹江 慶太郎, 廣田 勇士, 坂東 弘教, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 528 - 528, Japanese


• ICIとTKI使用後に原発性副腎不全を生じた腎癌の2例

  西坂 まり華, 坂東 弘教, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 533 - 533, Japanese


• paragangliomaとganglioneuromaの混合腫瘍の1例

  佐々木 百合子, 山本 雅昭, 神澤 真紀, 蟹江 慶太郎, 重村 克巳, 神田 知紀, 上田 真莉子, 坂東 弘教, 芳野 啓, 廣田 勇士, 藤澤 正人, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, Oct. 2021, 日本内分泌学会雑誌, 97(2) (2), 539 - 539, Japanese


• 【意外と知られていない!? 自科の常識・他科の非常識】(第10章)内分泌 先端巨大症を疑ったらGHでなくIGF-Iでスクリーニングを行う

  蟹江 慶太郎, 福岡 秀規

  (株)南江堂, Sep. 2021, 内科, 128(3) (3), 698 - 700, Japanese


• ALP酵素療法により効果を認めた新規ALPL A205T変異による成人発症低ホスファターゼ症の1例

  西影 星二, 福岡 秀規, 山本 雅昭, 稲葉 惟子, 廣田 勇士, 小川 渉

  (一社)日本骨粗鬆症学会, Sep. 2021, 日本骨粗鬆症学会雑誌, 7(Suppl.1) (Suppl.1), 346 - 346, Japanese


• 【日常診療で内分泌疾患を見逃さない!】代表的内分泌疾患 下垂体疾患 プロラクチノーマ 月経異常を見逃さない!

  坂東 弘教, 福岡 秀規

  (株)医学書院, Aug. 2021, Medicina, 58(9) (9), 1355 - 1359, Japanese


• 大動脈解離を合併した生殖細胞系ARMC5遺伝子変異を持つ原発性両側性大結節性副腎皮質過形成の家族例

  辻本 泰貴, 小畠 正樹, 中村 友昭, 福岡 秀規, 重村 重巳, 藤澤 正人, 神澤 真紀, 森本 晶子, 臼井 健, 千原 和夫

  (一社)日本内分泌学会, Jul. 2021, 日本内分泌学会雑誌, 97(Suppl.Update) (Suppl.Update), 62 - 65, Japanese


• 成人成長ホルモン分泌不全症に対する治療のポイントと課題

  福岡 秀規

  (一社)日本内分泌学会, Jul. 2021, 日本内分泌学会雑誌, 97(3) (3), 652 - 652, Japanese


• 播種性クリプトコッカス症を含む日和見感染症の原因と考えられたACTH産生下垂体腺腫を解剖にて同定しえた一例

  菅野 天裕, 神澤 真紀, 兵頭 俊紀, 近藤 武史, 三好 園子, 尾下 寿彦, 穂積 かおり, 神田 知紀, 福岡 秀規, 伊藤 智雄, 横崎 宏

  (株)文光堂, Jun. 2021, 病理と臨床, 39(6) (6), 611 - 616, Japanese


• 【内分泌疾患2】(Part 2)どこまでを専門家がみて,どこから総合内科医がみるのか? 下垂体 下垂体卒中,視床下部・下垂体炎

  福岡 秀規

  (株)メディカル・サイエンス・インターナショナル, Jun. 2021, Hospitalist, 9(2) (2), 425 - 429, Japanese


• 反応性低血糖により診断に至ったA型インスリン抵抗症の1例

  西影 星二, 廣田 勇士, 高吉 倫史, 竹内 健人, 浜口 哲矢, 稲葉 惟子, 芳野 啓, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, May 2021, 糖尿病, 64(Suppl.1) (Suppl.1), I - 7, Japanese


• CSII療法施行中1型糖尿病患者の朝食絶食による血中ケトン体推移に関する検討

  井上 朋也, 廣田 勇士, 松本 梨佐, 齋藤 修一郎, 新井 尚樹, 後藤 美菜子, 西影 星二, 芳野 啓, 稲葉 惟子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, May 2021, 糖尿病, 64(Suppl.1) (Suppl.1), I - 3, Japanese


• 間歇スキャンCGM(isCGM)使用中の1型糖尿病患者におけるTIR、TAR、TBRの季節性変動に関する検討

  大井 佑夏, 廣田 勇士, 西影 星二, 山本 あかね, 浦井 伸, 高吉 倫史, 中川 靖, 松岡 敦子, 芳野 啓, 稲葉 惟子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, May 2021, 糖尿病, 64(Suppl.1) (Suppl.1), III - 6, Japanese


• 視床下部下垂体疾患アップデート 先端巨大症を除く下垂体機能性腫瘍のアップデート

  福岡 秀規

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 186 - 186, Japanese


• 糖質コルチコイドによる正のフィードバック機構の関与が想定されるクッシング病

  辻本 泰貴, 志智 大城, 福岡 秀規, 中村 友昭, 神澤 真紀, 石田 敦士, 山田 正三, 小川 渉, 高橋 裕, 千原 和夫

  (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 225 - 225, Japanese


• 下垂体腫瘍オルガノイド樹立への挑戦

  藤田泰功, 浦井伸, 志智大城, 福岡秀規, 蟹江慶太郎, 山本雅昭, 井口元三, 井口元三, 青井貴之, 青井貴之, 谷口理章, 山田正三, 小川渉, 高橋裕, 高橋裕

  2021, 日本間脳下垂体腫瘍学会プログラム・抄録集, 31st


• CSII療法施行中1型糖尿病患者の朝食絶食による血中ケトン体推移に関する検討

  井上朋也, 廣田勇士, 松本梨佐, 齋藤修一郎, 新井尚樹, 後藤美菜子, 西影星二, 芳野啓, 稲葉惟子, 山本雅昭, 福岡秀規, 小川渉

  2021, 糖尿病(Web), 64(Suppl) (Suppl)


• 反応性低血糖により診断に至ったA型インスリン抵抗症の1例

  西影星二, 廣田勇士, 高吉倫史, 竹内健人, 浜口哲矢, 稲葉惟子, 芳野啓, 山本雅昭, 福岡秀規, 小川渉

  2021, 糖尿病(Web), 64(Suppl) (Suppl)


• 間歇スキャンCGM(isCGM)使用中の1型糖尿病患者におけるTIR,TAR,TBRの季節性変動に関する検討

  大井佑夏, 廣田勇士, 西影星二, 山本あかね, 浦井伸, 高吉倫史, 中川靖, 松岡敦子, 芳野啓, 稲葉惟子, 山本雅昭, 福岡秀規, 小川渉

  2021, 糖尿病(Web), 64(Suppl) (Suppl)


• iPS細胞を用いた革新的下垂体疾患モデルの作成と病因・病態解析

  高橋裕, 松本隆作, 蟹江慶太郎, 伊藤剛, 金子新, 須賀秀隆, 福岡秀規, 井口元三

  2021, 日本下垂体研究会学術集会プログラム・講演要旨集, 35th


• Nivolumab投与開始1年半後に劇症1型糖尿病様病態で発症した糖尿病の1例

  大町 侑香, 鈴木 正暉, 伊藤 潤, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 57 - 57, Japanese


• 下垂体腺腫摘出術後に早朝の血糖上昇が改善した先端巨大症の1例

  山本 雅昭, 廣田 勇士, 福満 隼人, 福岡 秀規, 高橋 裕, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 63 - 63, Japanese


• CSII療法中1型糖尿病患者のSGLT2阻害薬服用下での絶食中血中ケトン体変化

  西山 美菜子, 鈴木 正暉, 芳野 啓, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 82 - 82, Japanese


• 複合要因により自発性低血糖を頻発したアルコール多飲習慣のあるC型肝炎合併透析患者

  西影 星二, 西山 信晴, 山本 直希, 芳野 啓, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, Jan. 2021, 糖尿病, 64(1) (1), 84 - 84, Japanese


• 大動脈解離を合併した原発性両側大結節性副腎皮質過形成の家族例

  辻本 泰貴, 中村 友昭, 小畠 正樹, 福岡 秀規, 重村 克巳, 藤澤 正人, 神澤 真紀, 森本 晶子, 千原 和夫

  (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 494 - 494, Japanese


• クッシング病の診断と治療

  福岡 秀規

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 167 - 167, Japanese


• 副腎性クッシング症候群の治療実態

  福岡 秀規

  (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 183 - 183, Japanese


• 1型糖尿病患者における発症様式の違いは骨密度に影響を与える

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 雅昭, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本糖尿病学会, Aug. 2020, 糖尿病, 63(Suppl.1) (Suppl.1), S - 219, Japanese


• 高用量デキサメタゾン抵抗性サブクリニカルクッシング病in vitroでの検証

  臼谷 真理, 高安 忍, 志智 大城, 福岡 秀規, 山田 正三, 井下 尚子, 山形 聡, 杉山 綾, 照井 健, 川嶋 詳子, 蔭山 和則, 高橋 裕, 大門 眞

  (一社)日本内分泌学会, Jul. 2020, 日本内分泌学会雑誌, 96(Suppl.Update) (Suppl.Update), 104 - 106, Japanese


• バイオ医薬の経粘膜吸収促進技術の最前線 経粘膜吸収促進技術が臨床にもたらすインパクト 糖尿病・内分泌内科医の立場から

  福岡 秀規

  (公社)日本薬剤学会, May 2020, 日本薬剤学会年会講演要旨集, 35年会, 78 - 78, Japanese


• 特発性アルドステロン症を合併したサブクリニカルクッシング症候群の1例

  神澤 真紀, 瀬尾 あかね, 福岡 秀規, 岡田 佳輔, 藤沢 正人, 青山 弥生, 中村 保宏, 高橋 裕, 伊藤 智雄

  (一社)日本内分泌学会, Feb. 2020, 日本内分泌学会雑誌, 95(4) (4), 1693 - 1693, Japanese


• プロラクチノーマとして治療されていたaggressiveな機能性FSH産生下垂体腺腫の1例

  鈴木正暉, 福岡秀規, 山本雅昭, 神澤真紀, 岡田裕子, 廣田勇士, 井口元三, 井口元三, 谷口理章, 小川渉, 高橋裕, 高橋裕

  2020, 日本内分泌学会雑誌, 96(Suppl. HPT (Web)) (Suppl. HPT (Web))


• 1型糖尿病患者における発症様式の違いは骨密度に影響を与える

  鈴木正暉, 浦井伸, 福岡秀規, 廣田勇士, 山本雅昭, 岡田裕子, 井口元三, 井口元三, 小川渉, 高橋裕

  2020, 糖尿病(Web), 63(Suppl) (Suppl)


• プラダー・ウィリ症候群における診療ガイドラインの作成に関する研究 トランジションを主に

  高橋裕, 福岡秀規, 山本雅昭

  2020, プラダー・ウィリ症候群における診療ガイドラインの作成 令和元年度 総括研究報告書(Web)


• Pazopanibにより改善を認めた非膵島細胞腫瘍性低血糖症の一例

  山本直希, 山本雅昭, 稲葉惟子, 清田尚臣, 西山信晴, 西影星二, 福田いずみ, 福岡秀規, 小川渉

  (一社)日本内分泌学会, 2020, 日本内分泌学会雑誌, 96(2) (2), 564 - 564, Japanese


• AcroQoLを用いた高齢先端巨大症患者QoLの特徴と解析

  山本直希, 浦井伸, 福岡秀規, 高吉倫史, 山本雅昭, 吉田健一, 井口元三, 井口元三, 小川渉, 高橋裕

  2020, 日本間脳下垂体腫瘍学会プログラム・抄録集, 30th


• プロラクチノーマとして治療されていたaggressiveな機能性FSH産生下垂体腺腫の1例

  鈴木正暉, 福岡秀規, 山本雅昭, 神澤真紀, 岡田裕子, 廣田勇士, 井口元三, 谷口理章, 小川渉, 高橋裕

  (一社)日本内分泌学会, 2020, 日本間脳下垂体腫瘍学会プログラム・抄録集, 30th(Suppl.HPT) (Suppl.HPT), 63 - 66, Japanese


• 先端巨大症患者のオクトレオチド試験は術前投与における短期間のソマトスタチンアナログ治療効果を予測する

  浦井伸, 山本雅昭, 福岡秀規, 志智大城, 蟹江慶太郎, 藤田泰功, 井口元三, 井口元三, 小川渉, 高橋裕

  2020, 日本間脳下垂体腫瘍学会プログラム・抄録集, 30th


• 1型糖尿病患者における心エコー図を用いた左室拡張機能の検討

  浦井伸, 山本雅昭, 福岡秀規, 岡田裕子, 田中秀和, 廣田勇士, 小川渉

  2020, 糖尿病(Web), 63(7) (7)


• SAP療法中の1型糖尿病患者におけるPLGS機能導入半年後の効果についての検討

  山本あかね, 廣田勇士, 山本雅昭, 福岡秀規, 岡田裕子, 小川渉

  2020, 糖尿病(Web), 63(7) (7)


• SAP療法中1型糖尿病患者におけるカニューレ交換後の血糖推移に関する検討

  穂積かおり, 浦井伸, 山本雅昭, 岡田裕子, 福岡秀規, 廣田勇士, 小川渉

  2020, 糖尿病(Web), 63(7) (7)


• 先端巨大症 (特集 内分泌Up To Date) -- (間脳・下垂体)

  福岡 秀規

  南江堂, Dec. 2019, 内科 = Internal medicine : 臨床雑誌, 124(6) (6), 2423 - 2428, Japanese


• 内分泌機能検査道場 このデータ、どう読む?

  在原 善英, 福岡 秀規

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 656 - 656, Japanese


• 患者さんの声を聴く 患者会"下垂会"のアンケート結果より

  亀田 啓, 福岡 秀規, 山田 正三, 島津 章

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 657 - 657, Japanese


• 前立腺癌に異所性ACTH発現を認めたACTH単独欠損症の一例

  藤田 泰功, 井口 元三, 神澤 真紀, 蟹江 慶太郎, 志智 大城, 浦井 伸, 山本 雅昭, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 706 - 706, Japanese


• 先端巨大症のオクトレオチド試験は3ヵ月後の薬物効果を予測する

  浦井 伸, 山本 雅昭, 福岡 秀規, 志智 大城, 蟹江 慶太郎, 藤田 泰功, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 707 - 707, Japanese


• bigACTHがないにも関わらずACTH/F高値を認めたクッシング病の1例

  桂 由佳梨, 浦井 伸, 山本 雅昭, 福岡 秀規, 内山 奏, 佐藤 伊都子, 井下 尚子, 三木 伸泰, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 708 - 708, Japanese


• 重症ニューモシスチス肺炎を呈した異所性ACTH症候群の一例

  穂積 かおり, 福岡 秀規, 山本 雅昭, 杉澤 良介, 江木 盛時, 大路 剛, 梅澤 佳乃子, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 711 - 711, Japanese


• 抗PIT-1抗体症候群は新たな傍腫瘍症候群である

  蟹江 慶太郎, 井口 元三, 山本 雅昭, 犬塚 恵, 榊 健太郎, 谷口 孝夫, 志智 大城, 藤田 泰功, 浦井 伸, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 720 - 720, Japanese


• SCSに両側性PAを合併したPBMAHの一例

  合田 菜穂, 福岡 秀規, 岡田 裕子, 廣田 勇士, 井口 元三, 臼井 健, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 738 - 738, Japanese


• 高齢先端巨大症患者におけるQOL低下に関連する因子の検討

  山本 直希, 浦井 伸, 福岡 秀規, 高吉 倫史, 山本 雅昭, 吉田 健一, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 767 - 767, Japanese


• SIADHとの鑑別が困難であった低Na血症の一例

  小畠 正樹, 福岡 秀規, 山本 雅昭, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 781 - 781, Japanese


• アルドステロン産生腺腫の分泌能は腫瘍径と正の相関を示す

  福満 隼人, 山本 雅昭, 重村 克己, 高吉 倫史, 井口 元三, 福岡 秀規, 藤澤 正人, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 796 - 796, Japanese


• 副甲状腺摘出術によって膵NETの改善を認めたMEN1の1例

  志智 大城, 福岡 秀規, 高橋 陸, 浦井 伸, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 810 - 810, Japanese


• 1型糖尿病患者における骨密度低下に関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 雅昭, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 815 - 815, Japanese


• 成人期診断22q11.2欠失症候群における内分泌異常の特徴

  横井 愛紗, 福岡 秀規, 穂積 かおり, 山本 雅昭, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 821 - 821, Japanese


• 前立腺癌に異所性ACTH発現を認めたACTH単独欠損症の一例

  藤田 泰功, 井口 元三, 神澤 真紀, 蟹江 慶太郎, 志智 大城, 浦井 伸, 山本 雅昭, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 706 - 706, Japanese


• 先端巨大症のオクトレオチド試験は3ヵ月後の薬物効果を予測する

  浦井 伸, 山本 雅昭, 福岡 秀規, 志智 大城, 蟹江 慶太郎, 藤田 泰功, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 707 - 707, Japanese


• 抗PIT-1抗体症候群は新たな傍腫瘍症候群である

  蟹江 慶太郎, 井口 元三, 山本 雅昭, 犬塚 恵, 榊 健太郎, 谷口 孝夫, 志智 大城, 藤田 泰功, 浦井 伸, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 720 - 720, Japanese


• SCSに両側性PAを合併したPBMAHの一例

  合田 菜穂, 福岡 秀規, 岡田 裕子, 廣田 勇士, 井口 元三, 臼井 健, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 738 - 738, Japanese


• 高齢先端巨大症患者におけるQOL低下に関連する因子の検討

  山本 直希, 浦井 伸, 福岡 秀規, 高吉 倫史, 山本 雅昭, 吉田 健一, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 767 - 767, Japanese


• アルドステロン産生腺腫の分泌能は腫瘍径と正の相関を示す

  福満 隼人, 山本 雅昭, 重村 克己, 高吉 倫史, 井口 元三, 福岡 秀規, 藤澤 正人, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 796 - 796, Japanese


• 副甲状腺摘出術によって膵NETの改善を認めたMEN1の1例

  志智 大城, 福岡 秀規, 高橋 陸, 浦井 伸, 蟹江 慶太郎, 藤田 泰功, 山本 雅昭, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 810 - 810, Japanese


• 1型糖尿病患者における骨密度低下に関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 雅昭, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 815 - 815, Japanese


• パミドロン酸の効果を認めた閉経後骨形成不全症V型の一例

  福岡 秀規, 浦井 伸, 伊賀 真紀子, 中島 進介, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本骨粗鬆症学会, Sep. 2019, 日本骨粗鬆症学会雑誌, 5(Suppl.1) (Suppl.1), 437 - 437, Japanese


• 【Somatic/germline変異とがん医療】多発性内分泌腫瘍のgermline変異

  福岡 秀規

  (株)メディカルレビュー社, Jun. 2019, がん分子標的治療, 17(1) (1), 46 - 50, Japanese


• 【診療力を上げる! 症例問題集】(第10章)代謝・内分泌 症例問題 食思不振と低ナトリウム血症を呈する高齢男性

  福岡 秀規

  (株)南江堂, Apr. 2019, 内科, 123(4) (4), 1013 - 1015, Japanese


• リンパ節転移を認めた副腎ganglioneuromaの1例

  神澤 真紀, 福岡 秀規, 伊藤 智雄

  (一社)日本病理学会, Apr. 2019, 日本病理学会会誌, 108(1) (1), 395 - 395, Japanese


• 難治性Cushing病の治療戦略 薬物療法による治療戦略

  福岡 秀規, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 218 - 218, Japanese


• 下垂体発生における視床下部-口腔外胚葉間FGFの役割

  松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 352 - 352, Japanese


• 疾患iPS細胞を用いた抗PIT-1抗体症候群疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 松本 隆作, 六車 恵子, 志智 大城, 藤田 泰功, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 390 - 390, Japanese


• 副腎神経節腫の合併を認めた特発性低ゴナドトロピン性性腺機能低下症の1例

  高吉 倫史, 福岡 秀規, 植村 憲, 神澤 真紀, 重村 克巳, 岡田 裕子, 廣田 勇士, 井口 元三, 藤澤 正人, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 404 - 404, Japanese


• 下垂体発生における視床下部-口腔外胚葉間FGFの役割

  松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 408 - 408, Japanese


• プロラクチノーマの治療経過中に先端巨大症を発症した一例

  藤原 えり, 福岡 秀規, 山田 正三, 井下 尚子, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 415 - 415, Japanese


• ACTH単独欠損症において抗コルチコトロフ抗体の存在は重症度と関連する

  藤田 泰功, 坂東 弘教, 井口 元三, 飯田 啓二, 志智 大城, 蟹江 慶太郎, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 430 - 430, Japanese


• 下垂体卒中を呈したACTH産生下垂体腺腫の1例

  志智 大城, 福岡 秀規, 坂本 洋一, 蟹江 慶太郎, 藤田 泰功, 松本 隆作, 隅田 健太郎, 井口 元三, 井下 尚子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 446 - 446, Japanese


• 起立性調節障害と診断されていた若年発症インスリノーマの1例

  鈴木 宏隆, 福岡 秀規, 斎藤 修一郎, 高吉 倫史, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 466 - 466, Japanese


• 下垂体発生における視床下部-口腔外胚葉間FGFの役割

  松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 352 - 352, Japanese


• 疾患iPS細胞を用いた抗PIT-1抗体症候群疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 松本 隆作, 六車 恵子, 志智 大城, 藤田 泰功, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 390 - 390, Japanese


• 副腎神経節腫の合併を認めた特発性低ゴナドトロピン性性腺機能低下症の1例

  高吉 倫史, 福岡 秀規, 植村 憲, 神澤 真紀, 重村 克巳, 岡田 裕子, 廣田 勇士, 井口 元三, 藤澤 正人, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 404 - 404, Japanese


• 下垂体発生における視床下部-口腔外胚葉間FGFの役割

  松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 408 - 408, Japanese


• プロラクチノーマの治療経過中に先端巨大症を発症した一例

  藤原 えり, 福岡 秀規, 山田 正三, 井下 尚子, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 415 - 415, Japanese


• ACTH単独欠損症において抗コルチコトロフ抗体の存在は重症度と関連する

  藤田 泰功, 坂東 弘教, 井口 元三, 飯田 啓二, 志智 大城, 蟹江 慶太郎, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 430 - 430, Japanese


• 下垂体卒中を呈したACTH産生下垂体腺腫の1例

  志智 大城, 福岡 秀規, 坂本 洋一, 蟹江 慶太郎, 藤田 泰功, 松本 隆作, 隅田 健太郎, 井口 元三, 井下 尚子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 446 - 446, Japanese


• 起立性調節障害と診断されていた若年発症インスリノーマの1例

  鈴木 宏隆, 福岡 秀規, 斎藤 修一郎, 高吉 倫史, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95(1) (1), 466 - 466, Japanese


• 祖母の診断を契機に3歳時に診断に至った家族性中枢性尿崩症の一例

  坊亮輔, 粟野宏之, 井口元三, 山本雅昭, 福岡秀規, 高橋裕, 飯島一誠

  2019, 日本小児内分泌学会学術集会プログラム・抄録集, 53rd


• Changes in insulin requirements during pregnancy in women with type 1 diabetes mellitus : Comparison of continuous subcutaneous insulin infusion and Sensor Augmented Pump

  坂本 洋一, 岡田 裕子, 山田 倫子, 西本 祐希, 苛原 彩, 小原 靖子, 瀬尾 あかね, 中野 温子, 藤原 えり, 菅原 健二, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  日本糖尿病・妊娠学会, 2019, 糖尿病と妊娠 : 日本糖尿病・妊娠学会誌 = Diabetes & pregnancy : the journal of the Japanese Society of Diabetes and Pregnancy, 19(1) (1), 28 - 36, Japanese


• Cushing病の治療 症例を通した現状と今後の方向性

  福岡 秀規, 山田 正三, 高橋 裕

  (一社)日本内分泌学会, Dec. 2018, 日本内分泌学会雑誌, 94(4) (4), 1676 - 1676, Japanese


• Cushing病の治療 症例を通した現状と今後の方向性

  福岡 秀規, 山田 正三, 高橋 裕

  (一社)日本内分泌学会, Dec. 2018, 日本内分泌学会雑誌, 94(4) (4), 1676 - 1676, Japanese


• 妊娠中に高血圧と精神異常を呈した副腎皮質・髄質混合腫瘍の1例

  神澤 真紀, 福岡 秀規, 重村 克己, 青山 弥生, 中村 保宏, 原 重雄, 高橋 裕, 伊藤 智雄

  (一社)日本内分泌学会, Dec. 2018, 日本内分泌学会雑誌, 94(4) (4), 1698 - 1698, Japanese


• 妊娠中に高血圧と精神異常を呈した副腎皮質・髄質混合腫瘍の1例

  神澤 真紀, 福岡 秀規, 重村 克己, 青山 弥生, 中村 保宏, 原 重雄, 高橋 裕, 伊藤 智雄

  (一社)日本内分泌学会, Dec. 2018, 日本内分泌学会雑誌, 94(4) (4), 1698 - 1698, Japanese


• 【内分泌症候群(第3版)-その他の内分泌疾患を含めて-】 視床下部・下垂体 下垂体ホルモン単独欠損症および複合欠損症 先天性GH・TSH・PRL・Gn複合欠損症(LHX3異常症)

  Fukuoka Hidenori

  (株)日本臨床社, Sep. 2018, 日本臨床, 別冊(別冊内分泌症候群I) (別冊内分泌症候群I), 96 - 98, Japanese

  [Refereed][Invited]

  Introduction scientific journal


• Luscan-Lumish症候群による巨人症の機序の解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 坂東 弘教, 高橋 路子, 千原 和夫, 鳴海 覚志, 小川 渉, 長谷川 奉延, 高橋 裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 277 - 277, Japanese


• ACTH産生下垂体腺腫の浸潤性に関連するLong noncoding RNA、CRNDEの同定

  吉田 健一, 福岡 秀規, 藤田 泰功, 蟹江 慶一郎, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 高橋 路子, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 313 - 313, Japanese


• 転写因子OTX2は視床下部からのFGFシグナルを介して下垂体を分化させる

  松本 隆作, 須賀 英隆, 井口 元三, 福岡 秀規, 長谷川 奉延, 六車 恵子, 小川 渉, 青井 貴之, 高橋 裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 314 - 314, Japanese


• RET遺伝子hot spotに変異を認めなかったMEN2Aの一家系

  苛原 彩, 福岡 秀規, 原 重雄, 神澤 真紀, 大月 直樹, 重村 克巳, 吉田 博, 西原 永潤, 岡田 裕子, 井口 元三, 藤澤 正人, 宮内 昭, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94(1) (1), 314 - 314, Japanese


• メトホルミン内服患者におけるビタミンB12欠乏の実態調査

  菅原健二, 岡田裕子, 野村和弘, 山田倫子, 中川靖, 福岡秀規, 廣田勇士, 細岡哲也, 坂口一彦, 木戸良明, 木戸良明, 小川渉

  2018, 糖尿病(Web), 61(Suppl) (Suppl)


• 当院における副腎腫瘍マネージメントにおける術後多科合同カンファレンスについて

  重村克巳, 重村克巳, 寺川智章, 千葉公嗣, 古川順也, 原田健一, 日向信之, 福岡秀規, 高橋裕, 中野雄造, 藤澤正人

  (一社)日本泌尿器内視鏡・ロボティクス学会, 2018, Japanese Journal of Endourology, 31(3 (Web)) (3 (Web)), ADP - 4, Japanese


• 妊娠中に高血圧と精神異常を呈した副腎皮質・髄質混合腫瘍の1例

  神澤真紀, 福岡秀規, 重村克己, 青山弥生, 中村保宏, 原重雄, 高橋裕, 伊藤智雄

  2018, 日本臨床内分泌病理学会学術総会プログラム・抄録集, 22nd, 78, Japanese


• 1型糖尿病合併妊娠におけるCSIIとSAP療法のインスリン必要量の変化についての検討

  坂本 洋一, 岡田 裕子, 山田 倫子, 西本 祐希, 苛原 彩, 小原 靖子, 瀬尾 あかね, 中野 温子, 藤原 えり, 菅原 健二, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病・妊娠学会, Nov. 2017, 糖尿病と妊娠, 17(3) (3), S - 92, Japanese


• CGMが診断・治療に有用であったダンピング症候群の乳児例

  松本 真明, 粟野 宏之, 福岡 秀規, 永井 正志, 坊 亮輔, 冨岡 和美, 前山 花織, 田中 司, 西山 将広, 永瀬 裕明, 飯島 一誠

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 544 - 544, Japanese


• 遺伝性平滑筋腫症・腎細胞癌症候群に合併した副腎腫瘍の意義

  隅田 健太郎, 福岡 秀規, 小野 克彦, 重村 克巳, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 坂東 弘教, 高橋 路子, 井口 元三, 木南 佐織, 千原 和夫, 藤澤 正人, 山崎 有人, 笹野 公伸, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 535 - 535, Japanese


• パシレオチドLARが奏功した先端巨大症の2例

  藤原 えり, 福岡 秀規, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 546 - 546, Japanese


• big ACTH分泌を認めたサブクリニカルクッシング病の一例

  小武 由紀子, 福岡 秀規, 金谷 雅之, 佐藤 伊都子, 蟹江 慶太郎, 藤田 泰功, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 550 - 550, Japanese


• 肺大細胞神経内分泌癌を合併したACTH単独欠損症の一例

  坂東 弘教, 井口 元三, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 550 - 550, Japanese


• 当院で経験した免疫チェックポイント阻害薬関連下垂体炎の4例

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 立花 真理子, 金谷 雅之, 山田 倫子, 藤田 泰功, 小武 由紀子, 吉田 健一, 松本 隆作, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 552 - 552, Japanese


• 自己免疫性溶血性貧血と偽性副甲状腺機能低下症を合併した一例

  坂本 洋一, 福岡 秀規, 野崎 高史, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 568 - 568, Japanese


• 術中SACI testで腫瘍核出術を行ったMEN1合併インスリノーマの1例

  苛原 彩, 福岡 秀規, 高橋 陸, 山田 倫子, 岡田 裕子, 井口 元三, 外山 博近, 福本 巧, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 587 - 587, Japanese


• 先端巨大症におけるHPA軸の検討

  小原 靖子, 福岡 秀規, 中山 真理子, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 596 - 596, Japanese


• 日本人Cushing症候群におけるCushingQoLの応用

  藤田 泰功, 福岡 秀規, 瀬尾 あかね, 中野 温子, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 井口 元三, Webb Susan, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 599 - 599, Japanese


• 副腎髄質過形成疑い病変に原発性副甲状腺機能亢進症を合併した例

  中野 温子, 福岡 秀規, 神保 直江, 岩橋 泰幸, 吉川 祥子, 亀村 幸平, 開發 謙次, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 640 - 640, Japanese


• 手術によって寛解後30年目に再発を認めたCushing病の一例

  瀬尾 あかね, 福岡 秀規, 吉田 健一, 小原 靖子, 苛原 彩, 中野 温子, 藤原 えり, 坂本 洋一, 菅原 健二, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2017, 日本内分泌学会雑誌, 93(2) (2), 599 - 599, Japanese


• 当院における腎移植後新規耐糖能異常の発症に関する検討

  坂本 洋一, 山田 倫子, 岡田 裕子, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 横山 直己, 石村 武志, 藤澤 正人, 小川 渉

  (一社)日本糖尿病学会, Sep. 2017, 糖尿病, 60(9) (9), 639 - 639, Japanese


• 2型糖尿病患者におけるインスリン治療とQOLの関連、および教育入院による変化

  立花 真莉子, 山田 倫子, 岡田 裕子, 高橋 陸, 平野 靖子, 村前 直和, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Sep. 2017, 糖尿病, 60(9) (9), 679 - 679, Japanese


• デュラグルチド導入後の血糖変動に与える短期効果についての検討

  平野 靖子, 村前 直和, 岡田 裕子, 立花 真莉子, 山田 倫子, 菅原 健二, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Sep. 2017, 糖尿病, 60(9) (9), 623 - 623, Japanese


• SGLT2阻害薬導入後に著明な高グルカゴン血症を呈した1例

  金谷 雅之, 菅原 健二, 岡田 裕子, 岩橋 泰幸, 山田 倫子, 村前 直和, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Sep. 2017, 糖尿病, 60(9) (9), 627 - 627, Japanese


• 下垂体腺腫に対する分子標的薬の可能性

  福岡 秀規

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 183 - 183, Japanese


• 腎移植後の耐糖能の長期的な推移についての検討

  山田 倫子, 岡田 裕子, 坂本 洋一, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 横山 直己, 石村 武志, 藤澤 正人, 小川 渉

  (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 378, Japanese


• 1型糖尿病合併妊娠におけるCSIIとSensor Augmented Pump(SAP)療法のインスリン必要量の変化についての検討

  坂本 洋一, 岡田 裕子, 山田 倫子, 西本 祐希, 岩橋 泰幸, 村前 直和, 菅原 健次, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 390, Japanese


• 持続血糖モニターを用いた妊娠糖尿病患者における分娩中の血糖動態についての検討

  黒飛 友里, 村前 直和, 岡田 裕子, 山田 倫子, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 谷村 憲司, 森實 真由美, 出口 雅士, 山田 秀人, 小川 渉

  (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 429, Japanese


• 正常耐糖能者における肥満とmetabolic flexibilityの関連についての検討

  村前 直和, 岡田 裕子, 三浦 洋, 山田 倫子, 末松 那都, 宋 杏奈, 中村 友昭, 駒田 久子, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 460, Japanese


• 周期性が疑われた嗅神経芽細胞腫による異所性ACTH症候群の一例

  金谷 雅之, 福岡 秀規, 菅原 大輔, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 237 - 237, Japanese


• 抗PIT-1抗体症候群の発症機序の解明

  坂東 弘教, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 隈田 健太郎, 西澤 衡, 福岡 秀規, 犬塚 恵, 杢保 敦子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 249 - 249, Japanese


• 疾患特異的iPS細胞を用いた先天性下垂体機能低下症の病態解明

  松本 隆作, 須賀 英隆, 青井 貴之, 坂東 弘教, 福岡 秀規, 井口 元三, 鳴海 覚志, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 249 - 249, Japanese


• Luscan-Lumish症候群による巨人症の機序の解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 鳴海 覚志, 小川 渉, 長谷川 奉延, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 263 - 263, Japanese


• 成長ホルモン分泌不全症における肝線維化を予測する非侵襲的マーカーの検討

  西澤 衡, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 264 - 264, Japanese


• Cushing症候群薬物療法中患者のバイオマーカーとしての唾液コルチゾールの有用性の検討

  吉田 健一, 福岡 秀規, 山田 倫子, 中島 進介, 立花 真莉子, 細川 友誠, 岩橋 泰幸, 伊藤 潤, 三浦 洋, 末松 那都, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 267 - 267, Japanese


• 周期性が疑われた嗅神経芽細胞腫による異所性ACTH症候群の一例

  金谷 雅之, 福岡 秀規, 菅原 大輔, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 302 - 302, Japanese


• 緩徐1型糖尿病、バセドウ病を合併した偽性偽性副甲状腺機能低下症の一例

  小武 由紀子, 福岡 秀規, 平田 悠, 高橋 陸, 毛利 華奈子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 岡田 裕子, 廣田 勇士, 高橋 路子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93(1) (1), 370 - 370, Japanese


• マイクロアレイ解析による、インスリノーマの分泌特性を規定する遺伝子発現量の検討

  菅原 健二, 岡田 裕子, 松田 友和, 坂本 洋一, 岩橋 泰幸, 村前 直和, 山田 倫子, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 208, Japanese


• インスリン治療中の2型糖尿病患者におけるSGLT-2阻害薬投与によるインスリン減量効果についての検討

  岩橋 泰幸, 岡田 裕子, 坂本 洋一, 村前 直和, 山田 倫子, 菅原 健二, 中村 友昭, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 406, Japanese


• 内科系症例検討 神経線維腫症I型に多彩な内分泌腫瘍を合併した先端巨大症の1例

  小武 由紀子, 福岡 秀規, 穂積 かおり, 佐藤 武志, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 井口 元三, 長谷川 奉延, 小川 渉, 高橋 裕

  (株)ライフ・サイエンス, Feb. 2017, Progress in Medicine, 37(2) (2), 292 - 293, Japanese


• Cushing病の基礎と臨床 Cushing病の腫瘍化メカニズムについて

  福岡 秀規

  (一社)日本内分泌学会, Jan. 2017, 日本内分泌学会雑誌, 92(3) (3), 719 - 719, Japanese


• 先端巨大症の薬物療法 現状と今後の展望

  福岡 秀規

  (一社)日本内分泌学会, Jan. 2017, 日本内分泌学会雑誌, 92(3) (3), 978 - 978, Japanese


• 特発性後天性全身性無汗症に中枢性尿崩症を合併した一例

  小畠 正樹, 福岡 秀規, 坂東 弘教, 高橋 陸, 山田 倫子, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Jan. 2017, 日本内分泌学会雑誌, 92(3) (3), 732 - 732, Japanese


• CHD7遺伝子変異を認めた複合型下垂体機能低下症合併Kallmann症候群の1例

  大橋 千裕, 福岡 秀規, 志智 大城, 岡田 裕子, 廣田 勇士, 井口 元三, 深見 真紀, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Jan. 2017, 日本内分泌学会雑誌, 92(3) (3), 735 - 735, Japanese


• ACTH産生下垂体腫瘍におけるErbB4受容体の役割の解明

  小武 由紀子, 福岡 秀規, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Jan. 2017, 日本内分泌学会雑誌, 92(3) (3), 724 - 724, Japanese


• インスリン使用/非使用GDM症例におけるインスリン分泌能・感受性指標の比較

  平野 靖子, 村前 直和, 高橋 陸, 山田 倫子, 中村 友昭, 福岡 秀規, 岡田 裕子, 廣田 勇士, 坂口 一彦, 谷村 憲司, 森實 真由美, 出口 雅士, 山田 秀人, 小川 渉

  (一社)日本糖尿病・妊娠学会, Oct. 2016, 糖尿病と妊娠, 16(3) (3), S - 66, Japanese


• 下垂体腺腫治療のUpdate 内科の立場から

  福岡 秀規

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 435 - 435, Japanese


• 特発性後天性全身性無汗症に中枢性尿崩症を合併した一例

  高橋 隆, 福岡 秀規, 坂東 弘教, 山田 倫子, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 453 - 453, Japanese


• NF1に先端巨大症を含む多発性内分泌腫瘍を合併した一例

  小武 由紀子, 福岡 秀規, 穂積 かおり, 竹内 健人, 佐藤 武志, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 井口 元三, 長谷川 奉延, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 460 - 460, Japanese


• 下垂体機能低下症を呈する「抗PIT-1抗体症候群」4例の臨床的検討

  坂東 弘教, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 福岡 秀規, 犬塚 恵, 杢保 敦子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 495 - 495, Japanese


• 健常人における血中IGF-I濃度を規定する因子の検討

  松本 隆作, 古賀 正史, 笠山 宗正, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 501 - 501, Japanese


• リチウム製剤により腎性尿崩症・副甲状腺機能亢進症を呈した1例

  吉田 健一, 福岡 秀規, 山田 佳子, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 516 - 516, Japanese


• 2型糖尿病患者におけるIGF-I低値に寄与する因子の解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 528 - 528, Japanese


• 低K、低アルドステロン血症、低身長を呈した若年性高血圧の一例

  細川 友誠, 福岡 秀規, 菅原 健二, 竹内 健人, 山田 倫子, 中村 友昭, 岡田 裕子, 廣田 勇士, 井口 元三, 本間 桂子, 長谷川 奉延, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 475 - 475, Japanese


• 性同一性障を伴うコルチゾール、アンドロゲン産生副腎腫瘍の1例

  岩橋 泰幸, 福岡 秀規, 毛利 華奈子, 菅原 健二, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2016, 日本内分泌学会雑誌, 92(2) (2), 491 - 491, Japanese


• インスリン頻回注射法からSensor Augmented Pump(SAP)に変更した1型糖尿病患者の治療効果の検討

  細川 友誠, 廣田 勇士, 伊藤 潤, 佐藤 洋幸, 浦井 伸, 竹内 健人, 三浦 洋, 山田 倫子, 浜口 哲矢, 松岡 敦子, 岡田 裕子, 福岡 秀規, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2016, 糖尿病, 59(Suppl.1) (Suppl.1), S - 286, Japanese


• インスリン施注中の高結合能・低親和性インスリン抗体に関連する因子についての検討

  竹内 健人, 廣田 勇士, 伊藤 潤, 佐藤 洋幸, 浦井 伸, 細川 友誠, 三浦 洋, 山田 倫子, 岡田 裕子, 福岡 秀規, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2016, 糖尿病, 59(Suppl.1) (Suppl.1), S - 440, Japanese


• 新たな下垂体炎、視床下部自己抗体疾患 下垂体機能低下症を呈する新たな疾患概念「抗PIT-1抗体症候群」

  高橋 裕, 坂東 弘教, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 140 - 140, Japanese


• 抗PIT-1抗体症候群は新たな胸腺腫関連自己免疫疾患である

  坂東 弘教, 井口 元三, 福岡 秀規, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 西沢 衡, 高橋 路子, 杢保 敦子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 202 - 202, Japanese


• IGF-Iの細胞老化促進作用を介した新たな肝臓調節機構と治療応用

  西沢 衡, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 219 - 219, Japanese


• ACTH産生下垂体腫瘍の新たな発症機序 Cyclin EはHOTAIRを負に制御する

  吉田 健一, 福岡 秀規, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 231 - 231, Japanese


• グルコースクランプ法を用いて検討した原発性アルドステロン症の手術前後の病態変化

  坂口 一彦, 駒田 久子, 中村 友昭, 末松 那都, 岡田 裕子, 井口 元三, 福岡 秀規, 廣田 勇士, 高橋 裕, 田島 慶彦, 河合 正昭, 佐藤 利彦, 小川 渉

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 252 - 252, Japanese


• 褐色細胞腫診断マーカーとしての血漿レニン活性の有用性

  山田 倫子, 福岡 秀規, 岡田 裕子, 細川 友誠, 竹内 健人, 伊藤 潤, 佐藤 弘幸, 浦井 伸, 三浦 洋, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 255 - 255, Japanese


• 非機能性副腎腺腫患者における1mgデキサメタゾン抑制後コルチゾール値と心血管リスクについての検討

  細川 友誠, 福岡 秀規, 山田 倫子, 竹内 健人, 伊藤 潤, 佐藤 洋幸, 浦井 伸, 三浦 洋, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 255 - 255, Japanese


• ACTH産生下垂体腫瘍におけるErbB4の発現量と臨床像との関連

  小武 由紀子, 福岡 秀規, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 260 - 260, Japanese


• 疾患特異的iPS細胞を用いた下垂体疾患の病態解明

  松本 隆作, 須賀 英隆, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, 青井 貴之, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 300 - 300, Japanese


• ヒストンメチル基転移酵素SETD2遺伝子変異を認めた巨人症の一例

  隅田 健太郎, 鳴海 覚志, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西沢 衡, 高橋 路子, 小川 渉, 長谷川 奉延, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 301 - 301, Japanese


• 新規アディポカイン、ケマリンは副腎髄質を介して褐色脂肪機能を調節する

  高橋 路子, 置村 康彦, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 福岡 秀規, 井口 元三, 北澤 理子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 309 - 309, Japanese


• 原発性アルドステロン症69例における片側性あるいは両側性病変の臨床的特徴の検討

  井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92(1) (1), 319 - 319, Japanese


• 糖尿病合併先端巨大症における糖尿病性血管合併症の頻度

  隈田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本糖尿病学会, Apr. 2016, 糖尿病, 59(Suppl.1) (Suppl.1), S - 154, Japanese


• クッシング病の内科的治療 現状と将来的展望

  福岡 秀規

  間脳・下垂体・副腎系研究会, Mar. 2016, ACTH RELATED PEPTIDES, 27, 52 - 53, Japanese


• 甲状腺ホルモン不応症とTSH産生腫瘍の鑑別に苦慮した一例

  浦井 伸, 福岡 秀規, 吉田 健一, 廣田 勇士, 工藤 工, 西原 永潤, 井口 元三, 宮内 昭, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 787 - 787, Japanese


• 本邦先端巨大症における包括的原因遺伝子解析

  松本 隆作, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 797 - 797, Japanese


• 先端巨大症における膵嚢胞性病変の合併頻度とその関連因子の検討

  小武 由紀子, 福岡 秀規, 有坂 好史, 小西 淳也, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 799 - 799, Japanese


• 糖尿病合併先端巨大症における糖尿病性血管合併症の頻度

  隅田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 800 - 800, Japanese


• 治療に苦慮したTR-Ab著明高値バセドウ病合併妊娠の1例

  吉田 健一, 福岡 秀規, 深田 修司, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 井口 元三, 豊永 綾香, 上中 美月, 西田 浩輔, 森岡 一朗, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 810 - 810, Japanese


• 著明な高カルシウム血症を認めたバセドウ病の一例

  佐藤 洋幸, 福岡 秀規, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 811 - 811, Japanese


• CHD7遺伝子異常が疑われたKallmann症候群の1例

  志智 大城, 福岡 秀規, 浦井 伸, 山田 佳子, 加藤 慶太郎, 三浦 洋, 末松 那都, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 841 - 841, Japanese


• トルバブタンが著効した低AVP血症性低ナトリウム血症の一例

  坂東 弘教, 井口 元三, 福岡 秀規, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 高橋 路子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 856 - 856, Japanese


• 30歳まで無治療で経過した家族性中枢性尿崩症の一例

  伊藤 潤, 福岡 秀規, 芳野 啓, 廣田 勇士, 井口 元三, 長崎 弘, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 857 - 857, Japanese


• 集学的治療によって長期生存している悪性褐色細胞腫の一例

  西澤衡, 福岡秀規, 井口元三, 小武由紀子, 吉田健一, 松本隆作, 坂東弘教, 隅田健太郎, Mukohara Toru, 小川渉, 高橋裕

  (一社)日本内分泌学会, Oct. 2015, 日本内分泌学会雑誌, 91(3) (3), 861 - 861, Japanese

  Introduction other


• 脳と下垂体の臨床update 病態・診断・治療 下垂体機能低下症を呈する新たな疾患概念

  高橋 裕, 坂東 弘教, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, Sep. 2015, 日本内分泌学会雑誌, 91(2) (2), 502 - 502, Japanese


• 成長ホルモン産生下垂体腺腫の腫瘍浸潤性に関連するLong non-coding RNAの同定と作用機序の解明

  福岡 秀規, 井下 尚子, 山田 正三, 高橋 裕

  (公財)成長科学協会, Aug. 2015, 成長科学協会研究年報, (38) (38), 135 - 136, Japanese


• IGF-Iはテロメア短縮および細胞老化を惹起する 先端巨大症における新たな病態の提唱

  松本 隆作, 福岡 秀規, 井口 元三, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2015, 日本内分泌学会雑誌, 91(1) (1), 266 - 266, Japanese


• 2型糖尿病における細小および大血管合併症と血中IGF-I値の関連

  隅田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2015, 日本内分泌学会雑誌, 91(1) (1), 270 - 270, Japanese


• IFITM5遺伝子にc.-14C>T変異を認め、骨形成不全症V型と診断した一例

  浦井 伸, 福岡 秀規, 横井 伯英, 伊賀 真紀子, 中島 進介, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2015, 日本内分泌学会雑誌, 91(1) (1), 286 - 286, Japanese


• 新規胸腺腫関連自己免疫疾患としての"抗PIT-1抗体症候群"

  坂東 弘教, 井口 元三, 福岡 秀規, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 高橋 路子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2015, 日本内分泌学会雑誌, 91(1) (1), 382 - 382, Japanese


• Cushing症候群患者におけるメチラポン治療効果指標としての唾液中コルチゾールの有用性

  吉田 健一, 福岡 秀規, 中島 進介, 岩橋 泰幸, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 井口 元三, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2015, 日本内分泌学会雑誌, 91(1) (1), 397 - 397, Japanese


• 免疫染色により責任病巣を評価しえたPA/SCS合併の1症例

  西澤 衡, 福岡 秀規, 生天目 侑子, 廣田 勇士, 井口 元三, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 坂口 一彦, 笹野 公伸, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, Apr. 2015, 日本内分泌学会雑誌, 91(1) (1), 365 - 365, Japanese


• 【最新臨床大腸癌学-基礎研究から臨床応用へ-】 インスリン抵抗性と癌発症

  Fukuoka Hidenori, Ogawa Wataru

  (株)日本臨床社, Apr. 2015, 日本臨床, 73(増刊4 最新臨床大腸癌学) (増刊4 最新臨床大腸癌学), 699 - 704, Japanese

  [Invited]

  Introduction commerce magazine


• New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases

  Hidenori Fukuoka

  Apr. 2015, PITUITARY, 18(2) (2), 274 - 278, English

  [Refereed]

  Introduction scientific journal


• Hypophysitis

  Hidenori Fukuoka

  Mar. 2015, ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 44(1) (1), 143 - +, English

  [Refereed]

  Introduction scientific journal


• 男性低ゴナドトロピン性性腺機能低下症における性腺ホルモン補充療法がQuality of Lifeに与える影響

  加藤慶太郎, 福岡秀規, 山田佳子, 志智大城, 浦井伸, 末松那都, 三浦洋, 廣田勇士, 井口元三, 小川渉, 高橋裕

  2015, 日本間脳下垂体腫瘍学会プログラム・抄録集, 25th


• The Role of Genetic and Epigenetic Changes in Pituitary Tumorigenesis

  Hidenori Fukuoka, Yutaka Takahashi

  Dec. 2014, NEUROLOGIA MEDICO-CHIRURGICA, 54(12) (12), 943 - 957, English

  [Refereed]

  Introduction scientific journal


• インスリン抗体陽性2型糖尿病のHLAに関する検討

  平田 悠, 廣田 勇士, 岩橋 泰幸, 藤田 泰功, 播 悠介, 伊賀 真紀子, 中島 進介, 西本 祐希, 向井 美希, 福岡 秀規, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Nov. 2014, 糖尿病, 57(11) (11), 869 - 869, Japanese


• IgG4関連下垂体炎との鑑別を要した多発性血管炎性肉芽腫症の一例

  坂東 弘教, Iguchi Genzo, 福岡 秀規, 齋藤 幹, 河野 誠司, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, Takahashi Michiko, 谷口 理章, 森信 暁雄, Kohmura Eiji, 小川 渉, Takahashi Yutaka

  (一社)日本内分泌学会, Oct. 2014, 日本内分泌学会雑誌, 90(3) (3), 922 - 922, Japanese

  Meeting report


• The Effect of Type 2 Diabetes on Serum GH and IGF-I Levels in Relatively Lean Japanese Patients

  Kentaro Suda, Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Yushi Hirota, Hironori Bando, Hitoshi Nishizawa, Michiko Takahashi, Kazuhiko Sakaguchi, Yutaka Takahashi

  Jun. 2014, ENDOCRINE REVIEWS, 35(3) (3), English

  Summary international conference


• 1型糖尿病の暁現象に影響を与える因子に関する検討

  平田 悠, 廣田 勇士, 岩橋 泰幸, 藤田 泰功, 播 悠介, 伊賀 真紀子, 中島 進介, 西本 祐希, 向井 美希, 福岡 秀規, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, Apr. 2014, 糖尿病, 57(Suppl.1) (Suppl.1), S - 382, Japanese


• クッシング病 薬物療法の現状と展望

  福岡 秀規

  間脳・下垂体・副腎系研究会, Mar. 2014, ACTH RELATED PEPTIDES, 25, 106 - 108, Japanese


• プロラクチノーマ

  福岡秀規, 高橋 裕

  中外医学社, 2013, 内科外来基本処方Navi, Japanese

  Introduction scientific journal


• Expression and function of ErbB receptors and ligands in the pituitary

  Odelia Cooper, George Vlotides, Hidenori Fukuoka, Mark I. Greene, Shlomo Melmed

  Dec. 2011, ENDOCRINE-RELATED CANCER, 18(6) (6), R197 - R211, English

  Book review


• IGF-Iは血管平滑筋細胞において細胞老化を促進する

  Handayaningsih Anastasia Evi, 井口 元三, 福岡 秀規, 西沢 衡, 高橋 路子, 山本 雅昭, Herningtyas Henny, 置村 康彦, 加治 秀介, 千原 和夫, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Mar. 2010, 日本内分泌学会雑誌, 86(1) (1), 101 - 101, Japanese


• Sirt1は肝細胞におけるGHによるIGF-I産生を抑制する

  山本 雅昭, 福岡 秀規, 西沢 衡, 高橋 路子, Evi Handayaningsih, 千原 和夫, 清野 進, 高橋 裕

  (一社)日本内分泌学会, Apr. 2009, 日本内分泌学会雑誌, 85(1) (1), 353 - 353, Japanese


• IGF-1シグナル伝達とその生物学的作用における活性酸素種の重要な役割(Reactive oxygen species play an essential role in IGF-I signaling and its biological action)

  Evi Handayaningsih, 福岡 秀規, 西沢 衡, 高橋 路子, 山本 雅昭, Henny Herningtyas, 置村 康彦, 加治 秀介, 清野 進, 千原 和夫, 高橋 裕

  (一社)日本内分泌学会, Apr. 2009, 日本内分泌学会雑誌, 85(1) (1), 353 - 353, English


• 先端巨大症における高トリグリセライド血症は耐糖能と血清GH値に関連する

  福岡 秀規, 高橋 裕, 工藤 工, 村脇 あゆみ, 西沢 衡, 今中 真理, 竹野 亮子, 高橋 路子, 井口 元三, 高橋 健太郎, 飯田 啓二, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, 20 Jun. 2008, 日本内分泌学会雑誌, 84(Suppl.) (Suppl.), 120 - 122, Japanese


• 成長ホルモン受容体拮抗剤により著明に耐糖能が改善した先端巨大症の1例

  高橋 裕, 飯田 啓二, 福岡 秀規, 今中 真理, 西沢 衡, 竹野 亮子, 置村 康彦, 加治 秀介, 春日 雅人, 千原 和夫

  (一社)日本糖尿病学会, Jun. 2008, 糖尿病, 51(6) (6), 567 - 567, Japanese


• GH/IGF-1はNASHモデルマウスにおける肝線維化を抑制する

  西澤 衡, 高橋 裕, 飯田 啓二, 吉岡 嗣朗, 高橋 健太郎, 福岡 秀規, 高橋 路子, 今中 真理, 村脇 あゆみ, 井口 元三, 置村 康彦, 加治 秀介, 春日 雅人, 千原 和夫

  (一社)日本内分泌学会, Apr. 2008, 日本内分泌学会雑誌, 84(1) (1), 226 - 226, Japanese


• 成長ホルモンはC2C12細胞においてMechano growth factorの発現を誘導し筋肉幹細胞を活性化する

  今中 真理, 飯田 啓二, 村脇 あゆみ, 西澤 衡, 福岡 秀規, 竹野 亮子, 高橋 裕, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Apr. 2008, 日本内分泌学会雑誌, 84(1) (1), 288 - 288, Japanese


• 【内分泌クリニカル・カンファランス】副腎(皮質・髄質) 部分的11β-hydroxylase欠損症の合併が疑われた巨大副腎腫瘍の一例

  今中 真理, 高橋 健太郎, 西澤 衡, 本多 久子, 福岡 秀規, 竹野 亮子, 飯田 啓二, 高橋 裕, 置村 康彦, 加治 秀介, 笹野 公伸, 千原 和夫

  (有)医学の世界社, Mar. 2008, ホルモンと臨床, 56(春季増刊) (春季増刊), 121 - 126, Japanese


• オクトレオチド徐放性製剤、カベルゴリンの併用が著効した臨床症状に乏しいGH産生巨大下垂体腺腫の一例（第２報）

  福岡秀規, 高橋裕, 飛松崇子, 村脇あゆみ, 西沢衡, 今中真里, 竹野亮子, 高橋健太郎, 井口元三, 飯田啓二, 春日雅人, 千原和夫

  2008, 日本間脳下垂体腫よう学会プログラム抄録集 vol.18, 108


• 先端巨大症における高TG血症は耐糖能と血清GH値に関連する

  福岡 秀規, 高橋 裕, 工藤 工, 村脇 あゆみ, 西沢 衡, 今中 真理, 竹野 亮子, 高橋 健太郎, 井口 元三, 飯田 啓二, 置村 康彦, 加治 秀介, 春日 雅人, 千原 和夫

  (一社)日本内分泌学会, Dec. 2007, 日本内分泌学会雑誌, 83(3) (3), 740 - 740, Japanese


• 1型糖尿病の治療中にTSH単独欠損症の合併が判明した1症例

  村脇 あゆみ, 飯田 啓二, 廣田 勇士, 坂口 一彦, 西海 智子, 土居 久子, 西沢 衡, 今中 真理, 福岡 秀規, 内藤 純子, 梶 博史, 高橋 裕, 春日 雅人

  (一社)日本内分泌学会, Dec. 2007, 日本内分泌学会雑誌, 83(3) (3), 774 - 774, Japanese


• 成長ホルモンは、Fox01の遺伝子発現、活性を調節し脂肪細胞におけるインスリンシグナルに拮抗する

  福岡 秀規, 高橋 裕, 中江 淳, 西沢 衡, 今中 真理, 竹野 亮子, 飯田 啓二, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Sep. 2007, 日本内分泌学会雑誌, 83(2) (2), 408 - 408, Japanese


• Basedow病寛解に伴い著明な改善がみられた内分泌疾患に伴う糖尿病の1例

  今中 真理, 高橋 健太郎, 比佐 伊都子, 西沢 衡, 福岡 秀規, 竹野 亮子, 飯田 啓二, 高橋 裕, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本糖尿病学会, Jun. 2007, 糖尿病, 50(6) (6), 427 - 427, Japanese


• Graves病寛解に伴い糖尿病の著明な改善がみられた一例

  今中 真理, 高橋 健太郎, 飯田 啓二, 西澤 衡, 福岡 秀規, 竹野 亮子, 高橋 裕, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Apr. 2007, 日本内分泌学会雑誌, 83(1) (1), 169 - 169, Japanese


• IGF-Iは脂肪細胞において活性酸素種(ROS)の産生促進を介し、インスリン依存性糖取り込みを抑制する

  福岡 秀規, 高橋 裕, 西澤 衡, 今中 真理, 竹野 亮子, 井口 元三, 高橋 路子, 高橋 健太郎, 飯田 啓二, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Apr. 2007, 日本内分泌学会雑誌, 83(1) (1), 200 - 200, Japanese


• 新規ケモカイン、メタボカイン1はインスリン感受性と脂質代謝を調節する

  高橋 路子, 高橋 裕, 高橋 健一, Zolotaryov, Fyodor N, 洪 卿秀, 飯田 啓二, 高橋 健太郎, 竹野 亮子, 福岡 秀規, 今中 真理, 西澤 衡, 加治 秀介, 置村 康彦, 清成 寛, 大島 尚子, 相澤 慎一, 北澤 理子, 北澤 荘平, 千原 和夫

  (一社)日本内分泌学会, Apr. 2007, 日本内分泌学会雑誌, 83(1) (1), 178 - 178, Japanese


• 術後20年経過し再発した悪性褐色細胞腫の1例

  井上 喜文, 飯田 啓二, 比佐 伊都子, 飛松 崇子, 西澤 衡, 今中 真理, 福岡 秀規, 竹野 亮子, 内藤 純子, 高橋 健太郎, 梶 博史, 高橋 裕, 千原 和夫, 置村 康彦, 加治 秀介, 横山 邦彦

  (一社)日本内分泌学会, Mar. 2007, 日本内分泌学会雑誌, 82(4) (4), 835 - 835, Japanese


• プレクリニカルクッシング症候群を伴った副腎皮質癌の一例

  竹野 亮子, 飯田 啓二, 井上 喜文, 西沢 衡, 今中 真理, 福岡 秀規, 高橋 健太郎, 高橋 裕, 置村 康彦, 加治 秀介, 笹野 公伸, 千原 和夫

  (一社)日本内分泌学会, Dec. 2006, 日本内分泌学会雑誌, 82(3) (3), 675 - 675, Japanese


• 2A型VHL病の一家系におけるVHL遺伝子解析

  今中 真理, 飯田 啓二, 高橋 健太郎, 辻 和雄, 西沢 衡, 本多 久子, 福岡 秀規, 竹野 亮子, 高橋 裕, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Dec. 2006, 日本内分泌学会雑誌, 82(3) (3), 681 - 681, Japanese


• 先端巨大症においてIGF-I/GH比の低下は耐糖能異常と関連する

  福岡 秀規, 高橋 裕, 工藤 工, 西沢 衡, 今中 真理, 竹野 亮子, 井口 元三, 高橋 健太郎, 飯田 啓二, 置村 康彦, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Dec. 2006, 日本内分泌学会雑誌, 82(3) (3), 682 - 682, Japanese


• 両側副腎腫大を伴うプレクリニカルクッシング症候群の1例

  今中 真理, 飯田 啓二, 板倉 崇泰, 福岡 秀規, 竹野 亮子, 高橋 健太郎, 高橋 裕, 置村 康彦, 加治 秀介, 千原 和夫

  (有)医学の世界社, 30 Sep. 2006, ホルモンと臨牀, 54(秋季増刊) (秋季増刊), 150 - 155, Japanese


• Growth hormone regulates FOXO1 protein levels and its transcriptional activity in adipose tissue

  Hidenori Fukuoka, Yutaka Takahashi, Jun Nakae, Hitoshi Nishizawa, Mari Imanaka, Ryoko Takeno, Kentaro Takahashi, Keiji Iida, Yasuhiko Okimura, Hidesuke Kaji, Kazuo Chihara

  May 2006, FRONTIERS IN NEUROENDOCRINOLOGY, 27(1) (1), 32 - 33, English

  Summary international conference


• 組織特異的GFP発現系を使用したES細胞からGH産生細胞への分化の解析

  工藤 工, 井口 元三, 置村 康彦, 福岡 秀規, 竹野 亮子, 高橋 健太郎, 飯田 啓二, 高橋 裕, 加治 秀介, 千原 和夫

  (一社)日本内分泌学会, Apr. 2005, 日本内分泌学会雑誌, 81(1) (1), 159 - 159, Japanese


• 悪性関節リウマチの治療中に発症した皮膚結核

  正木 太朗, 中村 敦子, 谷 昌寛, 福岡 秀規, 草野 仁, 富岡 洋海, 佐野 勝洋

  (公社)日本皮膚科学会, Mar. 2004, 日本皮膚科学会雑誌, 114(3) (3), 614 - 614, Japanese


• インスリン抗体を伴い治療困難であった糖尿病の1例

  福岡 秀規, 前田 賢吾, 石原 慶子, 五明 水脈子, 船曳 あゆみ, 有澤 健司, 田村 孝雄, 山田 浩幸, 大原 毅, 谷口 洋, 春日 雅人

  (一社)日本糖尿病学会, May 2001, 糖尿病, 44(5) (5), 440 - 440, Japanese